<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV - Bjerrum, S - 2019 | Cochrane Library</title> <meta content="Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV - Bjerrum, S - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011420.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV - Bjerrum, S - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011420.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011420.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV" name="citation_title"/> <meta content="Stephanie Bjerrum" name="citation_author"/> <meta content="steph@medicinsk.dk" name="citation_author_email"/> <meta content="Ian Schiller" name="citation_author"/> <meta content="McGill University Health Centre ‐ Research Institute" name="citation_author_institution"/> <meta content="Nandini Dendukuri" name="citation_author"/> <meta content="McGill University Health Centre ‐ Research Institute" name="citation_author_institution"/> <meta content="Mikashmi Kohli" name="citation_author"/> <meta content="McGill University" name="citation_author_institution"/> <meta content="Ruvandhi R Nathavitharana" name="citation_author"/> <meta content="Beth Israel Deaconess Medical Center, Harvard Medical School" name="citation_author_institution"/> <meta content="Alice A Zwerling" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Claudia M Denkinger" name="citation_author"/> <meta content="Karen R Steingart" name="citation_author"/> <meta content="Department of Clinical Sciences, Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Maunank Shah" name="citation_author"/> <meta content="John Hopkins University School of Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD011420.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/10/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011420.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011420.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011420.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Biomarkers [urine]; CD4 Lymphocyte Count; HIV Seropositivity [*complications]; Lipopolysaccharides [*urine]; Point-of-Care Systems; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Tuberculosis [*diagnosis]; Tuberculosis, Pulmonary [diagnosis]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011420.pub3&amp;doi=10.1002/14651858.CD011420.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011420\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011420\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","fr","zh_HANS","ms"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD011420.pub3",title:"Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV",firstPublishedDate:"Oct 21, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011420.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011420.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011420.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011420.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011420.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011420.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011420.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011420.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011420.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011420.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10161 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011420.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-sec-0102"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-sec-0030"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-sec-0031"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-sec-0037"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-sec-0040"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/appendices#CD011420-sec-0107"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/table_n/CD011420StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/table_n/CD011420StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#CD011420-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Stephanie Bjerrum</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#CD011420-cr-0003">Ian Schiller</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#CD011420-cr-0004">Nandini Dendukuri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#CD011420-cr-0005">Mikashmi Kohli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#CD011420-cr-0006">Ruvandhi R Nathavitharana</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#CD011420-cr-0007">Alice A Zwerling</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#CD011420-cr-0008">Claudia M Denkinger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#CD011420-cr-0009">Karen R Steingart</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information#CD011420-cr-0010">Maunank Shah</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information/en#CD011420-sec-0151">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 October 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011420.pub3">https://doi.org/10.1002/14651858.CD011420.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011420-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011420-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011420-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011420-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011420-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011420-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011420-abs-0001" lang="en"> <section id="CD011420-sec-0001"> <h3 class="title" id="CD011420-sec-0001">Background</h3> <p>The lateral flow urine lipoarabinomannan (LF‐LAM) assay Alere Determine™ TB LAM Ag is recommended by the World Health Organization (WHO) to help detect active tuberculosis in HIV‐positive people with severe HIV disease. This review update asks the question, "does new evidence justify the use of LF‐LAM in a broader group of people?”, and is part of the WHO process for updating guidance on the use of LF‐LAM. </p> </section> <section id="CD011420-sec-0002"> <h3 class="title" id="CD011420-sec-0002">Objectives</h3> <p>To assess the accuracy of LF‐LAM for the diagnosis of active tuberculosis among HIV‐positive adults with signs and symptoms of tuberculosis (symptomatic participants) and among HIV‐positive adults irrespective of signs and symptoms of tuberculosis (unselected participants not assessed for tuberculosis signs and symptoms). </p> <p>The proposed role for LF‐LAM is as an add on to clinical judgement and with other tests to assist in diagnosing tuberculosis. </p> </section> <section id="CD011420-sec-0003"> <h3 class="title" id="CD011420-sec-0003">Search methods</h3> <p>We searched the Cochrane Infectious Diseases Group Specialized Register; MEDLINE, Embase, Science Citation Index, Web of Science, Latin American Caribbean Health Sciences Literature, Scopus, the WHO International Clinical Trials Registry Platform, the International Standard Randomized Controlled Trial Number Registry, and ProQuest, without language restriction to 11 May 2018. </p> </section> <section id="CD011420-sec-0004"> <h3 class="title" id="CD011420-sec-0004">Selection criteria</h3> <p>Randomized trials, cross‐sectional, and observational cohort studies that evaluated LF‐LAM for active tuberculosis (pulmonary and extrapulmonary) in HIV‐positive adults. We included studies that used the manufacturer's recommended threshold for test positivity, either the updated reference card with four bands (grade 1 of 4) or the corresponding prior reference card grade with five bands (grade 2 of 5). The reference standard was culture or nucleic acid amplification test from any body site (microbiological). We considered a higher quality reference standard to be one in which two or more specimen types were evaluated for tuberculosis diagnosis and a lower quality reference standard to be one in which only one specimen type was evaluated. </p> </section> <section id="CD011420-sec-0005"> <h3 class="title" id="CD011420-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data using a standardized form and REDCap electronic data capture tools. We appraised the quality of studies using the Quality Assessment of Diagnostic Accuracy Studies‐2 (QUADAS‐2) tool and performed meta‐analyses to estimate pooled sensitivity and specificity using a bivariate random‐effects model and a Bayesian approach. We analyzed studies enrolling strictly symptomatic participants separately from those enrolling unselected participants. We investigated pre‐defined sources of heterogeneity including the influence of CD4 count and clinical setting on the accuracy estimates. We assessed the certainty of the evidence using the GRADE approach. </p> </section> <section id="CD011420-sec-0006"> <h3 class="title" id="CD011420-sec-0006">Main results</h3> <p>We included 15 unique studies (nine new studies and six studies from the original review that met the inclusion criteria): eight studies among symptomatic adults and seven studies among unselected adults. All studies were conducted in low‐ or middle‐income countries. Risk of bias was high in the patient selection and reference standard domains, mainly because studies excluded participants unable to produce sputum and used a lower quality reference standard. </p> <p><i><b>Participants with tuberculosis symptoms</b> </i> </p> <p>LF‐LAM pooled sensitivity (95% credible interval (CrI) ) was 42% (31% to 55%) (moderate‐certainty evidence) and pooled specificity was 91% (85% to 95%) (very low‐certainty evidence), (8 studies, 3449 participants, 37% with tuberculosis). </p> <p>For a population of 1000 people where 300 have microbiologically‐confirmed tuberculosis, the utilization of LF‐LAM would result in: 189 to be LF‐LAM positive: of these, 63 (33%) would not have tuberculosis (false‐positives); and 811 to be LF‐LAM negative: of these, 174 (21%) would have tuberculosis (false‐negatives). </p> <p>By clinical setting, pooled sensitivity was 52% (40% to 64%) among inpatients versus 29% (17% to 47%) among outpatients; and pooled specificity was 87% (78% to 93%) among inpatients versus 96% (91% to 99%) among outpatients. Stratified by CD4 cell count, pooled sensitivity increased, and specificity decreased with lower CD4 cell count. </p> <p><i><b>Unselected participants not assessed for signs and symptoms of tuberculosis</b> </i> </p> <p>LF‐LAM pooled sensitivity was 35% (22% to 50%), (moderate‐certainty evidence) and pooled specificity was 95% (89% to 96%), (low‐certainty evidence), (7 studies, 3365 participants, 13% with tuberculosis). </p> <p>For a population of 1000 people where 100 have microbiologically‐confirmed tuberculosis, the utilization of LF‐LAM would result in: 80 to be LF‐LAM positive: of these, 45 (56%) would not have tuberculosis (false‐positives); and 920 to be LF‐LAM negative: of these, 65 (7%) would have tuberculosis (false‐negatives). </p> <p>By clinical setting, pooled sensitivity was 62% (41% to 83%) among inpatients versus 31% (18% to 47%) among outpatients; pooled specificity was 84% (48% to 96%) among inpatients versus 95% (87% to 99%) among outpatients. Stratified by CD4 cell count, pooled sensitivity increased, and specificity decreased with lower CD4 cell count. </p> </section> <section id="CD011420-sec-0007"> <h3 class="title" id="CD011420-sec-0007">Authors' conclusions</h3> <p>We found that LF‐LAM has a sensitivity of 42% to diagnose tuberculosis in HIV‐positive individuals with tuberculosis symptoms and 35% in HIV‐positive individuals not assessed for tuberculosis symptoms, consistent with findings reported previously. Regardless of how people are enrolled, sensitivity is higher in inpatients and those with lower CD4 cell, but a concomitant lower specificity. As a simple point‐of‐care test that does not depend upon sputum evaluation, LF‐LAM may assist with the diagnosis of tuberculosis, particularly when a sputum specimen cannot be produced. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011420-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011420-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011420-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011420-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011420-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011420-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011420-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011420-abs-0005" lang="en"> <h3>Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV </h3> <p><b>Why is improving the diagnosis of tuberculosis important?</b> </p> <p>Tuberculosis causes more deaths in people living with HIV than any other disease. The lateral flow urine lipoarabinomannan assay (LF‐LAM, Alere Determine™ TB LAM Ag assay) is a World Health Organization‐recommended rapid test to assist in detection of active tuberculosis in HIV‐positive people with severe HIV disease. Rapid and early tuberculosis diagnosis may allow for prompt treatment and alleviate severe illness and death. An incorrect tuberculosis diagnosis may result in anxiety and unnecessary treatment. </p> <p><b>What is the aim of this review?</b> </p> <p>To find out how accurate LF‐LAM is for diagnosing tuberculosis in HIV‐positive people with tuberculosis symptoms (symptomatic participants) and those not assessed for tuberculosis symptoms (unselected participants). This is an update of the 2016 Cochrane Review. </p> <p><b>What was studied in this review?</b> </p> <p>LF‐LAM is a commercially available point‐of‐care test that detects lipoarabinomannan (LAM), a component of the bacterial cell walls, present in some people with active tuberculosis. The test is simple and shows results in 25 minutes. LF‐LAM results were measured against culture or molecular tests (benchmark). </p> <p><b>What are the main results of this review?</b> </p> <p>Fifteen studies: eight studies evaluated LF‐LAM for tuberculosis among symptomatic participants and seven studies among unselected participants. All studies were conducted in low‐ or middle‐income countries. </p> <p>Tuberculosis diagnosis among symptomatic participants: LF‐LAM registered positive in 42% (sensitivity) of people who actually had tuberculosis and did not register positive in 91% of people who were actually negative (specificity). </p> <p>Tuberculosis diagnosis among unselected participants: LF‐LAM sensitivity was 35% and specificity 95%. </p> <p><b>How confident are we in the review’s results?</b> </p> <p>Several studies excluded participants who could not produce sputum and most studies relied on a lower quality benchmark. Few studies and participants were included in some analyses and only one study was conducted outside of sub‐Saharan Africa. Results should be interpreted with caution. </p> <p><b>What do the results mean?</b> </p> <p>Among symptomatic participants, in theory, for a population of 1000 people where 300 have microbiologically‐confirmed tuberculosis, the utilization of LF‐LAM would result in: 189 to be LF‐LAM positive: of these, 63 (33%) would not have tuberculosis (false‐positives); and 811 to be LF‐LAM negative: of these, 174 (21%) would have tuberculosis (false‐negatives). </p> <p>Among unselected participants, in theory, for a population of 1000 people where 100 have microbiologically‐confirmed tuberculosis, the utilization of LF‐LAM would result in: 80 to be LF‐LAM positive: of these, 45 (56%) would not have tuberculosis (false‐positives); and 920 to be LF‐LAM negative: of these, 65 (7%) would have tuberculosis (false‐negatives). </p> <p><b>Who do the review’s results apply to?</b> </p> <p>HIV‐positive people with tuberculosis symptoms and those not assessed for tuberculosis symptoms. </p> <p><b>What are the implications of this review?</b> </p> <p>LF‐LAM has sensitivity around 40% to detect tuberculosis. As the test does not require sputum collection, LF‐LAM may be the only way to diagnose tuberculosis when sputum cannot be produced. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>To 11 May 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011420-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011420-sec-0102">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011420-sec-0200">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011420-sec-0102"></div> <h3 class="title" id="CD011420-sec-0103">Implications for practice</h3> <section id="CD011420-sec-0103"> <p>For people living with HIV, this review found overall lower sensitivity of the lateral flow urine lipoarabinomannan assay (LF‐LAM) than the internationally suggested target of minimum 65% overall for non‐sputum based tuberculosis diagnostic tests (<a href="./references#CD011420-bbs2-0166" title="World Health Organization. High‐priority target product profiles for new tuberculosis diagnostics, Report of a consensus meeting. Geneva: World Health Organization, 2014:98. ">WHO TTP 2014</a>). This was consistent whether the test is used for diagnosis of HIV‐associated tuberculosis (without consideration of sites of disease involvement) among symptomatic (sensitivity of 42%) or unselected (i.e. not assessed for symptoms) participants (sensitivity of 35%). The estimated sensitivity suggests that if LF‐LAM were to be used alone, more than half of all tuberculosis cases would be missed. Whether diagnostic accuracy differs for specific sites of tuberculosis is unknown (e.g. pulmonary tuberculosis, tuberculosis meningitis, or lymph node tuberculosis). There was a lack of data to evaluate diagnostic accuracy for active tuberculosis in asymptomatic participants, but studies among unselected outpatients that included a combination of symptomatic and asymptomatic participants (i.e. unselected participants) showed lower sensitivity (31%). </p> <p>Despite the estimated sensitivity, two randomized controlled trials implementing LF‐LAM in high‐prevalence settings in sub‐Saharan Africa have demonstrated reduced mortality and impact on other clinical outcomes when used to guide tuberculosis treatment in hospitalized HIV‐positive adults. </p> <p>LF‐LAM is being considered as a diagnostic test that may be used as an add on to clinical judgement and with other tests for the diagnosis of HIV‐associated tuberculosis. The test does not have a role as a replacement or triage test. The test may improve important health outcomes among HIV‐positive hospitalized patients because it is feasible (i.e. can be done on urine which is easy to obtain in an inpatient) and may yield a positive result in those that are most likely to die from tuberculosis and are most likely to present atypically (i.e. patients with advanced HIV). Whether these results may be extrapolated to outpatients with advanced HIV disease or those that are seriously ill is unknown. </p> <p>Findings suggest that sensitivity increases with lower CD4 counts and in inpatient settings compared to outpatient settings. For unselected participants irrespective of symptoms, we found differences in LF‐LAM performance based on tuberculosis prevalence of the target population (when stratified at greater or less than 10%), with higher sensitivity when the study population had higher tuberculosis prevalence (≥ 10%). The difference in diagnostic accuracy of LF‐LAM by study setting and by degree of immunosuppression was consistent regardless of the approach to patient selection. Taking all findings into account, we think LF‐LAM has a role along with other tests among individuals with tuberculosis symptoms or with low CD4 cell count. However, we had limited data and these findings should be interpreted with caution. </p> <p>The test does not require sputum collection and is not site‐specific. Other favourable test characteristics include low‐cost, rapidity (&lt; one hour), ease of use (does not require extensive sample preparation), and the fact that the test does not require electricity or special instruments and equipment (<a href="./references#CD011420-bbs2-0166" title="World Health Organization. High‐priority target product profiles for new tuberculosis diagnostics, Report of a consensus meeting. Geneva: World Health Organization, 2014:98. ">WHO TTP 2014</a>). As a simple point‐of‐care test that does not depend upon sputum evaluation, LF‐LAM testing may be the only possible way to confirm a diagnosis when a sputum sample cannot be produced. </p> <p>Clinicians must consider the need for additional testing when interpreting negative LF‐LAM results. The consequences of false‐negative results are increased risk of morbidity and mortality, delayed treatment initiation, and the continued risk of tuberculosis transmission. The consequences of false‐positive results are delayed alternative diagnosis, likelihood of anxiety and morbidity caused by additional testing, unnecessary treatment, and possible adverse events; the possible stigma associated with a diagnosis of tuberculosis. As LF‐LAM does not offer information about drug resistance, a culture‐ or molecular‐based diagnosis should be attempted to enable drug susceptibility testing to avoid that patients with unidentified drug‐resistant tuberculosis may be inappropriately treated with a regimen appropriate only for drug‐susceptible disease. </p> <p>Ultimately, the use of LF‐LAM in a clinical algorithm will not be based on accuracy alone, but also on considerations of cost‐effectiveness, user perspectives and preferences, and the overall benefits and harms of the test. This updated review contributed accuracy data for the WHO Guideline Development Group Meeting in May 2019. The updated WHO guidelines on the use of Alere LAM are expected later in 2019. </p> </section> <h3 class="title" id="CD011420-sec-0104">Implications for research</h3> <section id="CD011420-sec-0104"> <p>Future studies that evaluate the diagnostic accuracy of non‐sputum‐based tests for tuberculosis, such as LF‐LAM, in people living with HIV should use a reference standard that includes at least two different specimens (e.g. sputum, and urine), and in addition, for presumed extrapulmonary tuberculosis, appropriate specimens from the suspected sites of involvement. Moreover, future studies should include patients unable to expectorate sputum in the analysis as these are most likely to benefit from the test. Characteristics that possibly drive performance of the test in addition to CD4 status, such as burden of disease, renal co‐morbidities or other should be evaluated. More studies should evaluate LF‐LAM accuracy in HIV‐positive children, as currently there are very limited data available (<a href="./references#CD011420-bbs2-0057" title="KroidlI , ClowesP , ReitherK , MtafyaB , Rojas‐PonceG , NtinginyaEN , et al. Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania. European Respiratory Journal2015;46(3):761‐70. [DOI: 10.1183/09031936.00003315] ">Kroidl 2015</a>; <a href="./references#CD011420-bbs2-0058" title="LacourseSM , PavlinacPB , CranmerLM , NjugunaIN , MugoC , GatimuJ , et al. Stool Xpert MTB/RIF and urine lipoarabinomannan for the diagnosis of tuberculosis in hospitalized HIV‐infected children. AIDS2018;32(1):69‐78. [DOI: 10.1097/QAD.0000000000001662] ">LaCourse 2018a</a>; <a href="./references#CD011420-bbs2-0074" title="NicolMP , AllenV , WorkmanL , IsaacsW , MunroJ , PienaarS , et al. Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective study. Lancet Global Health2014;2(5):e278–84. ">Nicol 2014</a>). While some studies enrolled unselected participants, our review suggests that a large proportion were symptomatic, particularly in the inpatient setting. Understanding whether there is value in using LF‐LAM for diagnosis of tuberculosis among HIV‐positive people who do not report any tuberculosis symptoms (particularly for those with CD4 &lt; 100) remains unknown. Further studies among asymptomatic individuals are needed to better define the scope of recommendations on the use of LF‐LAM. The indication of increased sensitivity with use of fresh urine and also morning urine needs further investigations, and studies in settings outside sub‐Saharan Africa are lacking. Further research on effective implementation of LF‐LAM within routine clinical practice is needed because the test can only influence clinical practice if the results are believed and acted upon. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011420-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011420-sec-0030"></div> <div class="table" id="CD011420-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">LF‐LAM for symptomatic participants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Review question:</b> what is the diagnostic accuracy of LF‐LAM for the diagnosis of active tuberculosis in HIV‐positive adults with signs and symptoms of tuberculosis? </p> <p><b>Studies:</b> cross‐sectional studies and randomized controlled trials </p> <p><b>Participants:</b> HIV‐positive adults with tuberculosis signs and symptoms </p> <p><b>Setting:</b> all settings (inpatient and outpatient) </p> <p><b>Index test:</b> LF‐LAM </p> <p><b>Threshold for index tests</b>: manufacturer's recommended threshold for positivity i.e. grade 1 of 4 (revised reference card) or the corresponding grade 2 of 5 (prior reference card) </p> <p><b>Reference standard:</b> microbiological (mycobacterial culture and/or nucleic acid amplification test) </p> <p><b>Role:</b> an add on to clinical judgement and with other tests to assist in tuberculosis diagnosis </p> <p><b>Pooled sensitivity (95%CrI): 42% (31% to 55%</b> ); <b>pooled specificity (95% CrI): 91% (85% to 95%)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1000 participants tested (95% CrI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 1%</b> </p> <p><b>Typically seen in asymptomatic persons in outpatient settings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> <p><b>Typically seen in symptomatic persons in all settings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> <p><b>Typically seen in seriously ill persons in inpatient settings</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True positives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4</b> (3 to 6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42</b> (31 to 55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>126</b> (93 to 165) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1277 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a,b,c,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False negatives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> (4 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>58</b> (45 to 69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>174</b> (135 to 207) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True negatives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>901</b> (842 to 941) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>819</b> (765 to 855) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>637</b> (595 to 665) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2172 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>c,e,f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False positives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>89</b> (49 to 148) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>81</b> (45 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>63</b> (35 to 105) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Abbreviations: Crl:</b> credible interval. </p> <p><b>Explanations</b> </p> <p><sup>a</sup>As assessed by QUADAS‐2, in the patient selection domain, we judged six studies (75%) at high risk of bias because they did not avoid inappropriate exclusions. We downgraded one level for risk of bias.<br/> <sup>b</sup>For individual studies, sensitivity estimates ranged from 23% to 68%. We thought that differences in enrolment criteria (different populations targeted) or CD4 count could explain in part the heterogeneity. We did not downgrade for inconsistency.<br/> <sup>c</sup>The median tuberculosis prevalence in the studies was 42% and thus the results tend to be more applicable to settings with a higher tuberculosis prevalence. For tuberculosis prevalence of 1% and 10%, whether or not to downgrade remains unclear. It is possible the test will perform differently at lower prevalences. We did not downgrade for indirectness.<br/> <sup>d</sup>We thought the 95% CrIs around true positives and false negatives would likely not lead to different decisions depending on which credible limits are assumed. We did not downgrade for imprecision.<br/> <sup>e</sup>As assessed by QUADAS‐2, in the reference standard domain, we judged seven studies (88%) at high risk of bias because we thought the reference standard used was unlikely to correctly classify the target condition. We downgraded two levels for risk of bias.<br/> <sup>f</sup>We thought the 95% CrIs around true negatives and false positives would likely lead to different decisions depending on which credible limits are assumed. We downgraded one level for imprecision.<br/> <br/> <b>GRADE certainty of evidence</b> (<a href="./references#CD011420-bbs2-0120" title="McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEpro 2015</a>; <a href="./references#CD011420-bbs2-0104" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>)<br/> <b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p>The table displays normalized frequencies within a hypothetical cohort of 1000 patients at three different prevalences of tuberculosis (pre‐test probabilities): 1%, 10% and 30%. Credible limits (Crls) were estimated based on those around the point estimates for pooled sensitivity and specificity. </p> <p><b>Note:</b> the results on this table should not be interpreted in isolation from the results of the individual included studies contributing to each summary test accuracy measure. These are reported in the main body of the text of the review. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011420-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">LF‐LAM for unselected participants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Review question:</b> what is the diagnostic accuracy of LF‐LAM for the diagnosis of active tuberculosis in HIV‐positive adults irrespective of signs and symptoms of tuberculosis? </p> <p><b>Studies:</b> cross‐sectional studies and randomized controlled trials </p> <p><b>Participants:</b> HIV‐positive unselected adults not assessed for signs and symptoms of tuberculosis i.e. irrespective of symptoms </p> <p><b>Setting:</b> all settings (inpatient and outpatient) </p> <p><b>Index test:</b> LF‐LAM </p> <p><b>Threshold for index tests</b>: manufacturer's recommended threshold for positivity i.e. grade 1 of 4 (revised reference card) or the corresponding grade 2 of 5 (prior reference card) </p> <p><b>Reference standard:</b> microbiological (mycobacterial culture and/or nucleic acid amplification test) </p> <p><b>Role:</b> an add on to clinical judgement and with other tests to assist in tuberculosis diagnosis </p> <p><b>Pooled sensitivity (95% CrI): 35% (22% to 50%); pooled specificity (95% CrI): (89% to 98%)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1000 participants tested (95% CrI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 1%</b> </p> <p><b>Typically seen in asymptomatic persons in outpatient settings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> <p><b>Typically seen in symptomatic persons in all settings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> <p><b>Typically seen in seriously ill persons in inpatient settings</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True positives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> (2 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>35</b> (22 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>105</b> (66 to 150) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>432 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False negatives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> (5 to 8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>65</b> (50 to 78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>195</b> (150 to 234) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True negatives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>941</b> (881 to 970) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>855</b> (801 to 882) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>665</b> (623 to 686) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2933 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>d,e,f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False positives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>49</b> (20 to 109) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>45</b> (18 to 99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>35</b> (14 to 77) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Abbreviations:</b> Crl: Credible interval. </p> <p><b>Explanations</b> </p> <p><sup>a</sup>As assessed by QUADAS‐2, in the patient selection domain, we judged four studies (57%) at high risk of bias because they did not avoid inappropriate exclusions. We downgraded one level for risk of bias.<br/> <sup>b</sup>For individual studies, sensitivity ranged from 0% to 67%. We thought that the percentage of patients with tuberculosis symptoms or differences in CD4 count could explain in part the heterogeneity. One study, <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>, with sensitivity of 0% differed from the other studies by including a) a population of exclusively pregnant women attending an antenatal care setting, b) a low proportion of symptomatic participants (19%), c) a low tuberculosis prevalence (1%), and d) a high median CD4 cell count (437 cells per µL). One study, <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>, with sensitivity 67% differed from the other studies by being conducted in Myanmar, and was the only study included in this review that evaluated LF‐LAM in a setting outside sub‐Saharan Africa. We did not downgrade for inconsistency.<br/> <sup>c</sup>We thought the 95% CrI around true positives and false negatives would likely not lead to different decisions depending on which credible limits are assumed. We did not downgrade for imprecision.<br/> <sup>d</sup>As assessed by QUADAS‐2, in the reference standard domain, we judged five studies (71%) at high risk of bias because we thought the reference standard used was unlikely to correctly classify the target condition. We downgraded one level for risk of bias.<br/> <sup>e</sup>For individual studies, specificity ranged from 67% to 99%. Eighty‐six per cent (6/7) of the included studies had specificity of 94% or higher. One study, <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>, with specificity 67% differed from the other studies by being conducted in Myanmar, and is the only study included in this review that evaluated LF‐LAM in a setting outside sub‐Saharan Africa. We did not downgrade for inconsistency.<br/> <sup>f</sup>We thought the wide 95% Crls around true negatives and false positives would lead to different decisions depending on which credible limits are assumed. We downgraded one level for imprecision.<br/> <br/> <b>GRADE certainty of evidence</b> (<a href="./references#CD011420-bbs2-0120" title="McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEpro 2015</a>; <a href="./references#CD011420-bbs2-0104" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>)<br/> <b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p>The table displays normalized frequencies within a hypothetical cohort of 1000 patients at three different prevalences of tuberculosis (pre‐test probabilities): 1%, 10% and 30%. Credible limits (Crls) were estimated based on those around the point estimates for pooled sensitivity and specificity. </p> <p><b>Note:</b> the results on this table should not be interpreted in isolation from the results of the individual included studies contributing to each summary test accuracy measure. These are reported in the main body of the text of the review. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011420-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011420-sec-0031">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011420-sec-0160">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011420-sec-0031"></div> <p>Tuberculosis is an infectious airborne disease caused by the bacillus <i>Mycobacterium tuberculosis</i> (<i>M tuberculosis</i> )<i>.</i> In 2017, an estimated 10.0 million people developed tuberculosis disease of which 920,000 (9%) occurred among people living with HIV (<a href="./references#CD011420-bbs2-0161" title="World Health Organization. Global Tuberculosis Report 2018. Licence: CC BY‐NC‐SA 3.0 IGO. Geneva: World Health Organization, 2018. ">WHO Global Tuberculosis Report 2018</a>). Although the number of tuberculosis deaths has fallen since 2000, tuberculosis was responsible for 1.6 million deaths in 2017 (<a href="./references#CD011420-bbs2-0161" title="World Health Organization. Global Tuberculosis Report 2018. Licence: CC BY‐NC‐SA 3.0 IGO. Geneva: World Health Organization, 2018. ">WHO Global Tuberculosis Report 2018</a>), and tuberculosis has surpassed HIV as the world's leading cause of death from an infectious disease. Among people living with HIV, tuberculosis is the major cause of hospitalisation and in‐hospital death despite increased access to antiretroviral treatment (ART) (<a href="./references#CD011420-bbs2-0116" title="FordN , MatteelliA , ShubberZ , HermansS , MeintjesG , GrinsztejnB , et al. TB as a cause of hospitalization and in‐hospital mortality among people living with HIV worldwide: a systematic review and meta‐analysis. Journal of the International AIDS Society2016;19(1):20714. ">Ford 2016</a>). A systematic review of the prevalence of tuberculosis identified at autopsy in resource‐limited settings, suggests that tuberculosis is responsible for up to 40% of all HIV‐related deaths and that tuberculosis often is disseminated and undiagnosed at the time of death (<a href="./references#CD011420-bbs2-0122" title="GuptaRK , LucasSB , FieldingKL , LawnSD . Prevalence of tuberculosis in post‐mortem studies of HIV‐infected adults and children in resource‐limited settings: a systematic review and meta‐analysis. AIDS2015;29(15):1987‐2002. ">Gupta 2015</a>). Globally in 2017, only 51% of the incident tuberculosis cases were reported among people living with HIV (<a href="./references#CD011420-bbs2-0161" title="World Health Organization. Global Tuberculosis Report 2018. Licence: CC BY‐NC‐SA 3.0 IGO. Geneva: World Health Organization, 2018. ">WHO Global Tuberculosis Report 2018</a>). However, most deaths from tuberculosis are preventable if the disease is detected early and effectively treated. Overall, it is estimated that 45 million lives were saved between 2000 and 2017 through effective diagnosis and treatment (<a href="./references#CD011420-bbs2-0161" title="World Health Organization. Global Tuberculosis Report 2018. Licence: CC BY‐NC‐SA 3.0 IGO. Geneva: World Health Organization, 2018. ">WHO Global Tuberculosis Report 2018</a>). </p> <p>Geographically, HIV and tuberculosis are often concentrated in areas of poverty with limited resources for diagnosis, treatment, and prevention of tuberculosis. Most of the 30 high tuberculosis/HIV burden countries are situated in sub‐Saharan Africa where HIV‐infection represents a major driver of the tuberculosis epidemic (<a href="./references#CD011420-bbs2-0161" title="World Health Organization. Global Tuberculosis Report 2018. Licence: CC BY‐NC‐SA 3.0 IGO. Geneva: World Health Organization, 2018. ">WHO Global Tuberculosis Report 2018</a>). HIV‐positive individuals have a 20‐ to 37‐fold increased risk of developing tuberculosis compared to HIV‐negative individuals (<a href="./references#CD011420-bbs2-0118" title="GetahunH , GunnebergC , GranichR , NunnP . HIV infection—associated tuberculosis: the epidemiology and the response. Clinical Infectious Diseases2010;50(Suppl 3):S201–7. ">Getahun 2010</a>). The risk of tuberculosis increases with decreasing CD4 cell count, and remains elevated throughout the course of HIV (<a href="./references#CD011420-bbs2-0121" title="GuptaA , WoodR , KaplanR , BekkerLG , LawnSD . Tuberculosis incidence rates during 8 years of follow‐up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLOS One2012;7(3):e34156. ">Gupta 2012</a>; <a href="./references#CD011420-bbs2-0128" title="LawnSD , MyerL , EdwardsD , BekkerLG , WoodR . Short‐term and long‐term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS2009;23(13):1717‐25. ">Lawn 2009</a>). </p> <p>Tuberculosis predominantly affects the lungs (pulmonary tuberculosis), but can affect most parts of the body, such as the lymph nodes, pleura, brain, or spine (extrapulmonary tuberculosis). Extrapulmonary tuberculosis represented 14% of the incident tuberculosis cases notified in 2017 (<a href="./references#CD011420-bbs2-0161" title="World Health Organization. Global Tuberculosis Report 2018. Licence: CC BY‐NC‐SA 3.0 IGO. Geneva: World Health Organization, 2018. ">WHO Global Tuberculosis Report 2018</a>). In comparison with HIV‐negative people, HIV‐positive people have higher rates of extrapulmonary tuberculosis or mycobacteraemia (tuberculosis bloodstream infection) (<a href="./references#CD011420-bbs2-0141" title="PaiM , BehrMA , DowdyD , DhedaK , DivangahiM , BoehmeCC , et al. Tuberculosis. Nature Reviews Disease Primers2016;2:16076. ">Pai 2016</a>; <a href="./references#CD011420-bbs2-0152" title="ShivakotiR , SharmaD , MamoonG , PhamK . Association of HIV infection with extrapulmonary tuberculosis: a systematic review. Infection2017;45(1):11‐21. ">Shivakoti 2017</a>). Signs and symptoms of tuberculosis in people living with HIV vary depending on the progression of immunodeficiency and involved site(s). Complaints are often non‐specific such as fever, weight loss, and fatigue. A cough for longer than two weeks is a common distinguishing feature of tuberculosis that prompts diagnostic testing for tuberculosis in people who are HIV negative, but is present in less than a third of people with tuberculosis who are HIV positive (<a href="./references#CD011420-bbs2-0110" title="CainKP , McCarthyKD , HeiligCM , MonkongdeeP , TasaneeyapanT , KanaraN , et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. New England Journal of Medicine2010;362(8):707‐16. ">Cain 2010</a>). Similarly, radiographic features of tuberculosis in people living with HIV may be misleading or atypical. Whereas upper lobe cavitary lesions are often seen in HIV‐negative people with tuberculosis, such lesions are less common in HIV‐positive people with tuberculosis (<a href="./references#CD011420-bbs2-0110" title="CainKP , McCarthyKD , HeiligCM , MonkongdeeP , TasaneeyapanT , KanaraN , et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. New England Journal of Medicine2010;362(8):707‐16. ">Cain 2010</a>). Identifying those who warrant further testing for tuberculosis can therefore be challenging. Tuberculosis diagnosis further relies heavily on a sputum‐based test strategy that may have limited accuracy as well as applicability among a population that may be sputum scarce and frequently has extrapulmonary and disseminated tuberculosis disease. Moreover, people living with HIV often have paucibacillary tuberculosis disease that makes diagnosis of tuberculosis by smear microscopy, nucleic acid amplification tests (NAATs), and culture less sensitive. </p> <p>Non‐sputum‐based point‐of‐care tuberculosis diagnostic tests are highly desired to improve tuberculosis case detection in people living with HIV and ensure timely treatment (<a href="./references#CD011420-bbs2-0166" title="World Health Organization. High‐priority target product profiles for new tuberculosis diagnostics, Report of a consensus meeting. Geneva: World Health Organization, 2014:98. ">WHO TTP 2014</a>). Desired characteristics of such a test would include minimal or non‐invasive sample collection, short time to result (under one hour), and ability to implement the test without need for special instruments, electricity, or specimen preparation (<a href="./references#CD011420-bbs2-0166" title="World Health Organization. High‐priority target product profiles for new tuberculosis diagnostics, Report of a consensus meeting. Geneva: World Health Organization, 2014:98. ">WHO TTP 2014</a>). </p> <p>Detection of mycobacterial antigen in urine has attracted great attention over time. Urine‐based antigen testing would allow for a tuberculosis diagnosis that is non‐site specific. In addition, urine is easy to collect and store, and lacks the infection control risks associated with sputum collection. Multiple platforms have been developed to detect lipoarabinomannan (LAM), a component of mycobacterial cell walls, initially as enzyme‐linked immunosorbent (ELISA) assays that were evaluated in several clinical settings (<a href="./references#CD011420-bbs2-0136" title="MinionJ , LeungE , TalbotE , DhedaK , PaiM , MenziesD . Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta‐analysis. European Respiratory Journal2011;38(6):1398‐405. ">Minion 2011</a>). Later, the lateral flow urine lipoarabinomannan (LF‐LAM, Alere Determine TB‐LAM assay) was developed as a simple point‐of‐care test for diagnosis of active tuberculosis in people living with HIV. The test is commercially available, does not require access to special laboratory equipment, and produces a result after 25 minutes (<a href="./references#CD011420-bbs2-0103" title="Abbott . Alere DetermineTM TB LAM Ag Product Information. alere.com/en/home/product‐details/determine‐tb‐lam.html (accessed July 18 2017:IN02740004 Rev. 07 2017/08. ">Alere 2017</a>), meeting many of the desired target product‐profile requirements (<a href="./references#CD011420-bbs2-0166" title="World Health Organization. High‐priority target product profiles for new tuberculosis diagnostics, Report of a consensus meeting. Geneva: World Health Organization, 2014:98. ">WHO TTP 2014</a>). </p> <p>The original Cochrane Review of LF‐LAM for tuberculosis included 12 studies (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>). In that review, six studies evaluated accuracy among symptomatic individuals and found a low pooled sensitivity of 45% (Credible Interval (CrI) 29% to 63%) and specificity of 92% (CrI 80% to 97%) against a microbiological reference standard (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>). In participants with CD4 ≤ 100 cells/μL, pooled sensitivity increased to 56% (CrI 41% to 70%) and specificity decreased to 90% (81% to 95%). In the original review, the accuracy of LF‐LAM was also evaluated in participants not assessed of symptoms (i.e. termed ‘TB screening’ and now described as studies among ‘unselected participants’) with sensitivity ranging from 0% to 44% (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>). </p> <p>In 2015, informed by the original Cochrane Review, the WHO made a conditional recommendation for using LF‐LAM to assist with the diagnosis of tuberculosis in HIV‐positive people with advanced disease (described below) and a strong recommendation against using the test “as a screening test for tuberculosis” based on the data among unselected participants (<a href="./references#CD011420-bbs2-0163" title="World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. WHO/HTM/TB/2015.25. Geneva: World Health Organization, 2015. ">WHO Lipoarabinomannan Policy Guidance 2015</a>). </p> <p>Since 2015, additional evidence for the use and clinical impact of LF‐LAM has emerged. This Cochrane Review update includes published studies evaluating the accuracy of the commercially available LF‐LAM, Alere Determine TB LAM Ag assay for diagnosis of active tuberculosis (pulmonary and extrapulmonary tuberculosis) in people living with HIV and informed the updated WHO guidelines on the use of the test. Of note, in 2018, preliminary performance characteristics of a second commercially developed lateral flow assay to detect LAM for the diagnosis of tuberculosis was announced based on data from frozen biobank specimens (Fujifilm SILVAMP TB LAM, Japan; FujiLAM) (<a href="./references#CD011420-bbs2-0109" title="BrogerT , SossenB , du ToitE , KerkhoffAD , SchutzC , ReipoldEI , et al. Novel lipoarabinomannan point‐of‐care tuberculosis test for people living with HIV: a diagnostic accuracy study. Lancet Infectious Diseases2019;19(8):852‐61. [DOI: 10.1016/S1473‐3099(19)30001‐5] ">Broger 2019</a>). The test is projected to become commercially available in 2020; no studies of FujiLAM accuracy are included in this updated review. </p> <section id="CD011420-sec-0032"> <h3 class="title" id="CD011420-sec-0032">Target condition being diagnosed</h3> <p>The target condition is active tuberculosis, which includes pulmonary and extrapulmonary tuberculosis. </p> </section> <section id="CD011420-sec-0033"> <h3 class="title" id="CD011420-sec-0033">Index test(s)</h3> <p>The urine‐based lateral flow lipoarabinomannan immunocapture assay (LF‐LAM) is a commercially available point‐of‐care test for active tuberculosis (Alere Determine™ TB LAM Ag, Abbott, Palatine, IL, USA, previous Alere Inc., Waltham, MA, USA). Lipoarabinomannan (LAM) is a lipopolysaccharide present in mycobacterial cell walls (<a href="./references#CD011420-bbs2-0107" title="BrennanPJ . Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb)2003;83(1‐3):91‐7. ">Brennan 2003</a>), which is released from metabolically active or degenerating bacterial cells during tuberculosis disease (<a href="./references#CD011420-bbs2-0108" title="BrikenV , PorcelliSA , BesraGS , KremerL . Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Molecular Microbiology2004;53(2):391‐403. ">Briken 2004</a>). LAM is detectable in urine of people with active tuberculosis disease and evaluated for both LAM ELISA and the LF‐LAM testing platforms (<a href="./references#CD011420-bbs2-0129" title="LawnSD . Point‐of‐care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV‐associated tuberculosis: a state of the art review. BMC Infectious Diseases2012;12(1):103. ">Lawn 2012</a>; <a href="./references#CD011420-bbs2-0136" title="MinionJ , LeungE , TalbotE , DhedaK , PaiM , MenziesD . Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta‐analysis. European Respiratory Journal2011;38(6):1398‐405. ">Minion 2011</a>; <a href="./references#CD011420-bbs2-0143" title="PeterJ , GreenC , HoelscherM , MwabaP , ZumlaA , DhedaK . Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Current Opinion of Pulmonary Medicine2010;16(3):262‐70. ">Peter 2010</a>; <a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>). The original Cochrane Review of LF‐LAM (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>) and a meta‐analysis of an earlier generation LAM ELISA test (<a href="./references#CD011420-bbs2-0136" title="MinionJ , LeungE , TalbotE , DhedaK , PaiM , MenziesD . Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta‐analysis. European Respiratory Journal2011;38(6):1398‐405. ">Minion 2011</a>) both demonstrated that the accuracy of urinary LAM detection was improved among people living with HIV with advanced immunosuppression. Several hypotheses may explain the higher sensitivity of urine LAM detection in people living with HIV including higher bacillary burden and antigen load (<a href="./references#CD011420-bbs2-0090" title="ShahM , MartinsonNA , ChaissonRE , MartinDJ , VariavaE , DormanSE . Quantitative analysis of a urine‐based assay for detection of lipoarabinomannan in patients with tuberculosis. Journal of Clinical Microbiology2010;48(8):2972‐4. ">Shah 2010</a>), greater likelihood of genitourinary tract tuberculosis involvement, and greater glomerular permeability to allow increased antigen levels in urine (<a href="./references#CD011420-bbs2-0132" title="LawnSD , Gupta‐WrightA . Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated TB with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications. Transactions of The Royal Society of Tropical Medicine and Hygiene2016;110(3):180‐5. ">Lawn 2016</a>; <a href="./references#CD011420-bbs2-0136" title="MinionJ , LeungE , TalbotE , DhedaK , PaiM , MenziesD . Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta‐analysis. European Respiratory Journal2011;38(6):1398‐405. ">Minion 2011</a>). </p> <p>LF‐LAM testing is performed manually by applying 60 µL of unprocessed urine to the sample pad of the DetermineTB LAM Ag test and leave the strip test to incubate at room temperature for 25 minutes (<a href="./references#CD011420-bbs2-0103" title="Abbott . Alere DetermineTM TB LAM Ag Product Information. alere.com/en/home/product‐details/determine‐tb‐lam.html (accessed July 18 2017:IN02740004 Rev. 07 2017/08. ">Alere 2017</a>; <a href="./appendices#CD011420-sec-0108">Appendix 1</a>). The strip is then inspected by eye. The intensity of any visible band is graded by comparing it with the intensities of the bands on a manufacturer‐supplied reference scale card. Of note, the reference scale was revised in January 2014. Prior to January 2014, the reference scale card included five bands (grade 1 representing a very low intensity band to grade 5 representing a high/dark intensity band). After January 2014, the manufacturer revised the reference scale card to have four reference bands, such that the band intensity for the new grade 1 corresponded to the band intensity for the previous grade 2 (<a href="./appendices#CD011420-sec-0109">Appendix 2</a>). Under the current manufacturer recommendations (using the revised four bands reference card), only bands that are grade 1 or higher are considered positive (<a href="./references#CD011420-bbs2-0103" title="Abbott . Alere DetermineTM TB LAM Ag Product Information. alere.com/en/home/product‐details/determine‐tb‐lam.html (accessed July 18 2017:IN02740004 Rev. 07 2017/08. ">Alere 2017</a>; <a href="./appendices#CD011420-sec-0109">Appendix 2</a>). </p> </section> <section id="CD011420-sec-0034"> <h3 class="title" id="CD011420-sec-0034">Clinical pathway</h3> <p>Based on current WHO guidelines (<a href="./references#CD011420-bbs2-0163" title="World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. WHO/HTM/TB/2015.25. Geneva: World Health Organization, 2015. ">WHO Lipoarabinomannan Policy Guidance 2015</a>), the proposed role for the LF‐LAM test is as an ‘add on’ to clinical judgement and with other tests to assist in tuberculosis diagnosis. The test does not have a role as a replacement or triage test. The reason for specifying ‘clinical judgement’ is that, in our view, clinical judgement for HIV‐associated tuberculosis carries more importance than in many other cases (i.e. tuberculosis treatment may be provided regardless of the test results). The reason for specifying ‘add on’ is that for settings where the test is not available, the same clinical judgement is used; hence for settings where the test is available, it is used ‘in addition’. Importantly, some HIV‐positive people may have difficulties in producing a good quality sputum specimen or any sputum at all. </p> <p>In the WHO policy guidance on the use of LAM, it is recommended that LF‐LAM "may be used to assist in the diagnosis of tuberculosis in HIV‐positive adult inpatients with signs and symptoms of tuberculosis (pulmonary/and/or extrapulmonary) and a CD4 cell count less than or equal to 100 cells/μL, or in people living with HIV who are ‘seriously ill' regardless of CD4 count or if the CD4 count is unknown" (<a href="./references#CD011420-bbs2-0163" title="World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. WHO/HTM/TB/2015.25. Geneva: World Health Organization, 2015. ">WHO Lipoarabinomannan Policy Guidance 2015</a>). The recommendations also apply to HIV‐positive outpatients and children with signs and symptoms of tuberculosis (pulmonary and/or extrapulmonary) based on the generalization of data from adult inpatients while acknowledging the limitation of available data (<a href="./references#CD011420-bbs2-0163" title="World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. WHO/HTM/TB/2015.25. Geneva: World Health Organization, 2015. ">WHO Lipoarabinomannan Policy Guidance 2015</a>). The WHO recommends that LF‐LAM should not be used for general tuberculosis screening "owing to suboptimal sensitivity" (<a href="./references#CD011420-bbs2-0163" title="World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. WHO/HTM/TB/2015.25. Geneva: World Health Organization, 2015. ">WHO Lipoarabinomannan Policy Guidance 2015</a>). </p> <p>In 2016, WHO developed an algorithm for managing people living with HIV presumed to have tuberculosis that was published as part of the guidelines on use of ART for treating and preventing HIV infection (<a href="./references#CD011420-bbs2-0160" title="World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd Edition. Geneva: World Health Organization, 2016. ">WHO ART Guidelines 2016</a>). The algorithm recommends the Xpert® MTB/RIF assay (Cepheid, Sunnyvale, USA) as the initial diagnostic test in adults and children with presumed HIV‐associated tuberculosis (<a href="./references#CD011420-bbs2-0168" title="World Health Organization. Automated real‐time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. WHO/HTM/TB/2013.16. Geneva: World Health Organization, 2013. ">WHO Xpert® Policy Update 2013</a>). It is recommended that Xpert® MTB/RIF should be used rather than conventional microscopy and culture for testing sputum and specific extra‐pulmonary specimens like cerebrospinal fluid and lymph nodes (<a href="./references#CD011420-bbs2-0168" title="World Health Organization. Automated real‐time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. WHO/HTM/TB/2013.16. Geneva: World Health Organization, 2013. ">WHO Xpert® Policy Update 2013</a>). The algorithm includes recommendations on use of LF‐LAM as a test that may assist in diagnosing active tuberculosis among seriously ill adults and children living with HIV, regardless of CD4 count (<a href="./references#CD011420-bbs2-0160" title="World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd Edition. Geneva: World Health Organization, 2016. ">WHO ART Guidelines 2016</a>). Use of LF‐LAM is also included as one of the components in the package for diagnosis of tuberculosis in the WHO guidelines for managing people presenting with advanced HIV (<a href="./references#CD011420-bbs2-0164" title="World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization, 2017. ">WHO Managing Advanced HIV Disease 2017</a>). </p> <p>When extrapulmonary tuberculosis is suspected, it is recommended to obtain "appropriate specimens from the suspected sites of involvement for microscopy, culture, and histopathological examination" (<a href="./references#CD011420-bbs2-0156" title="TB CAREI . International Standards for Tuberculosis Care, Edition 3. TB Care 1, The Hague. who.int/tb/publications/ISTC_3rdEd.pdf?ua=1 (accessed 16 Nov 2014):1‐87. ">TB CARE I 2014</a>). A newly published Cochrane Review found that Xpert MTB/RIF may be helpful in confirming the diagnosis of extrapulmonary tuberculosis (<a href="./references#CD011420-bbs2-0127" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD012768.pub2] ">Kohli 2018</a>). However, evaluation for extrapulmonary tuberculosis often requires invasive diagnostic procedures that may have low yield even in people with advanced disease. </p> <p>To identify those who need referral for tuberculosis diagnostic testing, the WHO guidelines on intensified case‐finding in people living with HIV recommend that, in resource‐constrained settings, people living with HIV who report "any one of the symptoms of current cough, fever, weight loss, or night sweats should be evaluated for tuberculosis and other diseases" referred to as the WHO symptom screening rule (<a href="./references#CD011420-bbs2-0119" title="GetahunH , KittikraisakW , HeiligCM , CorbettEL , AylesH , CainKP , et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource‐constrained settings: individual participant data meta‐analysis of observational studies. PLOS Medicine2011;8(1):e1000391. ">Getahun 2011</a>; <a href="./references#CD011420-bbs2-0162" title="World Health Organization Stop TB Dept Dept of HIV/AIDS. Guidelines for intensified tuberculosis case‐finding and isoniazid preventive therapy for people living with HIV in resource‐constrained settings. Geneva: World Health Organization, 2011. ">WHO ICF 2011</a>). People living with HIV with tuberculosis may however not exhibit common symptoms of tuberculosis disease. In some settings with high prevalence of tuberculosis, clinicians have therefore considered evaluating all patients presenting for care for tuberculosis without assessment or consideration of specific signs or symptoms of tuberculosis. </p> <p>In the context of LF‐LAM being recommended in combination with existing tuberculosis tests to increase early tuberculosis diagnosis and treatment, the downstream consequences of LF‐LAM testing include the following. </p> <p> <ul id="CD011420-list-0001"> <li> <p>True‐positive (TP): people would benefit from rapid non‐site specific diagnosis and early initiation of tuberculosis treatment. </p> </li> <li> <p>True‐negative (TN): people would be spared unnecessary treatment and would benefit from reassurance and pursuit of an alternative diagnosis. </p> </li> <li> <p>False‐positive (FP): people would likely experience anxiety and morbidity caused by additional testing, unnecessary treatment, and possible adverse effects; possible stigma associated with a tuberculosis diagnosis; and a FP result may halt further diagnostic evaluation. However, as FP results increase (specificity decrease) as CD4 count decrease, the observed FP results may be due to an inability of the sickest patients to produce a sputum specimen and are TP results being misclassified as FP. Given the high mortality in persons living with HIV, acting on all positive LF‐LAM results may balance the possibly adverse effects associated with unnecessary diagnosis and treatment. </p> </li> <li> <p>False‐negative (FN): people would experience increased risk of morbidity and mortality and delayed treatment initiation; there would be continuous risk of tuberculosis transmission. These concerns may, however, be limited when using LF‐LAM in combination with existing tuberculosis tests. </p> </li> </ul> </p> <p>Importantly, it should be noted that LF‐LAM does not provide information about drug resistance and some individuals with unidentified drug‐resistant tuberculosis may be inappropriately treated with a regimen appropriate for drug‐susceptible tuberculosis. </p> <section id="CD011420-sec-0035"> <h4 class="title">Alternative test(s)</h4> <p>In this section, we briefly describe selected alternative tests for detection of tuberculosis. For a comprehensive review of these tests, we refer the reader to several excellent resources (<a href="./references#CD011420-bbs2-0133" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official american thoracic society/Infectious diseases society of America/Centers for disease control and prevention clinical practice guidelines: Diagnosis of tuberculosis in adults and children. Clinical Infectious Diseases2017;64(2):111‐5. ">Lewinsohn 2017</a>; <a href="./references#CD011420-bbs2-0157" title="DBoyle . Tuberculosis Diagnostics Technology and Market Landscape. 5th Edition. Vernier: World Health Organization Unitaid Secretariat, 2017. ">Unitaid 2017</a>). </p> <p>Smear microscopy (light microscopy (Ziehl‐Neelsen), fluorescence microscopy, or light‐emitting diode (LED) fluorescence microscopy) is the examination of smears for acid‐fast bacilli (tuberculosis bacteria) under a microscope. Advantages of smear microscopy include its simplicity, low cost, speed, and high specificity in high tuberculosis burden areas. In addition, smear microscopy identifies the most infectious tuberculosis patients. Smear microscopy can be performed in basic laboratories. Drawbacks of smear microscopy include the need for specialized training and its relatively low sensitivity, 50% to 60% on average for a direct smear. Among people living with HIV sensitivity is reported as low as 22% to 43% (<a href="./references#CD011420-bbs2-0117" title="GetahunH , HarringtonM , O'BrienR , NunnP . Diagnosis of smear‐negative pulmonary tuberculosis in people with HIV infection or AIDS in resource‐constrained settings: informing urgent policy changes. Lancet2007;369(9578):2042‐9. ">Getahun 2007</a>). Around 5000 to 10,000 organisms per mL must be present in the specimen for tuberculosis bacteria to be visible by microscopy (<a href="./references#CD011420-bbs2-0133" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official american thoracic society/Infectious diseases society of America/Centers for disease control and prevention clinical practice guidelines: Diagnosis of tuberculosis in adults and children. Clinical Infectious Diseases2017;64(2):111‐5. ">Lewinsohn 2017</a>). Although, the sensitivity of microscopy can be improved by approximately 10% with fluorescence (<a href="./references#CD011420-bbs2-0155" title="SteingartKR , HenryM , NgV , HopewellPC , RamsayA , CunninghamJ , et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infectious Diseases2006;6(9):570‐81. ">Steingart 2006</a>), a large number of tuberculosis cases still go undiagnosed if tuberculosis diagnosis solely relies on sputum smear microscopy. Smear‐negative tuberculosis is disproportionately more common in HIV‐positive than HIV‐negative individuals, accounting for 24% to 61% of all pulmonary cases in people living with HIV, the yield decreasing with lower CD4 cell counts (<a href="./references#CD011420-bbs2-0117" title="GetahunH , HarringtonM , O'BrienR , NunnP . Diagnosis of smear‐negative pulmonary tuberculosis in people with HIV infection or AIDS in resource‐constrained settings: informing urgent policy changes. Lancet2007;369(9578):2042‐9. ">Getahun 2007</a>; <a href="./references#CD011420-bbs2-0142" title="PerkinsMD , CunninghamJ . Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. Journal of Infectious Diseases2007;196(Suppl 1):S15‐27. ">Perkins 2007</a>). </p> <p>Mycobacterial culture is a method used to grow bacteria on nutrient‐rich media. In comparison with microscopy, a positive culture requires only around 100 organisms per mL and therefore can detect lower numbers of tuberculosis bacteria (<a href="./references#CD011420-bbs2-0133" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official american thoracic society/Infectious diseases society of America/Centers for disease control and prevention clinical practice guidelines: Diagnosis of tuberculosis in adults and children. Clinical Infectious Diseases2017;64(2):111‐5. ">Lewinsohn 2017</a>). Additionally, culture is essential for species identification and drug susceptibility testing. However, culture may take up to six to eight weeks and requires a highly equipped laboratory. </p> <p>Nucleic acid amplification tests (NAATs) are molecular systems that can detect small quantities of genetic material (DNA or RNA) from microorganisms, such as <i>M tuberculosis</i>. The key advantage of NAATs is that they are rapid diagnostic tests, potentially providing results in a few hours. A variety of molecular amplification methods are available, of which polymerase chain reaction (PCR) is the most common. NAATs are available as commercial kits and in‐house tests (based on a protocol developed in a laboratory) and are used routinely in high‐income countries for tuberculosis detection. In‐house PCR is widely used in low‐income countries because these tests are less expensive than commercial kits. However, in‐house PCR is known to produce highly inconsistent results (<a href="./references#CD011420-bbs2-0115" title="FloresLL , PaiM , ColfordJMJr , RileyLW . In‐house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta‐analysis and meta‐regression. BMC Microbiology2005;5:55. ">Flores 2005</a>). </p> <p>Xpert MTB/RIF and Xpert Ultra, the newest version (Cepheid, Sunnyvale, USA), are fully automated NAATs, that simultaneously and rapidly detect <i>M tuberculosis</i> complex and rifampicin resistance (<a href="./references#CD011420-bbs2-0168" title="World Health Organization. Automated real‐time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. WHO/HTM/TB/2013.16. Geneva: World Health Organization, 2013. ">WHO Xpert® Policy Update 2013</a>; <a href="./references#CD011420-bbs2-0167" title="World Health Organization. WHO meeting report of a technical expert consultation: non‐inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization, 2017. ">WHO Xpert Ultra 2017</a>). A Cochrane Review found that Xpert MTB/RIF was sensitive and specific for both pulmonary tuberculosis detection and rifampicin resistance detection (<a href="./references#CD011420-bbs2-0126" title="HorneDJ , KohliM , ZifodyaJS , SchillerI , DendukuriN , TollefsonD , et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews2019, Issue 6. [DOI: 10.1002/14651858.CD009593.pub4] ">Horne 2019</a>). Compared with Xpert MTB/RIF, Xpert Ultra had higher sensitivity and lower specificity for tuberculosis and similar sensitivity and specificity for rifampicin resistance (one study) (<a href="./references#CD011420-bbs2-0126" title="HorneDJ , KohliM , ZifodyaJS , SchillerI , DendukuriN , TollefsonD , et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews2019, Issue 6. [DOI: 10.1002/14651858.CD009593.pub4] ">Horne 2019</a>). Although sputum testing with Xpert MTB/RIF has high sensitivity for smear‐positive pulmonary tuberculosis (98%), sensitivity is lower for smear‐negative pulmonary tuberculosis (67%) (<a href="./references#CD011420-bbs2-0126" title="HorneDJ , KohliM , ZifodyaJS , SchillerI , DendukuriN , TollefsonD , et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews2019, Issue 6. [DOI: 10.1002/14651858.CD009593.pub4] ">Horne 2019</a>). In another Cochrane Review including 66 studies evaluating Xpert MTB/RIF for detection of extrapulmonary tuberculosis, pooled sensitivity was found to vary across different types of specimens from 31% in pleural tissue to 97% in bone or joint fluid, whereas specificity varied less from 82% in bone or joint tissue to 99% in pleural fluid and urine (<a href="./references#CD011420-bbs2-0127" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD012768.pub2] ">Kohli 2018</a>). These finding have bearing for HIV‐associated tuberculosis where smear‐negative tuberculosis and extrapulmonary tuberculosis are disproportionately higher. In 2017, based on a non‐inferiority analysis of Xpert Ultra compared with Xpert MTB/RIF, the WHO stated that recommendations on the use of Xpert MTB/RIF also apply to the use of Xpert Ultra as the initial diagnostic test for all adults and children with signs and symptoms of tuberculosis (<a href="./references#CD011420-bbs2-0167" title="World Health Organization. WHO meeting report of a technical expert consultation: non‐inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization, 2017. ">WHO Xpert Ultra 2017</a>). </p> <p>The loop‐mediated isothermal amplification test, TB‐LAMP (Eiken Chemical Co., Tokyo, Japan), has been recommended by the WHO since 2016, for diagnosing pulmonary tuberculosis in adults (<a href="./references#CD011420-bbs2-0165" title="World Health Organization. The use of Loop‐mediated Isothermal Amplification (TB‐LAMP) for the diagnosis of pulmonary tuberculosis: Policy guidance. Geneva: World Health Organization, 2016. ">WHO TB‐LAMP 2016</a>). It is a manual and simple assay that can be performed directly on sputum samples with a result provided in less than one hour (<a href="./references#CD011420-bbs2-0170" title="YuanLY , LiY , WangM , KeZQ , XuWZ . Rapid and effective diagnosis of pulmonary tuberculosis with novel and sensitive loop‐mediated isothermal amplification (LAMP) assay in clinical samples: a meta‐analysis. Journal of Infection and Chemotherapy2014;20(2):86‐92. ">Yuan 2014</a>). It is suitable for use at peripheral health centres and is promoted as a test more sensitive than microscopy, but inferior to Xpert MTB/RIF (<a href="./references#CD011420-bbs2-0165" title="World Health Organization. The use of Loop‐mediated Isothermal Amplification (TB‐LAMP) for the diagnosis of pulmonary tuberculosis: Policy guidance. Geneva: World Health Organization, 2016. ">WHO TB‐LAMP 2016</a>). </p> <p>FujiLAM is a novel, lateral flow urine‐based, point‐of‐care test for tuberculosis diagnosis in people living with HIV in low‐resource settings. This assay was developed to detect LAM with results available in less than one hour and was announced on 26 September 2018, the day of the first United Nations General Assembly high‐level meeting on tuberculosis (<a href="./references#CD011420-bbs2-0114" title="Foundation for Innovative New Diagnostics (FIND). Call for trial partners now open to advance evaluation of an innovative, sensitive point‐of‐care test that detects tuberculosis in HIV‐positive people. finddx.org/publication/pr‐26sep18/ (accessed 14 June 2019). ">FIND 2018</a>). Fuji LAM has been evaluated on frozen biobank samples originating from various studies of hospitalized HIV‐positive patients with an estimated sensitivity of 70% (<a href="./references#CD011420-bbs2-0109" title="BrogerT , SossenB , du ToitE , KerkhoffAD , SchutzC , ReipoldEI , et al. Novel lipoarabinomannan point‐of‐care tuberculosis test for people living with HIV: a diagnostic accuracy study. Lancet Infectious Diseases2019;19(8):852‐61. [DOI: 10.1016/S1473‐3099(19)30001‐5] ">Broger 2019</a>). Studies are ongoing to evaluate FujiLAM performance on bio‐samples stored from outpatient HIV‐cohorts and prospective studies to evaluate the diagnostic accuracy of FujiLAM are now called for as the next step forward. These trials are being supported by the Global Health Innovative Technology fund and the German Federal Ministry of Education and Research. The Foundation for Innovative New Diagnostics (FIND) participated in development of the test, that was supported by the governments of the Netherlands and Australia, UK aid from the UK government, and the Bill &amp; Melinda Gates Foundation. </p> </section> </section> <section id="CD011420-sec-0036"> <h3 class="title" id="CD011420-sec-0036">Rationale</h3> <p>To address tuberculosis as the leading cause of morbidity and mortality among people living with HIV, new tests and strategies for detection of tuberculosis are urgently needed. Among the key priorities identified by the WHO, healthcare providers, patients, and advocacy groups is development of point‐of‐care, non‐site specific tests for tuberculosis (<a href="./references#CD011420-bbs2-0105" title="BatzHG , CookeGS , ReidSD . Towards lab‐free tuberculosis diagnosis. August 2011. msfaccess.org/sites/default/files/MSF_assets/TB/Docs/TB_Report_TowardsLabFreeTBDX_2011_ENG.pdf. London: Imperial College, (accessed 16 November 2014). ">Batz 2011</a>; <a href="./references#CD011420-bbs2-0140" title="PaiNP , PaiM . Point‐of‐care diagnostics for HIV and tuberculosis: landscape, pipeline, and unmet needs. Discovery Medicine2012;13(68):35‐45. ">Pai 2012</a>; <a href="./references#CD011420-bbs2-0158" title="WeyerK , CaraiS , NunnP . Viewpoint TB diagnostics: what does the world really need?. Journal of Infectious Diseases2011;204(Suppl 4):S1196‐202. ">Weyer 2011</a>; <a href="./references#CD011420-bbs2-0166" title="World Health Organization. High‐priority target product profiles for new tuberculosis diagnostics, Report of a consensus meeting. Geneva: World Health Organization, 2014:98. ">WHO TTP 2014</a>). To date, LF‐LAM is the only commercially available point‐of‐care test for tuberculosis. LF‐LAM, if sufficiently accurate, would satisfy many of the established minimum specifications for a point‐of‐care test for tuberculosis (<a href="./appendices#CD011420-sec-0110">Appendix 3</a>; <a href="./references#CD011420-bbs2-0105" title="BatzHG , CookeGS , ReidSD . Towards lab‐free tuberculosis diagnosis. August 2011. msfaccess.org/sites/default/files/MSF_assets/TB/Docs/TB_Report_TowardsLabFreeTBDX_2011_ENG.pdf. London: Imperial College, (accessed 16 November 2014). ">Batz 2011</a>). LF‐LAM testing could provide obvious benefits for HIV‐positive people by earlier detection of pulmonary tuberculosis that may be missed by sputum smear microscopy and sputum Xpert MTB/RIF and extrapulmonary tuberculosis that may be missed by sputum‐based testing. Studies that evaluate the impact of the use of LF‐LAM on mortality and other patient outcomes are becoming available. </p> <p>WHO guidelines on the use of urine LF‐LAM were published in 2015 (<a href="./references#CD011420-bbs2-0163" title="World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. WHO/HTM/TB/2015.25. Geneva: World Health Organization, 2015. ">WHO Lipoarabinomannan Policy Guidance 2015</a>). Since 2015, additional evidence on the diagnostic accuracy of LF‐LAM has emerged and is summarized in this Cochrane Review update. A draft of this review was used to inform the 2019 updated WHO guidelines on the use of LF‐LAM. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011420-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011420-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011420-sec-0166">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011420-sec-0037"></div> <section id="CD011420-sec-0038"> <h3 class="title" id="CD011420-sec-0038">Primary objectives</h3> <p>We had two primary objectives:</p> <p> <ol id="CD011420-list-0002"> <li> <p>To assess the accuracy of the lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis of active tuberculosis among HIV‐positive adults with signs and symptoms of tuberculosis. </p> </li> <li> <p>To assess the accuracy of LF‐LAM for the diagnosis of active tuberculosis among HIV‐positive adults irrespective of signs and symptoms of tuberculosis (i.e. unselected participants without consideration or assessment of tuberculosis signs and symptoms). </p> </li> </ol> </p> <p>To estimate accuracy in HIV‐positive individuals with signs and symptoms of tuberculosis (Objective 1), we combined studies in which presentation with signs and symptoms suggestive of tuberculosis was an inclusion criterion and refer to these as ‘Studies with symptomatic participants’. To estimate accuracy in HIV‐positive adults irrespective of signs and symptoms of tuberculosis (Objective 2), we combined studies that considered all HIV‐positive individuals eligible to participate, including both individuals with and individuals without symptoms of tuberculosis and refer to these as ‘Studies with unselected participants’. These studies enrolled participants without assessment or consideration of specific signs or symptoms of tuberculosis. </p> </section> <section id="CD011420-sec-0039"> <h3 class="title" id="CD011420-sec-0039">Secondary objectives</h3> <p>Our secondary objective was to investigate potential sources of heterogeneity in test accuracy, including clinical setting, CD4 cell count, and prevalence of tuberculosis in the studies. </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011420-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011420-sec-0040">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011420-sec-0169">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011420-sec-0040"></div> <section id="CD011420-sec-0041"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011420-sec-0042"> <h4 class="title">Types of studies</h4> <p>We included primary studies that evaluated the diagnostic accuracy of urine LF‐LAM assay for the detection of active tuberculosis in people living with HIV and compared the index test results with a defined microbiological reference standard. We included studies from which we could extract true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN) values.<br/> <br/> Diagnostic studies for tuberculosis are largely cross‐sectional in design, but may include some clinical follow‐up as part of patient classification. We included cross‐sectional studies and observational cohort studies. In addition, we included randomized controlled trials that evaluated the use of the index test on patient health outcomes, but that also reported sensitivity and specificity. Although the study design was a randomized trial for the purpose of determining the impact of the test on participant outcomes, the study design was a cross‐sectional study for the purpose of determining the diagnostic accuracy of the index test in this review. We excluded case‐control studies and other study designs. We excluded data reported only in abstracts, reviews, comments, and editorial notes. We did not include unpublished studies. </p> </section> <section id="CD011420-sec-0043"> <h4 class="title">Participants</h4> <p>People living with HIV are at increased risk of tuberculosis and may present with symptoms of tuberculosis but may also be asymptomatic or have symptoms not routinely associated with tuberculosis. We included participants who were adults (15 years and older is considered ‘adult' for purpose of tuberculosis surveillance) and HIV positive. We included studies in which there was a suspicion of tuberculosis among study participants based on the presence of signs and symptoms compatible with tuberculosis (studies with symptomatic participants), as well as studies that included participants who presented for medical care irrespective of signs and symptoms of tuberculosis (studies with unselected participants). Signs and symptoms of tuberculosis include cough, fever, weight loss, and night sweats. Participants who were known to have active tuberculosis and were taking anti‐tuberculosis drugs were not included. </p> </section> <section id="CD011420-sec-0044"> <h4 class="title">Index tests</h4> <p>We included studies that evaluated the lateral flow lipoarabinomannan (LF‐LAM) assay Alere Determine™ TB LAM Ag test (Abbott, Palatine, IL, USA, previous Alere Inc., Waltham, MA, USA) on urine samples. As of May 2019, the Alere Determine™ TB LAM Ag test was the only commercially available LF‐LAM assay that had been evaluated in published studies. </p> <p>We included studies that evaluated the test at the manufacturer's recommended threshold for positivity, i.e. grade 1 and above on the updated reference scale card with four band intensities graded on a scale of 1 to 4. For studies that used the prior reference scale card with band intensities graded on a scale of 1 to 5, we included those that evaluated the test at grade 2 and above corresponding to the current recommended positivity threshold. We excluded studies that did not use a positivity threshold corresponding to the manufacturer's recommendations. Results summarizing diagnostic accuracy at older thresholds (grade 1 on a scale of 1 to 5) can be found in the original review (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>). </p> </section> <section id="CD011420-sec-0045"> <h4 class="title">Target conditions</h4> <p>The target condition was active tuberculosis, which includes pulmonary and extrapulmonary tuberculosis. </p> </section> <section id="CD011420-sec-0046"> <h4 class="title">Reference standards</h4> <p>We required studies to diagnose tuberculosis using the following microbiological reference standard. </p> <p> <ul id="CD011420-list-0003"> <li> <p>‘Tuberculosis' is defined as a positive <i>M tuberculosis</i> culture or NAAT. </p> </li> <li> <p>‘Not tuberculosis' is defined as a negative <i>M tuberculosis</i> culture and NAAT (if performed). </p> </li> </ul> </p> <p>NAAT tests included: Enhanced Amplified Mycobacterium Tuberculosis Direct Test (E‐MTD, Gen‐Probe, San Diego, USA); Amplicor Mycobacterium tuberculosis Test (Amplicor, Roche Diagnostics, Basel, Switzerland); COBAS® TaqMan® MTB Test (Roche Diagnostics); GenoType MTBDR<i>plus</i> (HAIN Lifesciences, Nehren, Germany); Xpert® MTB/RIF assay (Cepheid, Sunnyvale, USA); and Xpert® MTB/RIF Ultra. </p> <p>We considered a higher quality reference standard to be one in which two or more specimen types were evaluated for tuberculosis diagnosis in all participants as part of a standardized study algorithm. We considered a lower quality reference standard to be one in which only one specimen type was evaluated for tuberculosis diagnosis, or if there was no algorithm defined to ensure a standardized approach for specimen collection and testing. </p> <p>A microbiological reference standard, primarily culture, is considered the best reference standard. We expected all studies to obtain sputum specimens and some studies to obtain additional specimens for culture. However, the primary concern with relying on sputum culture alone is that tuberculosis diagnosis may be missed for the following reasons: people living with HIV may not be able to provide sputum specimens of sufficient quality; sputum bacillary load is typically low in people living with HIV; and a substantial proportion of people with HIV‐associated tuberculosis cannot produce sputum at all (<a href="./references#CD011420-bbs2-0130" title="LawnSD , DhedaK , KerkhoffAD , PeterJG , DormanS , BoehmeCC , et al. Determine TB‐LAM lateral flow urine antigen assay for HIV‐associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infectious Diseases2013;13:407. ">Lawn 2013</a>), or have extrapulmonary tuberculosis without pulmonary tuberculosis. This means that index test TPs may be misclassified as FPs by sputum culture. Therefore, when evaluating LF‐LAM with respect to sputum culture, the number of FPs (classified as positive by the index test and negative by the reference test) may be increased and LF‐LAM specificity may be underestimated (<a href="./references#CD011420-bbs2-0131" title="LawnSD , KerkhoffAD , NicolPM , MeintjesG . Underestimation of the true specificity of the urine lipoarabinomannan (LAM) point‐of‐care diagnostic assay for HIV‐associated tuberculosis. Journal of Acquired Immune Deficiency Syndromes2015;69(4):e144‐6. ">Lawn 2015</a>). This misclassification may also lead to underestimation of sensitivity. Increasing the sensitivity of the reference standard by evaluating multiple specimens, including evaluating specimens from sites of disease for extrapulmonary tuberculosis, may reduce the number of cases of tuberculosis incorrectly classified as ‘not tuberculosis' by culture or NAAT if performed. </p> <p>In the original Cochrane Review, we additionally considered a ‘composite microbiological and clinical reference standard’ recognizing that microbiological reference standards alone may fail to detect tuberculosis in patients with tuberculosis. However, our original review found relatively little data using a composite reference standard; found heterogeneity in defining and applying composite reference standards; and found a relatively modest impact on pooled estimates of sensitivity and specificity comparing microbiological and composite reference standards. Results assessing diagnostic accuracy against a composite reference standard can be found in the original review (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>). </p> <p>Given the limitations of the reference standard, we might have considered pursuing latent class analysis (<a href="./references#CD011420-bbs2-0112" title="ChuH , ChenS , LouisTA . Random effects models in a meta‐analysis of the accuracy of two diagnostic tests without a gold standard. Journal of the American Statistical Association2009;104(486):512‐23. ">Chu 2009</a>; <a href="./references#CD011420-bbs2-0127" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD012768.pub2] ">Kohli 2018</a>). However, we lacked patient‐level data on the type of specimen and LAM is not site‐specific, meaning a positive LAM alone does not tell us whether the patient has pulmonary or extrapulmonary tuberculosis. </p> </section> </section> <section id="CD011420-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and ongoing). As mentioned, we only included published studies in this review. </p> <section id="CD011420-sec-0048"> <h4 class="title">Electronic searches</h4> <p>We performed literature searches up to 11 May 2018 in the following databases using the search terms reported in <a href="./appendices#CD011420-sec-0111">Appendix 4</a>: the Cochrane Infectious Diseases Group Specialized Register; MEDLINE (PubMed, from 1966); Embase (OVID, from 1947); Science Citation Index Expanded (SCI‐EXPANDED, from 1900), Conference Proceedings Citation Index‐ Science (CPCI‐S, from 1900), and BIOSIS Previews (from 1926), all three using the Web of Science platform; LILACS (BIREME, from 1982); and SCOPUS (from 1995). We also searched Clinicaltrials.gov and the search portal of the WHO International Clinical Trials Registry Platform (WHO ICTRP, <a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>) to identify ongoing trials, and ProQuest Dissertations &amp; Theses A&amp;l (from 1861) to identify relevant dissertations. We included search results from the original review and re‐evaluated previously included studies to determine if the studies met the refined inclusion criteria. </p> </section> <section id="CD011420-sec-0049"> <h4 class="title">Searching other resources</h4> <p>We further examined reference lists of relevant reviews and studies and searched the WHO websites. </p> </section> </section> <section id="CD011420-sec-0050"> <h3 class="title" id="CD011420-sec-0050">Data collection and analysis</h3> <section id="CD011420-sec-0051"> <h4 class="title">Selection of studies</h4> <p>We used Covidence systematic review software to manage the selection of studies (<a href="./references#CD011420-bbs2-0113" title="Veritas Health Innovation. Covidence systematic review software. Available at www.covidence.org. Melbourne: Veritas Health Innovation, 2017. ">Covidence 2017</a>). Two review authors (MS and SB) independently examined all titles and abstracts identified from the electronic search to determine potentially eligible studies. We obtained the full‐text articles of these potentially eligible studies and the same two review authors independently assessed inclusion based on predefined inclusion and exclusion criteria. We resolved disagreements through discussion and, if necessary, consulted a third review author (KRS). We included studies from the original review if still eligible according to the predefined eligibility criteria. We maintained a list of excluded studies and the reasons for exclusion, and recorded these details in the <a href="./references#CD011420-sec-0159" title="">Characteristics of excluded studies</a> table and we prepared a PRISMA diagram. </p> </section> <section id="CD011420-sec-0052"> <h4 class="title">Data extraction and management</h4> <p>We developed a standardized data extraction form and piloted the form on two of the included studies. Based on the pilot, we finalized the form (<a href="./appendices#CD011420-sec-0118">Appendix 5</a>). Then two review authors (MS and SB) independently extracted data from each included study on the following characteristics. </p> <p> <ul id="CD011420-list-0004"> <li> <p>Author, publication year, study design, country/countries, clinical setting (outpatient or inpatient). </p> </li> <li> <p>Participants: age, gender, HIV‐status, CD4 count, tuberculosis history, clinical status (asymptomatic, symptomatic). </p> </li> <li> <p>Quality Assessment of Diagnostic Accuracy Studies‐2 (QUADAS‐2) items.</p> </li> <li> <p>Cut‐off used for determining a positive index test result and the reference card used.</p> </li> <li> <p>Samples collected (sputum and/or extrapulmonary samples).</p> </li> <li> <p>Reference standard(s).</p> </li> <li> <p>The number of tuberculosis cases in the study.</p> </li> <li> <p>Number of TP, FN, FP, and TN values.</p> </li> <li> <p>Missing or unavailable test results.</p> </li> </ul> </p> <p>We assigned country income status (high income, upper‐ and lower‐middle income, and low income) as classified by the World Bank (<a href="./references#CD011420-bbs2-0169" title="WorldBank . World Bank Country Classifications by Income. Washington (District of Columbia): World Bank, 2018. ">World Bank 2018</a>). In addition, we classified a country as being high burden or not high burden for tuberculosis/HIV according to the post‐2015 era classification by the WHO (<a href="./references#CD011420-bbs2-0161" title="World Health Organization. Global Tuberculosis Report 2018. Licence: CC BY‐NC‐SA 3.0 IGO. Geneva: World Health Organization, 2018. ">WHO Global Tuberculosis Report 2018</a>). For studies that included both participants with HIV and without HIV infection, we extracted data only for participants with HIV. We contacted study authors for clarifications on the LF‐LAM positivity threshold used if data were missing. </p> <p>We used REDCap electronic data capture tools (<a href="./references#CD011420-bbs2-0125" title="HarrisPA , TaylorR , ThielkeR , PayneJ , GonzalezN , CondeJG . Research electronic data capture (REDCap)‐‐a metadata‐driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics2009;42(2):377‐81. ">Harris 2009</a>) hosted at OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark (<a href="./references#CD011420-bbs2-0151" title="Odense Patient data Explorative Network. OPEN. sdu.dk/en/Om_SDU/Institutter_centre/Klinisk_institut/Forskning/Forskningsenheder/open.aspx (accessed 10 June 2018). ">SDU Open</a>) to collect and manage study data. REDCap (Research Electronic Data Capture) is a secure, web‐based application designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless downloads to common statistical packages; and 4) procedures for importing data from external sources. With regard to the use of REDCap, the content in this review is solely the responsibility of the authors. </p> </section> <section id="CD011420-sec-0053"> <h4 class="title">Assessment of methodological quality</h4> <p>We used the QUADAS‐2 tool tailored to this review to assess the quality of the included studies (<a href="./references#CD011420-bbs2-0159" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , et al. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529–36. ">Whiting 2011</a>; <a href="./appendices#CD011420-sec-0119">Appendix 6</a>). QUADAS‐2 consists of four domains: patient selection, index test, reference standard, and flow and timing (flow and timing domain includes differential verification of tuberculosis status for study participants). We assessed all domains for risk of bias and the first three domains for concerns regarding applicability. As recommended, we first developed the guidance on how to appraise the questions in each domain. Then, one review author (SB) piloted the tool with two of the included studies and finalized the QUADAS‐2 tool. Two review authors (MS and SB) independently completed the QUADAS‐2 assessment. We resolved disagreements through discussion or consulted a third review author (KRS). We present the results of this quality assessment in the text, tables, and graphs. </p> </section> <section id="CD011420-sec-0054"> <h4 class="title">Statistical analysis and data synthesis</h4> <p>We performed descriptive analyses of the characteristics of the included studies using Stata 15 (<a href="./references#CD011420-bbs2-0154" title="StataCorp . Stata Statistical Software. Version 13. Texas: StataCorp LP, 2017. ">StataCorp 2017</a>), and presented key study characteristics in the ‘<a href="./references#CD011420-sec-0158" title="">Characteristics of included studies</a>' table. We used the number of TPs, FPs, FNs, and TNs to calculate the individual study estimates of sensitivity and specificity and their 95% confidence intervals (CIs). We presented individual study results graphically by plotting the estimates of sensitivity and specificity (and their 95% CIs) in forest plots using Review Manager 5 (RevMan 5) (<a href="./references#CD011420-bbs2-0148" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <p>We presented results at the current manufacturer reference scale card for test interpretation, with band intensities graded 1 to 4, and considered all test results at grade 1 and above as positive. The prior reference scale card with five band intensities was used in the original Cochrane Review with grade 2 considered as positivity threshold that corresponds to the current grade 1 band intensity (<a href="./appendices#CD011420-sec-0109">Appendix 2</a>). The original review also included several analyses at grade 1 which is no longer recommended for determining test positivity. To allow consistent comparisons, we converted results from older studies that used the ‘grade 2’ threshold and treated these as ‘grade 1’ in the updated review. As such, analyses labelled at ‘grade 2’ in the original Cochrane Review are in this review considered according to the new manufacturer reference card as ‘grade 1’. Studies in the original review that used the ‘grade 1’ threshold on the prior reference card were not included as this threshold is no longer recommended for determining test positivity. </p> <p>We grouped the studies evaluating LF‐LAM for: (I) diagnosis of tuberculosis in HIV‐positive people with signs and symptoms of tuberculosis i.e. ‘Studies with symptomatic participants' and (II) diagnosis of tuberculosis in HIV‐positive people, irrespective of signs and symptoms of tuberculosis i.e. ‘Studies with unselected participants'. </p> <p>When data were sufficient, we carried out meta‐analyses to estimate LF‐LAM pooled sensitivity and specificity with a bivariate random‐effects model (<a href="./references#CD011420-bbs2-0111" title="ChuH , ColeSR . Bivariate meta‐analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. Journal of Clinical Epidemiology2006;59(12):1331–2. ">Chu 2006</a>; <a href="./references#CD011420-bbs2-0147" title="ReitsmaJB , GlasAS , RutjesAW , ScholtenRJ , BossuytPM , ZwindermanAH . Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology2005;58(10):982‐90. ">Reitsma 2005</a>). This approach allowed us to calculate pooled sensitivity and specificity while dealing with potential sources of variation caused by: (1) imprecision of sensitivity and specificity estimates within individual studies; (2) correlation between sensitivity and specificity across studies; and (3) variation in sensitivity and specificity between studies. </p> <p>We estimated all models using a Bayesian approach implemented using OpenBUGS (<a href="./references#CD011420-bbs2-0134" title="LunnD , SpiegelhalterD , ThomasA , BestN . The BUGS project: Evolution, critique, and future directions. Statistics in Medicine2009;28:3049‐67. ">Lunn 2009</a>). Under the Bayesian approach, all unknown parameters must be provided a prior distribution that defines the range of possible values of the parameter and the weight of each of those values, based on information external to the data. Because most meta‐analyses involved few studies (eight or less), which could lead the model to be just identified, we chose to use low‐information prior distributions for most parameters and a more informative prior on the between‐study standard deviations which are particularly sensible in meta‐analyses with few studies (<a href="./references#CD011420-bbs2-0153" title="SpiegelhalterDJ , AbramsKR , MylesJP . Bayesian Approaches to Clinical Trials and Health Care Evaluation. New York: Wiley, 2004. ">Spiegelhalter 2004</a>). </p> <p>We defined prior distributions on the log‐odds scale over the pooled sensitivity and specificity parameters, their corresponding between‐study standard deviations (SDs) and the correlation between the sensitivities and specificities across studies. For the pooled log odds of the sensitivity or log odds of the specificity, we used a normal prior distribution with mean 0 and a variance of 4 (or a precision of 0.25). This corresponds to a roughly uniform distribution over the pooled sensitivity and pooled specificity on the probability scale. The 2.5% and 97.5% prior distribution quantiles for the pooled sensitivity or pooled specificity are 2.0% and 98.0%, slightly wider than for a standard normal distribution. For the between‐study precision we used a gamma distribution with a shape parameter of two and rate parameter of 0.5. This corresponds to a 95% prior credible interval (CrI) for the between‐study SD in the log odds of sensitivity or log odds of specificity ranging from roughly 0.29 to 1.44, corresponding to moderate to high values of between‐study heterogeneity. The resulting median 2.5% and 97.5% prior distribution quantiles for the predicted sensitivity or predicted specificity are 0.1% and 99.9%. Covariance terms followed a uniform prior distribution whose upper and lower limits were determined by the sensitivity of the two tests. We have summarized the models we used (including the prior distributions) and the OpenBUGS programs we used to estimate them in <a href="./appendices#CD011420-sec-0142">Appendix 7</a>. </p> <p>To study the sensitivity of our results to the choice of prior distributions given above, we considered alternative prior distributions that were less informative, which allowed a wider range of possible values. We increased the variance of the normal distributions over the pooled log odds of the sensitivity or specificity to 100. We used a uniform prior distribution ranging from zero to three over the between‐study SD on the log odds scale. We found that the pooled estimates remained roughly the same with these alternative priors, though the posterior CrIs were wider, as expected. We combined information from the prior distribution with the likelihood of the observed data, in accordance with Bayes’ theorem in the OpenBUGS program, which resulted in a sample from the posterior distribution of each unknown parameter. Using this sample, we calculated various descriptive statistics of interest. We estimated the median pooled sensitivity and specificity and their 95% CrI. The median or the 50% quantile is the value below which 50% of the posterior sample lies. We reported the median because the posterior distributions of some parameters may be skewed, and the median would be considered a better point estimate of the unknown parameter than the mean in such cases. The 95% CrI is the Bayesian equivalent of the classical (frequentist) 95% confidence interval (CI) (we indicated 95% CI for individual study estimates and 95% CrI for pooled study estimates as appropriate). The 95% CrI may be interpreted as an interval that has a 95% probability of capturing the true value of the unknown parameter given the observed data and the prior information. </p> <p>We also estimated the predicted sensitivity and specificity in a future study together with their 95% CrIs. The predicted estimate is our best guess for the estimate in a future study and is the same as the pooled estimate. The CrIs, however, may be different. These values were derived from the predicted region typically reported in a bivariate meta‐analysis plot. If there is no heterogeneity between the included studies, the CrI around the predicted estimate will be the same as the CrI around the pooled estimate. On the other hand, if there is considerable heterogeneity between studies, the CrI around the predicted estimate will be much wider than the CrI around the pooled estimate. We generated summary plots displaying the individual study estimates for sensitivity and specificity, the pooled estimate for sensitivity and specificity with the 95% credible region and the 95% prediction region using R (<a href="./references#CD011420-bbs2-0145" title="R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2018. ">R Statistical Computing 2018</a>). </p> <p>In our original review we evaluated the incremental change in sensitivity and specificity when combining LF‐LAM with smear microscopy or Xpert MTB/RIF (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>). We did not undertake analysis of incremental benefit in the current review as it was beyond the scope of this review, and data within published manuscripts were limited. </p> <section id="CD011420-sec-0055"> <h5 class="title">Approach to uninterpretable LF‐LAM results</h5> <p>We excluded uninterpretable test results from the meta‐analyses of sensitivity and specificity, but we reported the number and proportion of uninterpretable test results from each study when such data were available. </p> </section> </section> <section id="CD011420-sec-0056"> <h4 class="title">Investigations of heterogeneity</h4> <p>Initially, we investigated heterogeneity through visual examination of forest plots of sensitivities and specificities and through visual examination of the ROC plot of the raw data. When data were sufficient, we performed subgroup analyses with the following categorical covariates: clinical setting (inpatient versus outpatient); CD4 count (CD4 ≤ 200; CD4 ≤ 100; CD4 101‐200; CD4 &gt; 200 and; CD4 &gt; 100 cells per µL). To further investigate heterogeneity, we performed a subgroup analysis by the prevalence of tuberculosis in the studies and classified prevalence as greater than the median value versus less than or equal to the median value. We investigated heterogeneity separately for studies with symptomatic participants and studies with unselected participants. We generated the plots depicting the pooled results within CD4 count categories using R (<a href="./references#CD011420-bbs2-0145" title="R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2018. ">R Statistical Computing 2018</a>). </p> </section> <section id="CD011420-sec-0057"> <h4 class="title">Sensitivity analyses</h4> <p>We performed sensitivity analyses by limiting inclusion in the meta‐analysis to the following. </p> <p> <ul id="CD011420-list-0005"> <li> <p>Studies that avoided inappropriate exclusions, for example, studies that included participants who could not produce sputum. For this analysis we included studies that we scored as ‘yes' for the QUADAS‐2 question, "Did the study avoid inappropriate exclusions?" (low risk of bias for participant selection). </p> </li> <li> <p>Studies with a higher quality reference standard, for example studies that included two or more specimen types. For this analysis, we included studies that we scored as ‘yes’ for the QUADAS‐2 question, “Is the reference standard likely to correctly classify the target condition?” (low risk of bias for the reference standard). </p> </li> <li> <p>Studies that used only fresh urine specimens for LAM testing.</p> </li> <li> <p>Studies initially categorized as ‘studies among unselected participants’ that included more than 80% of symptomatic participants were re‐categorized as ‘studies with symptomatic participants’. We conducted this analysis to explore the possibility that these studies represented a comparable population to the studies of symptomatic participants even though participants were not explicitly enrolled in the study on the basis of specific tuberculosis symptoms. </p> </li> </ul> </p> </section> <section id="CD011420-sec-0058"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not carry out a formal assessment of publication bias using methods such as funnel plots or regression tests because such techniques have not been helpful for diagnostic test accuracy studies (<a href="./references#CD011420-bbs2-0135" title="MacaskillP , GatsonisC , DeeksJJ , HarbordRM , TakwoingiY . Chapter 10: Analysing and Presenting Results. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010. Available from http://srdta.cochrane.org/. ">Macaskill 2010</a>). </p> <section id="CD011420-sec-0059"> <h5 class="title">Assessment of the certainty of the evidence</h5> <p>We assessed the certainty of evidence as recommended using the GRADE approach (<a href="./references#CD011420-bbs2-0104" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>; <a href="./references#CD011420-bbs2-0149" title="SchünemannHJ , OxmanAD , BrozekJ , GlasziouP , JaeschkeR , VistGE , et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ2008;336(7653):1106‐11. ">Schünemann 2008</a>; <a href="./references#CD011420-bbs2-0150" title="SchünemannHJ , MustafaR , BrozekJ , SantessoN , Alonso‐CoelloP , GuyattG , et al. GRADE Working Group. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. Journal of Clinical Epidemiology2016 August;76:89‐98. ">Schünemann 2016</a>). As recommended, we rated the certainty of evidence as either high (not downgraded), moderate (downgraded by one level), low (downgraded by two levels), or very low (downgraded by more than two levels) based on five domains: risk of bias, indirectness, inconsistency, imprecision, and publication bias. For each outcome, the certainty of evidence started as high when there were high‐quality observational studies (cross‐sectional or cohort studies) that enrolled participants with diagnostic uncertainty. If we found a reason for downgrading, we used our judgement to classify the reason as either serious (downgraded by one level) or very serious (downgraded by two levels). </p> <p>Four review authors (SB, MS, ND, and KRS) discussed judgments and applied GRADE in the following way. </p> <p> <ul id="CD011420-list-0006"> <li> <p>Risk of bias: we used QUADAS‐2 to assess risk of bias.</p> </li> <li> <p>Indirectness: we used QUADAS‐2 for concerns of applicability and looked for important differences between the populations studied (for example, in the spectrum of disease), the setting, and index test and asked are differences sufficient to lower certainty in results? </p> </li> <li> <p>Inconsistency: GRADE recommends downgrading for unexplained inconsistency in sensitivity and specificity estimates. We carried out pre‐specified analyses to investigate potential sources of heterogeneity and did not downgrade when we felt we could explain inconsistency in the accuracy estimates. </p> </li> <li> <p>Imprecision: we considered a precise estimate to be one that would allow a clinically meaningful decision. We considered the width of the CrI, and asked ourselves, “Would we make a different decision if the lower or upper boundary of the CrI represented the truth?” In addition, we worked out projected ranges for TP, FN, TN, and FP for a given prevalence of tuberculosis and made judgements on imprecision from these calculations. </p> </li> <li> <p>Publication bias: we rated publication bias as undetected (not serious) for several reasons including the comprehensiveness of the literature search and extensive outreach to tuberculosis researchers to identify studies. </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011420-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011420-sec-0060"></div> <section id="CD011420-sec-0061"> <h3 class="title" id="CD011420-sec-0061">Results of the search</h3> <p>We identified 15 unique studies that met the inclusion criteria of this review. We included data from six published manuscripts from the original WHO Guidelines (<a href="./references#CD011420-bbs2-0163" title="World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. WHO/HTM/TB/2015.25. Geneva: World Health Organization, 2015. ">WHO Lipoarabinomannan Policy Guidance 2015</a>), and Cochrane Review (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>) that met the refined inclusion criteria (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0002" title="DrainPK , LosinaE , ColemanSM , GiddyJ , RossD , KatzJN , et al. Value of urine lipoarabinomannan grade and second test for optimising clinic‐based screening for HIV‐associated pulmonary tuberculosis. Journal of Acquired Immune Deficiency Syndromes2015;68(3):274‐80. ">Drain 2015a</a>; <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>; <a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a>; <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>), and nine new studies identified in the updated search (<a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a>; <a href="./references#CD011420-bbs2-0004" title="FloridiaM , CiccacciF , AndreottiM , HassaneA , SidumoZ , MagidNA , et al. Tuberculosis case finding with combined rapid point‐of‐care assays (Xpert MTB/RIF and Determine TB LAM) in HIV‐positive individuals starting antiretroviral therapy in Mozambique. Clinical Infectious Diseases2017;65(11):1878‐83. ">Floridia 2017</a>; <a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a>; <a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a>; <a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a>; <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a>; <a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>; <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>). Of six previously included studies, three were excluded because they did not use the currently recommended threshold for test positivity (<a href="./references#CD011420-bbs2-0019" title="BalchaTT , WinqvistN , SturegårdE , SkogmarS , ReepaluA , JemalZH , et al. Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV‐positive adults in Ethiopian health centres. Tropical Medicine &amp; International Health2014;19(6):734‐42. ">Balcha 2014</a>; <a href="./references#CD011420-bbs2-0035" title="DrainPK , LosinaE , ColemanSM , GiddyJ , RossD , KatzJN , et al. Diagnostic accuracy of a point‐of‐care urine test for tuberculosis screening among newly‐diagnosed HIV‐infected adults: a prospective, clinic‐based study. BMC Infectious Diseases2014;14:110. ">Drain 2014a</a>; <a href="./references#CD011420-bbs2-0061" title="LawnSD , KerkhoffAD , VogtM , WoodR . Diagnostic accuracy of a low‐cost, urine antigen, point‐of‐care screening assay for HIV‐associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infectious Diseases2012;12(3):201‐9. ">Lawn 2012a</a>); one previously included abstract (<a href="./references#CD011420-bbs2-0064" title="LawnSD , KerkhoffA , BurtonR , SchutzC , vanWykG , VogtM , et al. Massive diagnostic yield of HIV‐associated tuberculosis using rapid urine assays in South Africa. Conference on Retroviruses and Opportunistic Infections (CROI). Boston (MA), 2014. ">Lawn 2014</a>) was added as an updated published manuscript (<a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a>); one abstract remained unpublished (<a href="./references#CD011420-bbs2-0018" title="AndrewsB , MuchemwaL , LakhiS , BwalyaM , MabulaC , ChipiiG , et al. Validation of a clinical prediction score and performance of urine lipoarabinomannan test for detecting tuberculosis bacteremia in HIV‐positive patients with severe sepsis. American Thoracic Society. 2014:A2559. ">Andrews 2014</a>); and one abstract was published but did not provide diagnostic accuracy data (<a href="./references#CD011420-bbs2-0036" title="DrainP , GroblerA , GounderL , SahidF , WilsonD , BassettI , et al. Rapid urine lipoarabinomannan testing after two months of tuberculosis treatment independently predicts mortality in a resource‐limited setting. 44th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease. Paris, 2013; Vol. 17 (Suppl 2):S264. ">Drain 2014b</a>). Eight studies evaluated the accuracy of LF‐LAM for tuberculosis diagnosis in participants with signs and symptoms suggestive of tuberculosis. Seven studies evaluated the accuracy of LF‐LAM for diagnosis of unselected participants without assessment of symptoms (i.e. patients may or may not have had tuberculosis signs and symptoms at enrolment). </p> <p><a href="#CD011420-fig-0001">Figure 1</a> shows the flow of studies in the review. We listed the excluded studies and the reasons for their exclusion in the ‘<a href="./references#CD011420-sec-0159" title="">Characteristics of excluded studies</a>' section. All studies were written in English. </p> <div class="figure" id="CD011420-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD011420-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD011420-sec-0062"> <h3 class="title">Methodological quality of included studies</h3> <p>Risk of bias and applicability concerns for each of the 15 included studies is shown in <a href="#CD011420-fig-0002">Figure 2</a>; <a href="#CD011420-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011420-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Studies with symptomatic participants ‐ Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study." data-id="CD011420-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Studies with symptomatic participants ‐ Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study. </p> </div> </div> </div> <div class="figure" id="CD011420-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Studies with unselected participants ‐ Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study." data-id="CD011420-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Studies with unselected participants ‐ Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study. </p> </div> </div> </div> <section id="CD011420-sec-0063"> <h4 class="title">Studies with symptomatic participants</h4> <p>Eight studies were included that evaluated LF‐LAM for tuberculosis diagnosis among symptomatic participants suspected of tuberculosis. Risk of bias and applicability concerns for the studies with symptomatic participants are shown in <a href="#CD011420-fig-0002">Figure 2</a>. </p> <p>In the patient selection domain, we considered six studies (75%) to be at high risk of bias because: (1) the study excluded all smear‐positive participants (<a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a>); (2) the studies excluded participants who could not expectorate or produce sputum despite sputum induction (<a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a>; <a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a>; <a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>); (3) the study excluded participants from analysis if, in the absence of a positive reference standard result, there was one sample with no Xpert MTB/RIF result or contaminated result (culture) (<a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a>); (4) the study only included patients suspected of extrapulmonary tuberculosis and excluded patients suspected of pulmonary tuberculosis (<a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a>); (5) the study only included participants with pericardial effusion and suspected tuberculosis and excluded participants suspected of other forms of tuberculosis (<a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>). All studies were cross‐sectional, cohort or randomized controlled studies. Regarding applicability, seven studies (88%) had low concern in the patient selection domain because the studies included the appropriate participants and settings. We judged one study (12%) to have high concern for applicability as the participants did not resemble people with presumed HIV/tuberculosis co‐infection i.e. participants were smear‐negative HIV‐positive and HIV‐negative patients with a Karnofsky Performance score &lt; 50 (<a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a>). </p> <p>In the index test domain, we judged one study (12%) at high risk of bias as the study used grade 2 (on the updated reference scale card) as the test positivity threshold, as opposed to the current manufacturer recommendation to use grade 1 to define test positivity (<a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a>). We also considered this study to have high concern of applicability because the test procedure was inconsistent with the manufacturers' recommendations (<a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a>). The remaining studies all used the recommended threshold for positivity and interpreted the test without knowledge of the results of the reference standard, and we considered them to have low concern for applicability. </p> <p>In the reference standard domain, we considered seven studies (88%) to be at high risk of bias because: (1) the studies did not include testing of any extrapulmonary specimens (<a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a>, <a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>); (2) the study did not include testing of any respiratory samples (<a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a>); (3) the study only tested respiratory samples for some of the participants (<a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>); (4) the study only tested extrapulmonary specimens in addition to respiratory samples for some of the participants (<a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a>); (5) health providers selected the sites for testing based on their own clinical suspicion (<a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>). We deemed three studies at high concern for applicability as they lacked a study or protocol directed testing (<a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>; <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>). In these studies, health providers selected the sites for testing based on their own clinical suspicion, and it was unclear if their choice of reference standard would correctly classify tuberculosis. </p> <p>In the flow and timing domain, we considered four studies (50%) to be at high risk of bias because not all participants received the same reference standard (<a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a>; <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>), or because not all participants were included in the two‐by‐two tables ( <a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a>; <a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>). We judged the remaining studies to be at low risk of bias because all participants received the index test, the same reference standard and no participants were excluded from the two‐by‐two table. </p> </section> <section id="CD011420-sec-0064"> <h4 class="title">Studies with unselected participants</h4> <p>Seven studies contributed data for the purpose of evaluating LF‐LAM for tuberculosis diagnosis among unselected participants who may or may not have tuberculosis signs or symptoms. Risk of bias and applicability concerns for the studies with symptomatic participants are shown in <a href="#CD011420-fig-0003">Figure 3</a>. </p> <p>In the patient selection domain, we considered four studies (57%) to be at high risk of bias because these studies excluded participants who could not expectorate or produce sputum samples (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0002" title="DrainPK , LosinaE , ColemanSM , GiddyJ , RossD , KatzJN , et al. Value of urine lipoarabinomannan grade and second test for optimising clinic‐based screening for HIV‐associated pulmonary tuberculosis. Journal of Acquired Immune Deficiency Syndromes2015;68(3):274‐80. ">Drain 2015a</a>; <a href="./references#CD011420-bbs2-0004" title="FloridiaM , CiccacciF , AndreottiM , HassaneA , SidumoZ , MagidNA , et al. Tuberculosis case finding with combined rapid point‐of‐care assays (Xpert MTB/RIF and Determine TB LAM) in HIV‐positive individuals starting antiretroviral therapy in Mozambique. Clinical Infectious Diseases2017;65(11):1878‐83. ">Floridia 2017</a>; <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>). All studies were cross‐sectional or cohort studies. Regarding applicability, we judged that all studies (100%) included the appropriate participants and settings. </p> <p>In the index test domain, we considered all studies at low risk of bias as all studies used LF‐LAM, pre‐specified the grade used for positivity, and interpreted the test at the recommended positivity threshold without knowledge of the results of the reference standard. We considered the test conduct and interpretation in all studies to be applicable. </p> <p>In the reference standard domain, we considered five studies (71%) to be at high risk of bias because these studies did not include microbiological testing on extrapulmonary specimens (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0002" title="DrainPK , LosinaE , ColemanSM , GiddyJ , RossD , KatzJN , et al. Value of urine lipoarabinomannan grade and second test for optimising clinic‐based screening for HIV‐associated pulmonary tuberculosis. Journal of Acquired Immune Deficiency Syndromes2015;68(3):274‐80. ">Drain 2015a</a>; <a href="./references#CD011420-bbs2-0004" title="FloridiaM , CiccacciF , AndreottiM , HassaneA , SidumoZ , MagidNA , et al. Tuberculosis case finding with combined rapid point‐of‐care assays (Xpert MTB/RIF and Determine TB LAM) in HIV‐positive individuals starting antiretroviral therapy in Mozambique. Clinical Infectious Diseases2017;65(11):1878‐83. ">Floridia 2017</a>; <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>; <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>). <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a> also did not report if the reference standard results were interpreted without knowledge of the index test result. One study (<a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>) did not report if they speciated mycobacteria isolates and was judged to have unclear concern for applicability. We judged the remaining six studies to be of low concern in terms of applicability. </p> <p>In the flow and timing domain, we considered two studies (29%) to be at high risk of bias because the studies collected specimens for index and reference standard tests up to six months apart (<a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a>; <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>), and <a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a> excluded clinical tuberculosis cases from analysis. We considered the remaining five studies (71%) to be at low risk of bias because all participants received the index test and the same reference standard, and no participants enrolled were excluded from the two‐by‐two table. </p> </section> </section> <section id="CD011420-sec-0065"> <h3 class="title" id="CD011420-sec-0065">Findings</h3> <p>The 15 included studies involved 6814 participants, 1761 (26%) with tuberculosis. Eight studies evaluated the accuracy of LF‐LAM for tuberculosis diagnosis in participants with signs and symptoms suggestive of tuberculosis involving 3449 participants, 1277 (37%) with tuberculosis. Seven studies evaluated the accuracy of LF‐LAM for diagnosis of unselected participants that may or may not have had tuberculosis signs and symptoms at enrolment involving 3365 participants, 432 (13%) with tuberculosis. </p> <p>All studies were performed in countries with a high tuberculosis/HIV burden (<a href="./references#CD011420-bbs2-0161" title="World Health Organization. Global Tuberculosis Report 2018. Licence: CC BY‐NC‐SA 3.0 IGO. Geneva: World Health Organization, 2018. ">WHO Global Tuberculosis Report 2018</a>), and classified as low‐income or middle‐income countries (<a href="./references#CD011420-bbs2-0169" title="WorldBank . World Bank Country Classifications by Income. Washington (District of Columbia): World Bank, 2018. ">World Bank 2018</a>). We noted substantial differences in the studies for the following characteristics: type of population (‘studies with symptomatic participants' and ‘studies with unselected participants'); setting (inpatients versus outpatients); median CD4 cell count; tuberculosis prevalence; inclusion and exclusion of participants based on whether or not they could produce sputa; and whether patients were evaluated for pulmonary tuberculosis, extrapulmonary tuberculosis, or both. The key study characteristics are summarized in <a href="#CD011420-tbl-0003">Table 1</a> (Summary characteristics of included studies) and in <a href="./references#CD011420-sec-0158" title="">Characteristics of included studies</a>. </p> <div class="table" id="CD011420-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (% symptom)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median CD4 cell count per µL (IQR)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TB prevalence % (n/N)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Did the study avoid inappropriate exclusion?</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specimens collected</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High‐quality reference standard<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unique study characteristics</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>HIV‐positive adults with signs and symptoms of TB</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b><br/> Two of four TB‐related symptoms (cough, fever weight loss, night sweat) for &gt; 2 weeks; smear microscopy negative x 2 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168 (89 to 256)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63%<br/> (57/90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); HIV positive (93.2%); targeting a relatively well outpatient population; Karnofsky performance score &gt; 50 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Cough &gt; 2 weeks or any cough and one of weight loss, night sweats or fever; severely ill; CD4&lt; 200 or BMI below 17 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients (33%); Inpatients (67%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 (43 to 214)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57% (156/275)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples; urine Xpert only for patients without sputum available</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 15 years); LAM‐guided treatment; excluded many participants from analysis<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Suggestive of extrapulmonary TB, not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33%<br/> (29/67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Extrapulmonary samples only, no sputum samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 14 years), HIV‐positive (68%); excluded patients with concomitants active pulmonary TB </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Any of cough, fever weight loss, night sweat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients (45%); Inpatients (55%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 (41 to 337)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37%<br/> (367/997) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples; Blood culture for all</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); multisite; large sample size.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Presence of a pericardial effusion and suspected of pericardial TB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139<br/> (81 to 249) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%<br/> (36/38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Extrapulmonary samples (pericardial effusion); pulmonary samples for some</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); HIV‐positive (74%); excluded participants from analysis affecting specificity<sup>c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Any of cough, fever weight loss, night sweat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (47 to 197) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48%<br/> (116/241) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant pulmonary samples; clinically relevant extrapulmonary samples. No study defined algorithm. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); multisite; TB diagnostic work‐up was not standardized but up to clinical judgements </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Any of cough, fever weight loss, night sweat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210<br/> (103 to 375) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32%<br/> (181/569) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); multisite; nested within a randomized, parallel‐arm trial.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Any of cough, fever weight loss, night sweat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> <p>(26 to 198)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29%<br/> (342/1172) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples; clinically relevant extrapulmonary samples. No study defined algorithm.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); multisite; LAM arm of a randomized controlled trial.</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>HIV‐positive adults irrespective of signs and symptoms of TB</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>91% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients (85%); Inpatients (15%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/> (35 to 256) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12%<br/> (55/469) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); majority symptomatic.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0002" title="DrainPK , LosinaE , ColemanSM , GiddyJ , RossD , KatzJN , et al. Value of urine lipoarabinomannan grade and second test for optimising clinic‐based screening for HIV‐associated pulmonary tuberculosis. Journal of Acquired Immune Deficiency Syndromes2015;68(3):274‐80. ">Drain 2015a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>proportion symptomatic not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/> (107 to 379) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17%<br/> (54/320) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0004" title="FloridiaM , CiccacciF , AndreottiM , HassaneA , SidumoZ , MagidNA , et al. Tuberculosis case finding with combined rapid point‐of‐care assays (Xpert MTB/RIF and Determine TB LAM) in HIV‐positive individuals starting antiretroviral therapy in Mozambique. Clinical Infectious Diseases2017;65(11):1878‐83. ">Floridia 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>34% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278<br/> (142 to 395) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%<br/> (90/972) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 15 years). LAM‐guided treatment.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>53% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111<br/> (56 to 161) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%<br/> (40/408) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples; blood culture for all</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); CD4 &lt; 200; reference standard included any sample taken within six months from enrolment. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>19% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437<br/> (342 to 565) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%<br/> (3/266) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pregnant women (&gt; 16 years) attending ANC; healthy population; one person with CD4&lt; 400; Few TB cases (n = 3). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>91% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149<br/> (55‐312) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33%<br/> (139/413) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples; Blood culture for all; Clinically relevant extrapulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years). Included many samples from different sites</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>33% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients (90%); Inpatients (10%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270<br/> (128 to 443) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%<br/> (54/517) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conducted in Myanmar. Adults (median age 34). Reference standard included samples taken within six months from enrolment. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations: LF‐LAM:</b> lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); <b>ANC:</b> antenatal clinic; <b>BMI:</b> body mass index; <b>IQR:</b> interquartile range; <b>TB:</b> tuberculosis; <b>Xpert:</b> Xpert MTB/RIF<br/> <sup>a</sup>For a microbiological reference standard, we considered a higher quality reference standard to be one in which two or more specimen types were evaluated for TB diagnosis in all participants as part of a defined standardized study algorithm.<br/> <sup>b</sup><a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a> excluded participants from analysis if missing Xpert results or culture contaminated for any of the samples in the absence of a positive result; overall samples size 474 (156 with TB); 275 included in analysis (156 with TB).<br/> <sup>c</sup><a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a> excluded a large number of non‐TB participants from analysis; Overall samples size 102 (36 with TB); 38 included for analysis (36 TB cases). </p> </div> </div> <p><a href="#CD011420-tbl-0004">Table 2</a> presents pooled sensitivity and specificity results for LF‐LAM grouped by the type of population, ‘studies among symptomatic participants' and ‘studies among unselected participants’. </p> <div class="table" id="CD011420-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">LF‐LAM pooled sensitivity and specificity for TB diagnosis, by study population</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Type of analysis </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Symptomatic participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Unselected participants </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies (total participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with TB (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies (total participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with TB (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall accuracy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies</p> <p>(3449)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1277</p> <p>(37%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42%</p> <p>(31% to 55%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91%</p> <p>(85% to 95%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 studies</p> <p>(3365)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>432</p> <p>(13%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35%</p> <p>(22% to 50%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> <p>(89% to 98%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>By setting</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies</p> <p>(2253)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>868</p> <p>(39%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52%<br/> (40% to 64%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87%<br/> (78% to 93%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>(537)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> <p>(30%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62%<br/> (41% to 83%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84%<br/> (48% to 96%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(1196)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409</p> <p>(34%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29%</p> <p>(17% to 47%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96%</p> <p>(91% to 99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies</p> <p>(2828)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273</p> <p>(10%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31%</p> <p>(18% to 47%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> <p>(87% to 99%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>By CD4 cell</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 &gt; 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>(738)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> <p>(22%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16%<br/> (8% to 31%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94%<br/> (81% to 97%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>a</sup> </p> <p>(156)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(1825)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>722</p> <p>(40%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45%<br/> (31% to 61%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89%<br/> (77% to 94%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(706)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> <p>(12%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26%<br/> (9% to 56%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96%<br/> (87% to 98%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 &gt; 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(1519)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>425</p> <p>(28%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17%<br/> (10% to 27%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%<br/> (89% to 98%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(952)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> <p>(12%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%<br/> (10% to 35%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98%<br/> (95% to 99%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(1239)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>512</p> <p>(41%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54%<br/> (38% to 69%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88%<br/> (77% to 94%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>(417)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(31%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47%<br/> (40% to 64%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%<br/> (77% to 96%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 101‐199</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(586)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> <p>(36%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24%<br/> (14% to 38%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%<br/> (77 to 96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study</p> <p>(103)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> <p>(13%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>By CD4 and setting</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 200</p> <p>inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(1009)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> <p>(34%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54%</p> <p>(34% to 73%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> <p>(58% to 91%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>c</sup> </p> <p>(54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> <p>(26%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 100</p> <p>inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(734)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> <p>(37%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61%</p> <p>(40% to 78%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81%</p> <p>(61% to 91%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(200)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> <p>(42%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57%</p> <p>(33% to 79%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%</p> <p>(69% to 97%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 101‐199</p> <p>inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(275)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> <p>(28%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32%</p> <p>(16% to 57%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81%</p> <p>(55% to 92%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>d</sup> </p> <p>(9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> <p>(44%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 200</p> <p>outpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>f</sup> </p> <p>(249)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> <p>(39%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(652)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(10%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21%</p> <p>(8% to 48%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96%</p> <p>(89% to 99%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 100</p> <p>outpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>g</sup> </p> <p>(121)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(40%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(217)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> <p>(21%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> <p>(20 to 64)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87%</p> <p>(68 to 94)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 101‐199</p> <p>outpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>h</sup> </p> <p>(128)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> <p>(40%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>e</sup> </p> <p>(94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> <p>(10%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations: LF‐LAM:</b> lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); <b>Crl:</b> credible interval; <b>TB:</b> tuberculosis.<br/> <sup>a</sup><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, Sensitivity 27% (6% to 61%); Specificity 99% (96% to 100%); <sup>b</sup><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, Sensitivity 38% (14% to 68%); Specificity 99% (94% to 100%); <sup>c</sup><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, Sensitivity 64% (35% to 87%); Specificity 82% (67% to 93%); <sup>d</sup><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, Sensitivity 75% (19% to 99%); Specificity 100% (48% to 100%); <sup>e</sup><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, Sensitivity 22% (3% to 60%); Specificity 99% (94% to 100%); <sup>f</sup><a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>, Sensitivity 24% (16% to 33%); Specificity 94% (89% to 97%); <sup>g</sup><a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>, Sensitivity 30% (18% to 46%); Specificity 93% (85% to 98%); <sup>h</sup><a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>, Sensitivity 18% (8% to 31%); Specificity 95% (87% to 99%). </p> </div> </div> <section id="CD011420-sec-0066"> <h4 class="title">I. Diagnostic accuracy of LF‐LAM for tuberculosis diagnosis in HIV‐positive adults with signs and symptoms of tuberculosis </h4> <p>Of the 15 included studies, eight evaluated the accuracy of LF‐LAM for tuberculosis diagnosis in participants with signs and symptoms suggestive of tuberculosis (<a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a>; <a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a>; <a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a>; <a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a>; <a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>; <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>). The suggestive signs and symptoms of tuberculosis varied from study to study, as described in <a href="#CD011420-tbl-0003">Table 1</a> and in <a href="./references#CD011420-sec-0158" title="">Characteristics of included studies</a>, but were often based on any of cough, fever, weight loss, or night sweats as per the WHO symptom screening rule <a href="./references#CD011420-bbs2-0162" title="World Health Organization Stop TB Dept Dept of HIV/AIDS. Guidelines for intensified tuberculosis case‐finding and isoniazid preventive therapy for people living with HIV in resource‐constrained settings. Geneva: World Health Organization, 2011. ">WHO ICF 2011</a>. The tuberculosis prevalence in the study population ranged from 29% to 63%. Two studies were conducted exclusively among patients with presumed extrapulmonary tuberculosis (<a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a>; <a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>). Four studies were conducted exclusively in an inpatient setting (<a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a>; <a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>; <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>); two studies exclusively in an outpatient setting (<a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a>; <a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>); and two studies in both inpatient and outpatient settings (<a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a>; <a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a>). The median CD4 cell count ranged from 81 to 210 cells per µL across the eight studies, lower in studies evaluating inpatients (median CD4 between 81 to 139 cells per µL) compared to studies evaluating outpatients (median CD4 was 168 to 210 cells per µL). See <a href="#CD011420-tbl-0003">Table 1</a> and <a href="./references#CD011420-sec-0158" title="">Characteristics of included studies</a>. </p> <section id="CD011420-sec-0067"> <h5 class="title">Primary analysis, LF‐LAM for tuberculosis in HIV‐positive adults with signs and symptoms of tuberculosis </h5> <p>For determining the overall accuracy of LF‐LAM in HIV‐positive adults with signs and symptoms of tuberculosis, eight studies provided data for 3449 participants, including 1277 (37%) with tuberculosis. Sensitivity estimates ranged from 23% to 68%, and specificity estimates from 75% to 100% (<a href="#CD011420-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD011420-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among symptomatic participants. The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD011420-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among symptomatic participants. The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> </div> <p><a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a> evaluated diagnostic accuracy for extrapulmonary tuberculosis (all forms) exclusively and had the highest sensitivity of 68%. <a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a> evaluated accuracy for pericardial tuberculosis and found sensitivity of 33%. Sensitivity was lowest in the studies by <a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a> and <a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a> that both reported a sensitivity of 23%. Differences between these studies and the other studies in this analysis were the setting (outpatient only), focus on pulmonary tuberculosis (no extrapulmonary samples were taken), and exclusion of participants unable to produce sputum. In particular, <a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a> included smear‐negative participants with presumed tuberculosis and a small number of HIV‐negative participants. <a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a> further excluded participants with a low Karnofsky score in order to target relatively well outpatients, where smear‐negative tuberculosis is often seen. Specificity was lowest for <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a> a study that included only inpatients and differed from other studies in that both sputum and non‐sputum‐based sampling was performed at the discretion of the attending clinical team and not study directed. <a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a> reported the highest specificity of 100%. This study, as mentioned, differed from others by evaluating accuracy only for pericardial tuberculosis. The authors further excluded a number of participants in the analysis for unknown reasons and reported two true negatives and zero false positives that may have inflated specificity. The pooled sensitivity and specificity (95% credible interval (CrI)) were 42% (31% to 55%) and 91% (85% to 95%) (<a href="#CD011420-tbl-0004">Table 2</a>). <a href="./appendices#CD011420-sec-0144">Appendix 8</a> presents the pooled and predicted sensitivity and specificity estimates together with the credible and prediction regions for LF‐LAM for tuberculosis detection. Prediction intervals were very wide in all meta‐analysis models indicating between‐study heterogeneity (data not shown). </p> </section> <section id="CD011420-sec-0068"> <h5 class="title">Uninterpretable index test results</h5> <p>Studies reported few uninterpretable test results. <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a> reported that 1% to 2% of 423 tests remained ‘indeterminate' (defined as a broken band in the patient window) after repeat testing. <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a> reported that 0.3% (3/1172) test results remained ‘invalid' after a repeat test (defined as no control band identified in the patient window or a broken/ incomplete band in the patient window). <a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a> reported that fewer than 1% of LF‐LAM strip tests failed on the first attempt and required a second strip to produce valid results. Four studies reported that a valid LF‐LAM result was obtained on the first attempt for all tests (<a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a>; <a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a>; <a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a>; <a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a>), and one study did not provide information on uninterpretable tests (<a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>). </p> </section> <section id="CD011420-sec-0069"> <h5 class="title">Investigations of heterogeneity</h5> <section id="CD011420-sec-0070"> <h6 class="title">LF‐LAM accuracy among symptomatic participants, stratified by setting</h6> <section id="CD011420-sec-0071"> <p><b>LF‐LAM accuracy in inpatient settings</b></p> <p>Six studies were conducted among inpatients involving 2253 participants, 868 (39%) with tuberculosis (<a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a>; <a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a>; <a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a>; <a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>; <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>). Sensitivity estimates ranged from 33% to 69% and specificity estimates ranged from 75% to 100% (<a href="#CD011420-fig-0005">Figure 5</a>). The highest sensitivity (69%) was reported by <a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a> with a relatively low specificity (78%). This study enrolled inpatients with tuberculosis symptoms who had at least one of the following features: who were severely ill or who had CD4 &lt; 200 cell per µL (median CD4 109) or who had a low body mass index (BMI). The study did not include microbiological or histological evaluation of extrapulmonary specimens for tuberculosis in their reference standard, which may have led to LAM‐positive participants with extrapulmonary tuberculosis being misclassified as ‘false‐positive’ and lowered specificity. <a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a> reported the lowest sensitivity (33%) and a specificity of 100%. As mentioned, this study evaluated accuracy for pericardial tuberculosis and excluded participants from specificity analysis that may have affected the specificity estimate. The pooled sensitivity and specificity (95% CrI) among inpatients were 52% (40% to 64%) and 87% (78% to 93%) (<a href="#CD011420-tbl-0004">Table 2</a>). </p> <div class="figure" id="CD011420-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among symptomatic participants, by health care setting. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. The individual studies are ordered by decreasing sensitivity. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD011420-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among symptomatic participants, by health care setting. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. The individual studies are ordered by decreasing sensitivity. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> </div> </section> <section id="CD011420-sec-0072"> <p><b>LF‐LAM accuracy in outpatient settings</b></p> <p>Four studies were conducted among outpatients involving 1196 participants, 409 (34%) with tuberculosis (<a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a>; <a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a>; <a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014;</a><a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>). Sensitivity estimates ranged from 18% to 58% and specificity estimates ranged from 93% to 99% (<a href="#CD011420-fig-0005">Figure 5</a>). The highest sensitivity (58%) was reported by <a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a> where outpatients included were severely ill, or had a CD4 &lt; 200 cell per µL, or had a low BMI below 17 kg/m<sup>2</sup>. Among outpatients, pooled sensitivity and specificity were 29% (17% to 47%) and 96% (91% to 99%) (<a href="#CD011420-tbl-0004">Table 2</a>). </p> </section> </section> <section id="CD011420-sec-0073"> <h6 class="title">LF‐LAM accuracy among symptomatic participants, stratified by CD4 count</h6> <p>We included five studies in the analyses by CD4 count (<a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a>; <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>). See <a href="#CD011420-fig-0006">Figure 6</a> and <a href="#CD011420-fig-0007">Figure 7</a>. </p> <div class="figure" id="CD011420-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies with symptomatic participants, stratified by CD4 (CD4 &gt; 200 and CD4 ≤ 200; CD4 &gt; 100 and CD4 ≤ 100). The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD011420-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies with symptomatic participants, stratified by CD4 (CD4 &gt; 200 and CD4 ≤ 200; CD4 &gt; 100 and CD4 ≤ 100). The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> </div> <div class="figure" id="CD011420-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Plot by CD4 of diagnostic accuracy in adults with signs and symptoms of tuberculosis.(A) Sensitivity by CD4 strata; (B) Specificity by CD4 strata. The circle represents the pooled estimates (median), with bars representing 95% credible intervals." data-id="CD011420-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Plot by CD4 of diagnostic accuracy in adults with signs and symptoms of tuberculosis.</p> <p>(A) Sensitivity by CD4 strata; (B) Specificity by CD4 strata. The circle represents the pooled estimates (median), with bars representing 95% credible intervals. </p> </div> </div> </div> <section id="CD011420-sec-0074"> <p><b>LF‐LAM accuracy stratified by CD4 &gt; 200 cells per µL and ≤ 200 cells per µL</b></p> <p>Three studies evaluated LF‐LAM in participants with CD4 &gt; 200 cells per µL (<a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a>; <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>). Sensitivity estimates ranged from 9% to 27% and specificity estimates ranged from 83% to 99% (<a href="#CD011420-fig-0006">Figure 6</a>). In the four studies that evaluated participants with CD4 ≤ 200 cells per µL, sensitivity estimates ranged from 24% to 58% and specificity estimates ranged from 72% to 95% (<a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a>; <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>), (<a href="#CD011420-fig-0006">Figure 6</a>). The pooled sensitivity (95% CrI) was higher among participants with CD4 ≤ 200 cells per µL at 45% (31% to 61%) (4 studies, 1825 participants, 40% with tuberculosis) versus 16% (8% to 31%) among those with CD4 &gt; 200 cells per µL (3 studies, 738 participants, 22% with tuberculosis) (<a href="#CD011420-tbl-0004">Table 2</a>); a significant difference in pooled sensitivity (95% CrI) of ‐29% (‐47% to ‐9%). The pooled specificity was 89% (77% to 94%) for participants with CD4 ≤ 200 cells per µL and 94% (81% to 97%) for those with CD4 &gt; 200 cells per µL (<a href="#CD011420-tbl-0004">Table 2</a>), a difference in pooled specificity of 5% (‐8% to 17%). </p> <p>When we limited the analysis to studies involving inpatients with CD4 ≤ 200 cells per µL, the pooled sensitivity and specificity were 54% (34% to 73%) and 80% (58% to 91%) (2 studies, 1009 participants, 34% with tuberculosis) (<a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>). Only one study reported data for outpatients with CD4 ≤ 200 cells per µL (<a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>). </p> </section> <section id="CD011420-sec-0075"> <p><b>LF‐LAM accuracy stratified by CD4 &gt; 100 cells per µL and ≤ 100 cells per µL</b></p> <p>Four studies evaluated LF‐LAM in participants with CD4 &gt; 100 cells per µL (<a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a>; <a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>; <a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>). Sensitivity estimates ranged from 12% to 19% and specificity estimates ranged from 92% to 100% (<a href="#CD011420-fig-0006">Figure 6</a>). In the five studies that evaluated participants with CD4 ≤ 100 cells per µL, sensitivity estimates ranged from 30% to 65% and specificity estimates ranged from 75% to 94% (<a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a>; <a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>; <a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>). One study had no estimable specificity, as the authors reported zero true negatives (<a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a>). The pooled sensitivity (95% CrI) was higher among participants with CD4 ≤ 100 cells per µL at 54% (38% to 69%) (4 studies, 1239 participants, 41% with tuberculosis) versus 17% (10% to 27%), (4 studies, 1519 participants, 28% with tuberculosis) among those with CD4 &gt; 100 cells per µL, a significant difference in pooled sensitivity of ‐37% (‐53% to ‐19%). The pooled specificity was 88% (77% to 94%) for participants with CD4 ≤ 100 cells per µL and 95% (89% to 98%) for those with CD4 &gt; 100 cells per µL (<a href="#CD011420-tbl-0004">Table 2</a>), a difference in pooled specificity of 7% (‐1% to 18%). </p> <p>When we limited the analysis to studies involving inpatients with CD4 ≤ 100 cells per µL (<a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>), the pooled sensitivity and specificity were 61% (40% to 78%) and 81% (61% to 91%). Only one study reported data for outpatients with CD4 ≤ 100 cells per µL (<a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>). </p> </section> <section id="CD011420-sec-0076"> <p><b>LF‐LAM accuracy stratified by CD4 strata</b></p> <p>We observed that LF‐LAM pooled sensitivity increased as the degree of immunodeficiency increased, from 16% (8% to 31%) in patients with CD4 cell count &gt;200 cells per μL; to 24% (14% to 38%) in patients with CD4 count between 101 to 199; to 54% (38% to 69%) in patients with CD4 ≤ 100 (<a href="#CD011420-fig-0007">Figure 7</a>). Also, we observed that most participants contributing data for the CD4 ≤ 200 cells per µL stratum (1825 participants including 722 (40%) with tuberculosis) were participants with CD4 ≤ 100 cells per µL (1239 participants including 512 (41%) with tuberculosis) (<a href="#CD011420-tbl-0004">Table 2</a>). </p> </section> </section> <section id="CD011420-sec-0077"> <h6 class="title">LF‐LAM accuracy among symptomatic participants, stratified by tuberculosis prevalence</h6> <p>The median prevalence of tuberculosis in studies with symptomatic participants was 43% (interquartile range (IQR) 32% to 60%). In an analysis by tuberculosis prevalence, we found that pooled sensitivity and specificity for symptomatic participants in settings with tuberculosis prevalence of greater than 43% were 44% (27% to 62%) and 86% (73% to 94%) and 39% (21% to 63%) and 95% (89% to 97%) in settings with a tuberculosis prevalence less than 43%. </p> </section> </section> <section id="CD011420-sec-0078"> <h5 class="title">Sensitivity analyses</h5> <p>In evaluation of the accuracy of LF‐LAM for detection of tuberculosis, we undertook sensitivity analyses by limiting inclusion in the meta‐analysis to the following. </p> <p> <ul id="CD011420-list-0007"> <li> <p>Studies with low risk of bias for patient selection (two studies)</p> </li> <li> <p>Studies with low risk of bias in the reference standard domain (one study)</p> </li> <li> <p>Studies that used fresh urine samples (four studies) rather than stored urine sample</p> </li> </ul> </p> <p>Two studies with greater than 80% symptomatic participants (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a>) were re‐assigned from ‘studies of unselected participants' to ‘studies of symptomatic participants'. </p> <p>These sensitivity analyses only included few studies and participants and made little difference to any of the findings (<a href="#CD011420-tbl-0005">Table 3</a>). </p> <div class="table" id="CD011420-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses, LF‐LAM</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Type of analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Symptomatic participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Unselected participants</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Including studies at low risk of patient selection bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>1413</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48%</p> <p>(29% to 67%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82%</p> <p>(61% to 92%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>1338</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39%</p> <p>(17% to 66%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93%</p> <p>(69% to 98%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Including studies at low risk of reference standard bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study</p> <p>997</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>821</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24%</p> <p>(8% to 53%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99%</p> <p>(95% to 99%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Including studies that used only fresh specimens</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>2511</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52%</p> <p>(38% to 68%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91%</p> <p>(82% to 95%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies</p> <p>2544</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41%</p> <p>(26% to 56%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93%</p> <p>(82% to 97%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Re‐classificiation of <a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a> as studies among symptomatic participant (&gt; 80% participants symptomatic) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 studies 4331</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42%</p> <p>(33% to 52%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93%</p> <p>(88% to 96%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies</p> <p>2483</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31%</p> <p>(16% to 50%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94%</p> <p>(84% to 98%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations: LF‐LAM:</b> lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); <b>Crl:</b> Credible Interval </p> </div> </div> </section> </section> <section id="CD011420-sec-0079"> <h4 class="title">II. Diagnostic accuracy of LF‐LAM for tuberculosis diagnosis in HIV‐positive unselected adults irrespective of signs and symptoms for tuberculosis </h4> <p>Of the 15 studies included, seven studies evaluated the accuracy of LF‐LAM for diagnosis in participants, irrespective of sign and symptoms (‘unselected participants’) (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0002" title="DrainPK , LosinaE , ColemanSM , GiddyJ , RossD , KatzJN , et al. Value of urine lipoarabinomannan grade and second test for optimising clinic‐based screening for HIV‐associated pulmonary tuberculosis. Journal of Acquired Immune Deficiency Syndromes2015;68(3):274‐80. ">Drain 2015a</a>; <a href="./references#CD011420-bbs2-0004" title="FloridiaM , CiccacciF , AndreottiM , HassaneA , SidumoZ , MagidNA , et al. Tuberculosis case finding with combined rapid point‐of‐care assays (Xpert MTB/RIF and Determine TB LAM) in HIV‐positive individuals starting antiretroviral therapy in Mozambique. Clinical Infectious Diseases2017;65(11):1878‐83. ">Floridia 2017</a>; <a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a>; <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>; <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a>; <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>). The tuberculosis prevalence in the study population varied from 1% in <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a> to 33% in <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a>. Six of the studies reported the proportion of symptomatic participants that were included (e.g. having a positive WHO symptoms screen) which varied from 19% (<a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>) to more than 90% of participants in two studies (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a>). No studies reported results specifically for individuals who were asymptomatic. Four studies were carried out in an outpatient setting (<a href="./references#CD011420-bbs2-0002" title="DrainPK , LosinaE , ColemanSM , GiddyJ , RossD , KatzJN , et al. Value of urine lipoarabinomannan grade and second test for optimising clinic‐based screening for HIV‐associated pulmonary tuberculosis. Journal of Acquired Immune Deficiency Syndromes2015;68(3):274‐80. ">Drain 2015a</a>; <a href="./references#CD011420-bbs2-0004" title="FloridiaM , CiccacciF , AndreottiM , HassaneA , SidumoZ , MagidNA , et al. Tuberculosis case finding with combined rapid point‐of‐care assays (Xpert MTB/RIF and Determine TB LAM) in HIV‐positive individuals starting antiretroviral therapy in Mozambique. Clinical Infectious Diseases2017;65(11):1878‐83. ">Floridia 2017</a>; <a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a>; <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>), one study exclusively in an inpatient setting (<a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a>), and two studies in both inpatient and outpatient settings (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>). The median CD4 cell count across studies of unselected adults ranged from 111 to 437 cells per µL across studies. See <a href="#CD011420-tbl-0003">Table 1</a> and <a href="./references#CD011420-sec-0158" title="">Characteristics of included studies</a>. </p> <section id="CD011420-sec-0080"> <h5 class="title">Primary analysis, LF‐LAM for tuberculosis in HIV‐positive adults irrespective of signs and symptoms of tuberculosis </h5> <p>For determining the overall accuracy of LF‐LAM in HIV‐positive adults irrespective of signs and symptoms of tuberculosis, seven studies provided data for 3365 participants, including 432 (13%) with tuberculosis. Sensitivity estimates ranged from 0% to 67%, and specificity estimates from 64% to 99% (<a href="#CD011420-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD011420-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants not assessed for signs and symptoms of tuberculosis. The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD011420-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants not assessed for signs and symptoms of tuberculosis. The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> </div> <p>Sensitivity was lowest (0%) in <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>, that differed from the other studies by including a) a population of exclusively pregnant women attending an antenatal care setting, b) a low proportion of symptomatic participants (19%), c) a low tuberculosis prevalence (1%), and d) a high median CD4 cell count (437 cells per µL). Specificity was lowest (64%) in the study by <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a> that also reported the highest sensitivity (67%). This study reported that more than 90% of the FP results were grade 1 positive results (classified as positive according to current manufacturer recommendations). Participants included had a median CD4 at 270 cells per μL and 33% were symptomatic at enrolment. The study evaluated sputum samples only and allowed a follow‐up for six months from LF‐LAM testing at enrolment to final classification of participants as ‘Tuberculosis' or ‘Not tuberculosis' cases. <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a> further differed from the other studies by being conducted in Myanmar, and is the only study included in this review that evaluated LF‐LAM in a setting outside sub‐Saharan Africa. The pooled sensitivity and specificity (95% CrI) were 35% (22% to 50%) and 95% (89% to 98%) (<a href="#CD011420-tbl-0004">Table 2</a>). <a href="./appendices#CD011420-sec-0145">Appendix 9</a> presents the pooled and predicted sensitivity and specificity estimates together with the credible and prediction regions for LF‐LAM for tuberculosis detection. Prediction intervals were very wide in all meta‐analysis models indicating between‐study heterogeneity (data not shown). </p> </section> <section id="CD011420-sec-0081"> <h5 class="title">Uninterpretable index test results</h5> <p>The included studies reported no uninterpretable results.</p> </section> <section id="CD011420-sec-0082"> <h5 class="title">Investigations of heterogeneity</h5> <section id="CD011420-sec-0083"> <h6 class="title">LF‐LAM accuracy among unselected participants, stratified by setting</h6> <section id="CD011420-sec-0084"> <p><b>LF‐LAM accuracy in inpatient settings</b></p> <p>We identified three studies that evaluated accuracy among inpatients involving 537 participants, 159 (30%) with tuberculosis (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a>; <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>). Sensitivity estimates ranged from 39% to 88% and specificity estimates ranged from 39% to 99% (<a href="#CD011420-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD011420-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants, by health care setting. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. The individual studies are ordered by decreasing sensitivity. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD011420-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants, by health care setting. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. The individual studies are ordered by decreasing sensitivity. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> </div> <p><a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a> reported a very low specificity (39%) and a high sensitivity (88%), based on a relatively small sample size of 54 inpatients; eight (15%) with tuberculosis. The authors reported that 41 of the inpatients (76%) were symptomatic at enrolment with a median CD4 of 96 (IQR 37 to 277) cells per µL, which is comparable to evaluation of LF‐LAM in a population with advanced HIV disease. The study further differed from the other studies by allowing a follow‐up for six months for classification of participants and by being conducted in Myanmar as mentioned above. Most of the participants (91%) included in the studies by <a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a> and <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a> were symptomatic and thus comparable to studies with symptomatic participants. See <a href="#CD011420-tbl-0003">Table 1</a> and <a href="./references#CD011420-sec-0158" title="">Characteristics of included studies</a>. The pooled sensitivity and specificity (95% CrI) among unselected inpatients were 62% (41% to 83%) and 84% (48% to 96%) (<a href="#CD011420-tbl-0004">Table 2</a>). </p> </section> <section id="CD011420-sec-0085"> <p><b>LF‐LAM accuracy in outpatient settings</b></p> <p>Six studies were conducted among unselected outpatients, involving 2828 participants; 273 (10%) with tuberculosis (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0002" title="DrainPK , LosinaE , ColemanSM , GiddyJ , RossD , KatzJN , et al. Value of urine lipoarabinomannan grade and second test for optimising clinic‐based screening for HIV‐associated pulmonary tuberculosis. Journal of Acquired Immune Deficiency Syndromes2015;68(3):274‐80. ">Drain 2015a</a>; <a href="./references#CD011420-bbs2-0004" title="FloridiaM , CiccacciF , AndreottiM , HassaneA , SidumoZ , MagidNA , et al. Tuberculosis case finding with combined rapid point‐of‐care assays (Xpert MTB/RIF and Determine TB LAM) in HIV‐positive individuals starting antiretroviral therapy in Mozambique. Clinical Infectious Diseases2017;65(11):1878‐83. ">Floridia 2017</a>; <a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a>; <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>; <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>). Sensitivity estimates ranged from 0% to 63% and specificity estimates ranged from 67% to 99% (<a href="#CD011420-fig-0009">Figure 9</a>). Pooled sensitivity and specificity (95% CrI) were 31% (18% to 47%) and 95% (87% to 99%) (<a href="#CD011420-tbl-0004">Table 2</a>). </p> </section> </section> <section id="CD011420-sec-0086"> <h6 class="title">LF‐LAM accuracy among unselected participants, stratified by CD4 count</h6> <p>There were limited data to evaluate LF‐LAM by CD4 threshold for unselected participants. Five studies contributed data to the analyses by CD4 count (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0002" title="DrainPK , LosinaE , ColemanSM , GiddyJ , RossD , KatzJN , et al. Value of urine lipoarabinomannan grade and second test for optimising clinic‐based screening for HIV‐associated pulmonary tuberculosis. Journal of Acquired Immune Deficiency Syndromes2015;68(3):274‐80. ">Drain 2015a</a>; <a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a>; <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>; <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a>). See <a href="./appendices#CD011420-sec-0146">Appendix 10</a>; <a href="./appendices#CD011420-sec-0147">Appendix 11</a> and <a href="#CD011420-tbl-0004">Table 2</a>. </p> <section id="CD011420-sec-0087"> <p><b>LF‐LAM accuracy stratified by CD4 ≤ 200 cells per µL and &gt; 200 cells per µL</b></p> <p>Two studies evaluated LF‐LAM in unselected participants with CD4 ≤ 200 cells per µL, all settings. Sensitivity and specificity were 45% and 93% for <a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, and 7% and 99% for <a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a>, (<a href="./appendices#CD011420-sec-0146">Appendix 10</a>). Pooled sensitivity and specificity were 26% (9% to 56%) and 96% (87% to 98%) (706 participants, 12% with tuberculosis) (<a href="#CD011420-tbl-0004">Table 2</a>). </p> <p>For unselected outpatients with a CD4≤ 200 cells per µL, two studies contributed data (652 participants; 10% with tuberculosis). Sensitivity and specificity were 36% and 94% for <a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, and 7% and 99% for <a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a> (<a href="./appendices#CD011420-sec-0146">Appendix 10</a>). Pooled sensitivity and specificity were 21% (8% to 48%) and 96% (89% to 99%) (<a href="#CD011420-tbl-0004">Table 2</a>). </p> <p>When we limited the analysis to unselected inpatients with CD4 ≤ 200 cells per µL, only one study (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>) contributed data and found a sensitivity of 64% (95% CI: 35% to 87%) and specificity of 82% (67% to 93%) (54 participants, 26% with tuberculosis). </p> <p>For comparison, we assessed diagnostic accuracy among participants with CD4 &gt; 200 cells per µL, all settings. Only one study reported data for participants with CD4 &gt; 200 cells per µL and reported a sensitivity of 27% (95% CI: 6% to 61%) and specificity of 99% (95% CI; 96% to 100%) (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>). </p> </section> <section id="CD011420-sec-0088"> <p><b>LF‐LAM accuracy stratified by CD4 ≤ 100 cells per µL and &gt; 100 cells per µL</b></p> <p>Three studies evaluated patients with CD4 ≤ 100 cells per µL, all settings, and sensitivity estimates ranged from 37% to 55% and specificity from 80% to 98% (<a href="./appendices#CD011420-sec-0147">Appendix 11</a>). The pooled sensitivity and specificity (95% CrI) among participants with CD4 ≤ 100 cells per µL were 47% (30% to 64%) and 90% (77% to 96%) (3 studies, 417 participants, 31% with tuberculosis) (<a href="#CD011420-tbl-0004">Table 2</a>). </p> <p>When we limited the analysis to studies involving unselected inpatients with CD4 ≤ 100 cells per µL two studies contributed data, (200 participants; 42% with tuberculosis). Sensitivity and specificity were 60% and 80% for <a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, and 55% and 98% for <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a> (<a href="./appendices#CD011420-sec-0147">Appendix 11</a>). The pooled sensitivity and specificity were 57% (33% to 79%) and 90% (69% to 97%) (<a href="#CD011420-tbl-0004">Table 2</a>). </p> <p>Two studies contributed data for unselected outpatients with CD4 ≤ 100 cells per µL (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a>) (<a href="./appendices#CD011420-sec-0147">Appendix 11</a>). The pooled sensitivity and specificity were 40% (20% to 64%) and 87% (68% to 94%) (217 participants, 21% with tuberculosis) (<a href="#CD011420-tbl-0004">Table 2</a>). </p> <p>Four studies evaluated LF‐LAM in participants with CD4 &gt; 100 cells per µL (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0002" title="DrainPK , LosinaE , ColemanSM , GiddyJ , RossD , KatzJN , et al. Value of urine lipoarabinomannan grade and second test for optimising clinic‐based screening for HIV‐associated pulmonary tuberculosis. Journal of Acquired Immune Deficiency Syndromes2015;68(3):274‐80. ">Drain 2015a</a>; <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>; <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a>). Sensitivity estimates ranged from 0% to 33% and specificity estimates ranged from 95% to 99% (<a href="./appendices#CD011420-sec-0147">Appendix 11</a>). Pooled sensitivity and specificity (95% CrI) were 20% (10% to 35%) and 98% (95% to 99%), (952 participants, 12% with tuberculosis) (<a href="#CD011420-tbl-0004">Table 2</a>). </p> </section> </section> <section id="CD011420-sec-0089"> <h6 class="title">LF‐LAM accuracy among unselected participants, stratified by tuberculosis prevalence</h6> <p>The median prevalence of tuberculosis in studies with unselected participants was 10% (IQR 9% to 17%). In the analysis by tuberculosis prevalence, we found that pooled sensitivity and specificity for unselected participants in settings with tuberculosis prevalence of 10% or more were 45% (31% to 61%) and 92% (79% to 97%) (4 studies) compared to 16% (5% to 36%) and 98% (94% to 99%) in settings with tuberculosis prevalence less than 10% (3 studies). In general, tuberculosis prevalence increased in studies with a higher proportion of symptomatic participants. </p> </section> </section> <section id="CD011420-sec-0090"> <h5 class="title">Sensitivity analyses</h5> <p>As for studies among symptomatic participants, we undertook sensitivity analyses by limiting inclusion in the meta‐analysis to the following. </p> <p> <ul id="CD011420-list-0008"> <li> <p>Studies with low risk of bias for patient selection (three studies)</p> </li> <li> <p>Studies with low risk of bias in the reference standard domain (two studies)</p> </li> <li> <p>Studies that used fresh urine samples (five studies) rather than stored urine sample</p> </li> </ul> </p> <p>We further excluded the two studies with more than 80% of participants being symptomatic at inclusion (<a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a>). </p> <p>These sensitivity analyses made little difference to any of the findings (<a href="#CD011420-tbl-0005">Table 3</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011420-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011420-sec-0091">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011420-sec-0189">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011420-sec-0091"></div> <p>This systematic review updates the current literature and includes 15 unique studies on the accuracy of lateral flow urine lipoarabinomannan assay (LF‐LAM, Alere Determine™ TB LAM Ag) for tuberculosis in adults living with HIV and integrates nine new studies identified since the original WHO guidelines (<a href="./references#CD011420-bbs2-0163" title="World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. WHO/HTM/TB/2015.25. Geneva: World Health Organization, 2015. ">WHO Lipoarabinomannan Policy Guidance 2015</a>) and Cochrane Review (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>). A priori, we chose to evaluate performance of LF‐LAM separately for studies that enrolled strictly symptomatic participants and studies that enrolled unselected participants irrespective of signs and/or symptoms of tuberculosis, and we conducted investigations of heterogeneity based on CD4 counts and study setting (inpatient/outpatient). Eight studies used LF‐LAM for tuberculosis diagnosis in symptomatic adult participants with signs and symptoms suggestive of tuberculosis. These studies largely focused on inpatient settings and had high tuberculosis prevalence. Seven studies evaluated LF‐LAM for diagnosing tuberculosis in unselected participants who may or may not have had signs or symptoms suggestive of tuberculosis when enrolled in the study. The studies with unselected participant were conducted predominantly in outpatient settings and, compared to studies with exclusively symptomatic participants, had lower tuberculosis prevalence and involved patients with higher CD4 counts; the proportion of symptomatic participants in these studies ranged from 19% to 90%. All studies were conducted in low‐ and middle‐income countries with a high tuberculosis/HIV burden, and only one study outside sub‐Saharan Africa. </p> <section id="CD011420-sec-0092"> <h3 class="title" id="CD011420-sec-0092">Summary of main results</h3> <p>We have summarized the main findings in <a href="./full#CD011420-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD011420-tbl-0002">summary of findings Table 2</a>. The main findings of this updated review include the following. </p> <p>For tuberculosis diagnosis in HIV‐positive adults presenting with signs and symptoms of tuberculosis, the diagnostic accuracy of LF‐LAM is (95% credible interval (CrI)): </p> <p> <ul id="CD011420-list-0009"> <li> <p>In all settings, sensitivity 42% (31% to 55%) and specificity 91% (85% to 95%);</p> </li> <li> <p>In inpatient settings, sensitivity 52% (40% to 64%) and specificity 87% (78% to 93%);</p> </li> <li> <p>In outpatient settings, sensitivity 29% (17% to 47%) and specificity 96% (91% to 99%).</p> </li> </ul> </p> <p>For tuberculosis diagnosis in HIV‐positive adults irrespective of signs and symptoms of tuberculosis, the diagnostic accuracy of LF‐LAM is: </p> <p> <ul id="CD011420-list-0010"> <li> <p>In all settings, sensitivity 35% (22% to 50%) and specificity 95% (89% to 98%);</p> </li> <li> <p>In inpatient settings, sensitivity 62% (41% to 83%) and specificity 84% (48% to 96%);</p> </li> <li> <p>In outpatient settings, sensitivity 31% (18% to 47%) and specificity 95% (87% to 99%).</p> </li> </ul> </p> <p>We note that the band intensity of grade 1 in this review corresponds to the current manufacturer threshold for positivity (equivalent to that of grade 2 on the old manufacturer reference card) and all results were evaluated against a microbiological reference standard. </p> <section id="CD011420-sec-0093"> <h4 class="title">LF‐LAM for tuberculosis diagnosis in studies with symptomatic participants</h4> <p><a href="./full#CD011420-tbl-0001">summary of findings Table 1</a>. </p> <p>In planned investigations of heterogeneity, we found an inverse correlation between LF‐LAM sensitivity and CD4 count, with increasing sensitivity as patient CD4 count decreased (increased from 16% (CrI 8% to 31%) in patients with CD4 cell count &gt; 200 cells per µL to 24% (CrI 14% to 38%) in patients with CD4 cell count between 101 to 199 cells per µL, to 54% (CrI 38% to 69%) in patients with CD4 ≤ 100 cells per µL). Similarly, we a priori planned to investigate and expected to find higher sensitivity in patients who were hospitalized while specificity decreased.<br/> <br/> Results of these studies indicate that in theory, for a population of 1000 people where 300 have microbiologically‐confirmed tuberculosis, the utilization of LF‐LAM would result in: 189 to be LF‐LAM positive: of these, 63 (33%) would not have tuberculosis (false‐positives); and 811 to be LF‐LAM negative: of these, 174 (21%) would have tuberculosis (false‐negatives). </p> </section> <section id="CD011420-sec-0094"> <h4 class="title">LF‐LAM for tuberculosis diagnosis in studies with unselected participants (signs and symptoms not assessed as a condition of study inclusion) </h4> <p><a href="./full#CD011420-tbl-0002">summary of findings Table 2</a>. </p> <p>In the investigations of heterogeneity, we expected and found a higher sensitivity in patients with CD4 ≤ 100 cells per µL (47%) and among inpatients (62%) compared to patients with CD4 &gt; 100 cells per µL (20%) among outpatients (31%) respectively, though data to inform subgroup analyses were limited. We noted that participants included in the studies with unselected participants often presented with sign and symptoms suggestive of tuberculosis (a positive WHO tuberculosis screen), and in the studies evaluating inpatients most participants (&gt; 80%) were in fact presenting with signs and symptoms suggestive of tuberculosis. These studies may be considered more similar to studies with exclusively symptomatic participants. In additional analysis of heterogeneity, we examined diagnostic accuracy based on tuberculosis prevalence within the studied cohort, as an alternative surrogate to presence of symptoms or CD4 count as an assessment of pre‐test probability. We found that pooled sensitivity was 45% when tuberculosis prevalence within the study population was ≥ 10%, compared to only 16% when tuberculosis prevalence in the study population was &lt; 10%. </p> <p>Results of these studies indicate that in theory, for a population of 1000 people where 100 have microbiologically‐confirmed tuberculosis, the utilization of LF‐LAM would result in: 80 to be LF‐LAM positive: of these, 45 (56%) would not have tuberculosis (false‐positives); and 920 to be LF‐LAM negative: of these, 65 (7%) would have tuberculosis (false‐negatives). </p> </section> <section id="CD011420-sec-0095"> <h4 class="title">LF‐LAM for tuberculosis diagnosis, overall</h4> <p>The findings of this updated review are consistent with those of the original review (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>; <a href="./references#CD011420-bbs2-0163" title="World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. WHO/HTM/TB/2015.25. Geneva: World Health Organization, 2015. ">WHO Lipoarabinomannan Policy Guidance 2015</a>). Inclusion of additional studies in this updated review provided the basis for a more precise estimate of the LF‐LAM overall sensitivity and specificity. It further allowed us to address key questions regarding test accuracy and sources of heterogeneity including clinical setting and CD4 cell count in studies with symptomatic individuals and in studies with unselected participants. </p> <p>Overall, we found lower sensitivity for diagnosis of tuberculosis among people living with HIV than the internationally suggested target of minimum 65% overall for rapid non‐sputum tuberculosis tests (<a href="./references#CD011420-bbs2-0166" title="World Health Organization. High‐priority target product profiles for new tuberculosis diagnostics, Report of a consensus meeting. Geneva: World Health Organization, 2014:98. ">WHO TTP 2014</a>). We found that sensitivity increased when considering inpatients and individuals with lower CD4 counts, whether considering studies with exclusively symptomatic participants or those with unselected participants. The reasons for this heterogeneity remain unclear, and several hypotheses have been postulated including differences in bacterial burden, sites of tuberculosis disease, or degree of glomerular dysfunction that may be different across different settings or CD4 counts. </p> <p>When restricting analysis to studies that included participants unable to produce a sputum sample, the estimates of sensitivity increased. Sputum‐scarce patients may be the potential target population to benefit the most from urine‐based testing as they cannot have other sputum‐based diagnostic testing and are likely to have a high yield of urine lipoarabinomannan (LAM) test positivity (<a href="./references#CD011420-bbs2-0084" title="SaburNF , EsmailA , BrarMS , DhedaK . Diagnosing tuberculosis in hospitalized HIV‐infected individuals who cannot produce sputum: is urine lipoarabinomannan testing the answer?. BMC Infectious Diseases2017;17(1):803. [DOI: 10.1186/s12879‐017‐2914‐7] ">Sabur 2017</a>). However, only a few studies included participants who could not provide sputum samples for diagnostic testing. To the extent that inability to produce sputum is correlated with severity of tuberculosis disease and/or LAM positivity, this approach to participant selection could have lowered sensitivity estimates within these studies. Sensitivity analysis further revealed a higher sensitivity among studies evaluating LF‐LAM on fresh non‐stored urine samples without it affecting specificity. However, no study has made a direct comparison of performance on fresh versus frozen/stored urine samples and the significance of this is unclear. </p> <p>Overall, we found that the estimated specificity approached the recommended targets for non‐site‐specific, non‐sputum based test (<a href="./references#CD011420-bbs2-0166" title="World Health Organization. High‐priority target product profiles for new tuberculosis diagnostics, Report of a consensus meeting. Geneva: World Health Organization, 2014:98. ">WHO TTP 2014</a>), although lower specificity was found among inpatients and those with advanced immunosuppression compared to outpatients and those with higher CD4 counts. We expected that, if restricting the analysis to studies using a higher quality reference standard (e.g. inclusion of more than one specimen type), that estimates of specificity would increase, but had limited data to conduct such a sensitivity analysis. When evaluating an assay that is not site‐specific, future studies may consider systematic sampling of multiple sites to improve the quality of the reference standard. Future studies should include systematic sampling of sputum, blood, and urine for mycobacterial culture and/or nucleic acid amplification test (NAAT) testing from all participants as common sites of tuberculosis that may be identified by urinary LAM antigen detection; additional site‐specific samples (e.g. cerebrospinal fluid (CSF), tissue biopsies) should also be collected for culture and/or NAAT based on clinical presentation. </p> <p>We decided a priori to evaluate performance of LF‐LAM in HIV‐positive individuals with signs and symptoms of tuberculosis (symptomatic) separately from HIV‐positive individuals irrespective of signs and symptoms of tuberculosis (unselected participants). We considered evaluating LF‐LAM performance among specifically asymptomatic (i.e. exclusively those without symptoms) participants to assess the use of LF‐LAM for the purpose of tuberculosis screening or community‐based active case‐finding, but such data were lacking among included studies. We did find that several studies among unselected participants reported that a high proportion of study participants had signs and symptoms of tuberculosis, suggesting relative similarities to studies that enrolled exclusively symptomatic participants. Consequently, the overall performance of LF‐LAM among asymptomatic patients remains largely unknown. </p> <p>The overall differences in pooled estimates of sensitivity and specificity between studies of symptomatic versus unselected participants may have been attributable to differences in study setting and relative degree of immunosuppression of included participants, rather than type of population (i.e. unselected versus symptomatic participants). When examining inpatients, the pooled estimates for sensitivity were 52% (40% to 64%) and 62% (41% to 83%), when comparing studies of symptomatic participants and those including unselected participants. Among outpatients, the pooled sensitivity was 29% (17% to 47%) compared to 31% (18% to 47%) among studies of symptomatic participants and unselected participants, respectively. This indicates that other characteristics than lower CD4 may explain the higher sensitivity among inpatients like higher tuberculosis prevalence, higher mycobacterial burden, renal or genitourinary tract tuberculosis with LAM secretion in urine. </p> <p>Overall, our findings suggest that the diagnostic accuracy of LF‐LAM may vary by study setting, CD4 count, and tuberculosis prevalence among the target population. The authors hypothesize that these attributes (inpatients, low CD4 counts, or high tuberculosis prevalence) may collectively be surrogate indicators of participants with advanced tuberculosis disease or higher bacillary burden and LAM antigenuria in whom LF‐LAM may aid in the diagnosis of tuberculosis, including both pulmonary and extrapulmonary tuberculosis. Although subgroup comparisons in diagnostic accuracy reviews are observational and suffer from the same limitations as all observational findings (for example, confounding between characteristics), there is a scientific rationale for these finding in that inpatients, those with low CD4, or cohorts with higher tuberculosis prevalence are likely to have higher disease severity or higher bacillary burden. While the test does not identify all tuberculosis cases, our findings suggest that it may be of particular value in diagnosing tuberculosis among patients with increased disease severity. Other factors that may be considered in evaluating LF‐LAM may include ability to perform the test on individuals unable to produce sputum who cannot be diagnosed with other tuberculosis diagnostic tests, and ability to implement the test at the point‐of‐care with non‐invasive specimen collection (<a href="./references#CD011420-bbs2-0166" title="World Health Organization. High‐priority target product profiles for new tuberculosis diagnostics, Report of a consensus meeting. Geneva: World Health Organization, 2014:98. ">WHO TTP 2014</a>). </p> <p>We identified three published studies of LF‐LAM in children as the result of a broader search for studies in adults and children using the same inclusion criteria (<a href="./references#CD011420-bbs2-0057" title="KroidlI , ClowesP , ReitherK , MtafyaB , Rojas‐PonceG , NtinginyaEN , et al. Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania. European Respiratory Journal2015;46(3):761‐70. [DOI: 10.1183/09031936.00003315] ">Kroidl 2015</a>; <a href="./references#CD011420-bbs2-0058" title="LacourseSM , PavlinacPB , CranmerLM , NjugunaIN , MugoC , GatimuJ , et al. Stool Xpert MTB/RIF and urine lipoarabinomannan for the diagnosis of tuberculosis in hospitalized HIV‐infected children. AIDS2018;32(1):69‐78. [DOI: 10.1097/QAD.0000000000001662] ">LaCourse 2018a</a>; <a href="./references#CD011420-bbs2-0074" title="NicolMP , AllenV , WorkmanL , IsaacsW , MunroJ , PienaarS , et al. Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective study. Lancet Global Health2014;2(5):e278–84. ">Nicol 2014</a>). All three studies took place in countries in Africa with a high tuberculosis/HIV burden. Prevalence of microbiologically‐confirmed tuberculosis in the studies was 7% in <a href="./references#CD011420-bbs2-0058" title="LacourseSM , PavlinacPB , CranmerLM , NjugunaIN , MugoC , GatimuJ , et al. Stool Xpert MTB/RIF and urine lipoarabinomannan for the diagnosis of tuberculosis in hospitalized HIV‐infected children. AIDS2018;32(1):69‐78. [DOI: 10.1097/QAD.0000000000001662] ">LaCourse 2018a</a>, 22% in <a href="./references#CD011420-bbs2-0074" title="NicolMP , AllenV , WorkmanL , IsaacsW , MunroJ , PienaarS , et al. Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective study. Lancet Global Health2014;2(5):e278–84. ">Nicol 2014</a>; and 40% in <a href="./references#CD011420-bbs2-0057" title="KroidlI , ClowesP , ReitherK , MtafyaB , Rojas‐PonceG , NtinginyaEN , et al. Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania. European Respiratory Journal2015;46(3):761‐70. [DOI: 10.1183/09031936.00003315] ">Kroidl 2015</a>. <a href="./references#CD011420-bbs2-0057" title="KroidlI , ClowesP , ReitherK , MtafyaB , Rojas‐PonceG , NtinginyaEN , et al. Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania. European Respiratory Journal2015;46(3):761‐70. [DOI: 10.1183/09031936.00003315] ">Kroidl 2015</a> enrolled children six weeks to 14 years, median age (interquartile range (IQR)) 6.8 years (3.9 to 9.5) for all participants, including HIV‐positive and HIV‐negative children. <a href="./references#CD011420-bbs2-0058" title="LacourseSM , PavlinacPB , CranmerLM , NjugunaIN , MugoC , GatimuJ , et al. Stool Xpert MTB/RIF and urine lipoarabinomannan for the diagnosis of tuberculosis in hospitalized HIV‐infected children. AIDS2018;32(1):69‐78. [DOI: 10.1097/QAD.0000000000001662] ">LaCourse 2018a</a> enrolled children aged 12 years or less, median age (IQR) 24 months (13 to 58). <a href="./references#CD011420-bbs2-0074" title="NicolMP , AllenV , WorkmanL , IsaacsW , MunroJ , PienaarS , et al. Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective study. Lancet Global Health2014;2(5):e278–84. ">Nicol 2014</a> enrolled children aged 15 years or less, median age (IQR) 42.5 months (19.1 to 66.3) for all participants, including HIV‐positive and HIV‐negative children. A table summarizing the characteristics of studies in children can be found in <a href="./appendices#CD011420-sec-0148">Appendix 12</a>. <a href="./references#CD011420-bbs2-0057" title="KroidlI , ClowesP , ReitherK , MtafyaB , Rojas‐PonceG , NtinginyaEN , et al. Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania. European Respiratory Journal2015;46(3):761‐70. [DOI: 10.1183/09031936.00003315] ">Kroidl 2015</a> and <a href="./references#CD011420-bbs2-0074" title="NicolMP , AllenV , WorkmanL , IsaacsW , MunroJ , PienaarS , et al. Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective study. Lancet Global Health2014;2(5):e278–84. ">Nicol 2014</a> involved HIV‐positive children with tuberculosis symptoms. <a href="./references#CD011420-bbs2-0058" title="LacourseSM , PavlinacPB , CranmerLM , NjugunaIN , MugoC , GatimuJ , et al. Stool Xpert MTB/RIF and urine lipoarabinomannan for the diagnosis of tuberculosis in hospitalized HIV‐infected children. AIDS2018;32(1):69‐78. [DOI: 10.1097/QAD.0000000000001662] ">LaCourse 2018a</a> involved HIV‐positive children hospitalized for acute illness irrespective of tuberculosis signs and symptoms. <a href="./references#CD011420-bbs2-0057" title="KroidlI , ClowesP , ReitherK , MtafyaB , Rojas‐PonceG , NtinginyaEN , et al. Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania. European Respiratory Journal2015;46(3):761‐70. [DOI: 10.1183/09031936.00003315] ">Kroidl 2015</a> was conducted in an outpatient setting, <a href="./references#CD011420-bbs2-0058" title="LacourseSM , PavlinacPB , CranmerLM , NjugunaIN , MugoC , GatimuJ , et al. Stool Xpert MTB/RIF and urine lipoarabinomannan for the diagnosis of tuberculosis in hospitalized HIV‐infected children. AIDS2018;32(1):69‐78. [DOI: 10.1097/QAD.0000000000001662] ">LaCourse 2018a</a> in an inpatient setting, and <a href="./references#CD011420-bbs2-0074" title="NicolMP , AllenV , WorkmanL , IsaacsW , MunroJ , PienaarS , et al. Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective study. Lancet Global Health2014;2(5):e278–84. ">Nicol 2014</a> in both an inpatient and an outpatient setting (<a href="./appendices#CD011420-sec-0148">Appendix 12</a>). Given the differences in population and setting, we did not perform meta‐analyses and report sensitivity and specificity estimates for the individual studies, all measured against a microbiological reference standard. Sensitivity and specificity (95% CI) were 42% (15% to 72%) and 94% (73% to 100%), (30 participants) (<a href="./references#CD011420-bbs2-0057" title="KroidlI , ClowesP , ReitherK , MtafyaB , Rojas‐PonceG , NtinginyaEN , et al. Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania. European Respiratory Journal2015;46(3):761‐70. [DOI: 10.1183/09031936.00003315] ">Kroidl 2015</a>); 56% (21% to 86%) and 95% (90% to 98%), (130 participants) (<a href="./references#CD011420-bbs2-0058" title="LacourseSM , PavlinacPB , CranmerLM , NjugunaIN , MugoC , GatimuJ , et al. Stool Xpert MTB/RIF and urine lipoarabinomannan for the diagnosis of tuberculosis in hospitalized HIV‐infected children. AIDS2018;32(1):69‐78. [DOI: 10.1097/QAD.0000000000001662] ">LaCourse 2018a</a>); and 43% (23% to 66%) and 80% (69% to 88%), (106 participants) (<a href="./references#CD011420-bbs2-0074" title="NicolMP , AllenV , WorkmanL , IsaacsW , MunroJ , PienaarS , et al. Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective study. Lancet Global Health2014;2(5):e278–84. ">Nicol 2014</a>). We found limited evidence on the accuracy of LF‐LAM in children living with HIV. There were too few studies and participants to draw conclusions. </p> <p>We acknowledge that patient outcomes are clearly important to patients, decision makers, and the wider tuberculosis community. While, the primary focus of this Cochrane Review update was to evaluate the diagnostic accuracy of LF‐LAM, in the process of performing the review, we also assessed available data on LF‐LAM and patient‐important outcomes including mortality. We identified two randomized controlled trials (<a href="./references#CD011420-bbs2-0124" title="Gupta‐WrightA , CorbettEL , vanOosterhoutJJ , WilsonD , GrintD , Alufandika‐MoyoM , et al. Rapid urine‐based screening for tuberculosis in HIV‐positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel‐group, double‐blind, randomised controlled trial. Lancet2018;392:292–301. ">Gupta‐Wright, 2018a</a>; <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a>) that included data on the impact of LF‐LAM implementation on mortality and other patient outcomes. <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a> enrolled participants with tuberculosis symptoms, and <a href="./references#CD011420-bbs2-0124" title="Gupta‐WrightA , CorbettEL , vanOosterhoutJJ , WilsonD , GrintD , Alufandika‐MoyoM , et al. Rapid urine‐based screening for tuberculosis in HIV‐positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel‐group, double‐blind, randomised controlled trial. Lancet2018;392:292–301. ">Gupta‐Wright, 2018a</a> enrolled unselected participants irrespective of symptoms. Both trials were conducted in multiple countries in sub‐Saharan Africa. Both trials involved hospitalized, HIV‐positive patients, used the results of LF‐LAM to guide therapy, and assessed all‐cause mortality at eight weeks. <a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a> found that mortality was significantly reduced in participants receiving LF‐LAM compared to those receiving routine diagnostic tests alone (no LF‐LAM); adjusted relative risk reduction of 0.83 (95% CI: 0.73 to 0.96, P = 0.012). In <a href="./references#CD011420-bbs2-0124" title="Gupta‐WrightA , CorbettEL , vanOosterhoutJJ , WilsonD , GrintD , Alufandika‐MoyoM , et al. Rapid urine‐based screening for tuberculosis in HIV‐positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel‐group, double‐blind, randomised controlled trial. Lancet2018;392:292–301. ">Gupta‐Wright, 2018a</a>, the use of rapid urine screening with LF‐LAM and urine Xpert MTB/RIF (intervention group) was not associated with a statistically significant reduction in mortality compared with routine diagnostic tests alone (standard‐of‐care group, no LF‐LAM); adjusted risk reduction (aRD) of ‐2.8% (95% CI ‐5.8 to 0.3, P = 0.074). However, of importance, <a href="./references#CD011420-bbs2-0124" title="Gupta‐WrightA , CorbettEL , vanOosterhoutJJ , WilsonD , GrintD , Alufandika‐MoyoM , et al. Rapid urine‐based screening for tuberculosis in HIV‐positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel‐group, double‐blind, randomised controlled trial. Lancet2018;392:292–301. ">Gupta‐Wright, 2018a</a>, demonstrated that mortality was significantly lower in the intervention group than in the standard‐of‐care group for three of 12 prespecified subgroups: CD4 counts less than 100 cells per μL (aRD ‐7.1% (95% CI ‐13.7 to ‐0.4), P = 0.036); severe anaemia (aRD ‐9.0% (95% CI ‐16.6 to ‐1.3), P = 0.021); and participants with clinically suspected tuberculosis (aRD ‐5.7% (95% CI ‐10.9 to ‐0.5), P = 0.033). We will address the impact of testing with LF‐LAM on patient outcomes in greater depth in another Cochrane Review (a Cochrane Protocol is underway).<br/> <br/> Concerning economic evaluations, we are aware of six studies, all from settings in sub‐Saharan Africa (<a href="./references#CD011420-bbs2-0106" title="BoylesTH , GrieselR , StewartA , MendelsonM , MaartensG . Incremental yield and cost of urine Determine TB‐LAM and sputum induction in seriously ill adults with HIV. International Journal of Infectious Diseases2018;75:67‐73. ">Boyles 2018</a>; <a href="./references#CD011420-bbs2-0137" title="MukoraR , TlaliM , MonkweS , CharalambousS , KaratAS , FieldingKL , GrantAD , VassallA . Cost of point‐of‐care lateral flow urine lipoarabinomannan antigen testing in HIV‐positive adults in South Africa. International Journal of Tuberculosis and Lung Disease2018;22(9):1082‐7. ">Mukora 2018</a>; <a href="./references#CD011420-bbs2-0139" title="OrlandoS , TriulziI , CiccacciF , PallaI , PalombiL , MarazziMC , et al. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost‐effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF. PLOS One2018;13(7):e0200523. ">Orlando 2018</a>; <a href="./references#CD011420-bbs2-0146" title="ReddyKP , Gupta‐WrightA , FieldingKL , CostantiniS , ZhengA , CorbettEL , et al. Cost‐effectiveness of urine‐based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. Lancet Global Health2019;7(2):e200‐8. ">Reddy 2019</a>; <a href="./references#CD011420-bbs2-0091" title="ShahM , DowdyD , JolobaM , SsengoobaW , ManabeYC , EllnerJ , et al. Cost‐effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV‐infected individuals in Uganda. AIDS2013;27(18):2883‐92. ">Shah 2013</a>; <a href="./references#CD011420-bbs2-0094" title="SunD , DormanS , ShahM , ManabeYC , MoodleyVM , NicolMP , et al. Cost utility of lateral‐flow urine lipoarabinomannan for tuberculosis diagnosis in HIV‐infected African adults. International Journal of Tuberculosis and Lung Disease2013;17(4):552‐8. ">Sun 2013</a>). These study methods and populations were heterogeneous, assessing a range of diagnostic algorithms, and only four of the total studies assessed cost‐effectiveness (<a href="./references#CD011420-bbs2-0139" title="OrlandoS , TriulziI , CiccacciF , PallaI , PalombiL , MarazziMC , et al. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost‐effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF. PLOS One2018;13(7):e0200523. ">Orlando 2018</a>; <a href="./references#CD011420-bbs2-0146" title="ReddyKP , Gupta‐WrightA , FieldingKL , CostantiniS , ZhengA , CorbettEL , et al. Cost‐effectiveness of urine‐based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. Lancet Global Health2019;7(2):e200‐8. ">Reddy 2019</a>; <a href="./references#CD011420-bbs2-0091" title="ShahM , DowdyD , JolobaM , SsengoobaW , ManabeYC , EllnerJ , et al. Cost‐effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV‐infected individuals in Uganda. AIDS2013;27(18):2883‐92. ">Shah 2013</a>; <a href="./references#CD011420-bbs2-0094" title="SunD , DormanS , ShahM , ManabeYC , MoodleyVM , NicolMP , et al. Cost utility of lateral‐flow urine lipoarabinomannan for tuberculosis diagnosis in HIV‐infected African adults. International Journal of Tuberculosis and Lung Disease2013;17(4):552‐8. ">Sun 2013</a>), while <a href="./references#CD011420-bbs2-0137" title="MukoraR , TlaliM , MonkweS , CharalambousS , KaratAS , FieldingKL , GrantAD , VassallA . Cost of point‐of‐care lateral flow urine lipoarabinomannan antigen testing in HIV‐positive adults in South Africa. International Journal of Tuberculosis and Lung Disease2018;22(9):1082‐7. ">Mukora 2018</a> performed a detailed costing study, including both at clinical and above clinic level costs, and <a href="./references#CD011420-bbs2-0106" title="BoylesTH , GrieselR , StewartA , MendelsonM , MaartensG . Incremental yield and cost of urine Determine TB‐LAM and sputum induction in seriously ill adults with HIV. International Journal of Infectious Diseases2018;75:67‐73. ">Boyles 2018</a> assessed whether the addition of LF‐LAM in diagnostic algorithms could reduce total program costs. studies employed a range of different willingness to pay thresholds, all four studies were consistent in concluding LF‐LAM could be cost‐effective in a population of African adults living with HIV (particularly amongst hospitalized patients). Models found cost‐effectiveness of LF‐LAM to be robust across a variety of sensitivity analyses, and across different country settings and scenarios investigated. Key parameters that are likely most influential on cost‐effectiveness include: tuberculosis prevalence/target population, and LF‐LAM specificity, cost of treating tuberculosis and HIV and life expectancy post tuberculosis survival. Detailed empirical costing data are limited for LF‐LAM implementation, however one such study published in 2018 (<a href="./references#CD011420-bbs2-0137" title="MukoraR , TlaliM , MonkweS , CharalambousS , KaratAS , FieldingKL , GrantAD , VassallA . Cost of point‐of‐care lateral flow urine lipoarabinomannan antigen testing in HIV‐positive adults in South Africa. International Journal of Tuberculosis and Lung Disease2018;22(9):1082‐7. ">Mukora 2018</a>) estimates unit test costs for LF‐LAM implementation several fold higher (˜$23‐24) than most current models ($2‐4), where costs of implementation and staff time are not considered. Underestimation of LF‐LAM unit costs could result in overly optimistic cost‐effectiveness profiles. However, tuberculosis diagnostics costs likely represent just a small proportion of total costs, indeed inclusion of costs associated with antiretroviral treatment (ART) and HIV care resulted in higher incremental cost‐effectiveness ratios. While current evidence is consistent in suggesting LF‐LAM is likely cost‐effective among HIV‐positive patients in sub‐Saharan Africa, caution should be used when extrapolating from a small number of studies, and additional evidence from a wider range of populations, settings and diagnostic approaches will be necessary. A systematic review of economic evaluations is underway. </p> </section> <section id="CD011420-sec-0096"> <h4 class="title">Differences from original Cochrane Review</h4> <p>In comparison to the original Cochrane Review (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>), this updated review includes 15 published studies (nine new studies since the original review and six studies from the original review). The original review included data from 12 studies, of which six were excluded as they did not meet the eligibility criteria for this updated review. Three used an older threshold for determining test positivity that is no longer recommended and three were abstracts, of which one (<a href="./references#CD011420-bbs2-0064" title="LawnSD , KerkhoffA , BurtonR , SchutzC , vanWykG , VogtM , et al. Massive diagnostic yield of HIV‐associated tuberculosis using rapid urine assays in South Africa. Conference on Retroviruses and Opportunistic Infections (CROI). Boston (MA), 2014. ">Lawn 2014</a>) was added in this review as an updated published manuscript. For comparison, the main findings from the original review (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>) are listed in <a href="#CD011420-tbl-0006">Table 4</a>. </p> <div class="table" id="CD011420-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Original Alere LAM review, main findings</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Type of analysis </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Symptomatic participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Unselected participants </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies (total participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies (total participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall accuracy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies (2313)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45% (29% to 63%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92% (80% to 97%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies<sup>a</sup> (1055 ) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30% (20% to 43%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94% (86% to 97%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>By setting</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies (1299)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53% (38% to 70%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 % (73% to 96%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Insufficient data</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Insufficient data</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Insufficient data</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations: LF‐LAM:</b> lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); <b>Crl:</b> credible interval </p> <p>Main findings from the original review on LF‐LAM accuracy (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>).<br/> <sup>a</sup>Reported at grade 1 on the previous reference scale card with five bands that is outdated and no longer the recommended positivity threshold. </p> </div> </div> <p>In the evaluation of diagnostic accuracy among symptomatic participants, the pooled estimates for sensitivity (42% [CrI 31% to 55%] versus 45% [CrI 29% to 63%]) and specificity (91% [CrI 85% to 95%] versus 92% [CrI 80% to 97%]) remained similar, comparing the current review and prior review, respectively. When stratified by setting, the pooled estimates among inpatients for sensitivity (52% [CrI 40% to 64%] versus 53% [CrI 38% to 70%)]) and specificity (87% [CrI 78% to 93%] versus 90% [CrI 73% to 96%]) did not change substantially when comparing the current review and the prior review, respectively. Pooled estimates among outpatients at the current manufacturer threshold for positivity were not previously available. </p> <p>In <a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>, some studies were classified as ‘tuberculosis (TB) screening’ if they included participants irrespective of symptoms (i.e. with or without symptoms). Recognizing that these studies may have included a large proportion of symptomatic participants, these studies have been more clearly labelled as studies among ‘unselected participants’ in the current review. In the prior review, there were insufficient data to perform meta‐analysis among unselected participants at the currently recommended manufacturer threshold for test positivity. There were previously insufficient data to investigate heterogeneity due to study setting or CD4 count. In the current review, we report on diagnostic accuracy among inpatients and outpatients and by CD4. In both the current and prior review, data to assess diagnostic accuracy among asymptomatic participants (without signs or symptoms of tuberculosis) were unavailable. </p> <p>This updated review did not assess diagnostic accuracy at an older threshold for determining test positivity (grade 1 out of 5, on an older reference card); data on diagnostic accuracy for this threshold can be found in the prior review (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>). Similarly, in this updated review we did not evaluate accuracy against a composite reference standard, results of which were included in the prior review (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>). Finally, given the relative lack of data on evaluating the incremental yield of LF‐LAM in combination with sputum smear microscopy and Xpert MTB/RIF, we did not include these analyses in the updated review, but a summary of available data is found in the prior review (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>). </p> <p>We note that the band intensity of grade 1 in this review corresponds to the current manufacturer threshold for positivity (equivalent to that of grade 2 on the old manufacturer reference card) and all results were evaluated against a microbiological reference standard. </p> </section> </section> <section id="CD011420-sec-0097"> <h3 class="title" id="CD011420-sec-0097">Strengths and weaknesses of the review</h3> <p>The findings in this review are based on comprehensive searching, strict inclusion criteria, and standardized data extraction. The strength of our review is that it enabled an assessment of the accuracy of LF‐LAM in people living with HIV when applied to different enrolment criteria ‐ accuracy among individuals with signs and symptoms of tuberculosis, and accuracy when used without assessment of signs and symptoms of tuberculosis (i.e. patients may or may not have had symptoms). This updated review included new studies published since the original review. However, we found considerable heterogeneity across studies with respect to clinical setting, CD4 count and tuberculosis prevalence. For some analyses, few studies and participants contributed data and results should, therefore, be interpreted with caution. The review was further limited by the number of studies that used a lower quality reference standard and the high risk of selection bias in several studies owing to exclusion of patients unable to produce sputum. </p> <section id="CD011420-sec-0098"> <h4 class="title">Completeness of evidence</h4> <p>This data set involved comprehensive searching and correspondence with experts in the field and the test manufacturer to identify additional studies, as well as correspondence with study authors to obtain additional and unpublished data on study characteristics. The search strategy included studies published in all languages. However, as diagnostic accuracy studies are poorly indexed, we acknowledge that we may have missed some studies despite the comprehensive search. </p> </section> <section id="CD011420-sec-0099"> <h4 class="title">Accuracy of the reference standards used</h4> <p>In a diagnostic test accuracy systematic review, the reference standard is the best available test to determine the presence or absence of the target condition. We only included studies with a microbiological reference standard, which is considered the best currently available reference standard for tuberculosis. We included studies that evaluated LF‐LAM for diagnosis of pulmonary tuberculosis, extrapulmonary tuberculosis, or both pulmonary and extrapulmonary tuberculosis. However, we recognize that a substantial number of tuberculosis cases may not be verified by microbiological testing if only sputum is tested and when patients with advanced HIV are assessed. We acknowledge difficulties in diagnosing HIV‐associated tuberculosis with extrapulmonary and disseminated forms of disease and considered a standardized reference standard using two or more specimen types consistently for all participants to be of higher quality than a reference standard using one specimen type. The higher quality reference standard is better at classifying which patients have and do not have tuberculosis. A lower quality reference standard may miss some tuberculosis cases and classify some tuberculosis patients as not having tuberculosis. This may make a truly positive LF‐LAM result seem like a false‐positive result leading to an underestimation of specificity. In this review, only one study (12%) for tuberculosis diagnosis among symptomatic participants and two studies (29%) for tuberculosis diagnosis among unselected participants used a higher quality reference standard for all participants. </p> <p>We did not assess performance against a composite reference standard that uses microbiological or clinical information to classify tuberculosis. This was done in the original WHO guideline (<a href="./references#CD011420-bbs2-0163" title="World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. WHO/HTM/TB/2015.25. Geneva: World Health Organization, 2015. ">WHO Lipoarabinomannan Policy Guidance 2015</a>), and Cochrane Review ((<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>), but found little impact on pooled estimates of sensitivity and specificity relative to performance measured against a microbiological reference standard. </p> <p>We could not determine whether heterogeneity in specificity estimates was fully attributable to misclassification bias. Some studies (<a href="./references#CD011420-bbs2-0138" title="NelJS , LippincottCK , BerhanuR , SpencerDC , SanneIM , IveP . Does disseminated nontuberculous mycobacterial disease cause false‐positive Determine TB‐LAM lateral flow assay results? A retrospective review. Clinincal Infectious Diseases2017;65(7):1226‐8. ">Nel 2017</a>; <a href="./references#CD011420-bbs2-0144" title="QvistT , JohansenIS , PresslerT , HoibyN , AndersenA B , KatzensteinTL , et al. Urine lipoarabinomannan point‐of‐care testing in patients affected by pulmonary nontuberculous mycobacteria ‐ experiences from the Danish Cystic Fibrosis cohort study. BMC Infectious Diseases2014;14:655. ">Qvist 2014</a>) have postulated that infection with (disseminated) nontuberculous mycobacteria (NTM) may also result in false‐positive results, although this hypothesis is still questioned (<a href="./references#CD011420-bbs2-0123" title="Gupta‐WrightA , KerkhoffA D , MeintjesG , CorbettEL . Urinary lipoarabinomannan detection and disseminated nontuberculous mycobacterial disease. Clinical Infectious Diseases2018;66(1):158. ">Gupta‐Wright 2018</a>). Only one study (<a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>) was conducted outside of sub‐Saharan Africa, and was noted to report the lowest specificity estimates of all included studies. Reasons for potential false‐positive results remain unclear and it is unknown if differences in the epidemiology of disseminated NTM and other opportunistic infections across settings could contribute to variation in specificity. </p> </section> <section id="CD011420-sec-0100"> <h4 class="title">Quality and quality of reporting of the included studies</h4> <p>There were few studies that included participants unable to expectorate sputum and few studies that included extrapulmonary specimens in addition to sputum. We had limited data to address these quality items in sensitivity analyses and acknowledge that these features may have contributed to risk of bias in the accuracy estimates. For studies among symptomatic participants, in the patient selection domain, we considered six studies (75%) to be at high risk of bias, and in the reference standard domain, we considered seven studies (88%) to be at high risk of bias. For studies with unselected participants, in the patient selection domain, we considered four studies (57%) to be at high risk of bias and in the reference standard domain, we considered five studies (71%) to be at high risk of bias. Risk of bias was considered low for the index test and flow and timing domains. </p> <p>Using the GRADE approach, we judged the evidence for LF‐LAM sensitivity to be moderate. This means that we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. We judged the evidence for LF‐LAM specificity to be low or very low. This means that we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>In general, studies were fairly well reported, though we corresponded with some of the primary study authors to ask for clarification mainly in relation to interpretation of test positivity. </p> </section> </section> <section id="CD011420-sec-0101"> <h3 class="title" id="CD011420-sec-0101">Applicability of findings to the review question</h3> <p>Overall, we had low concern about the applicability of the included studies to our review question as assessed by Quality Assessment of Diagnostic Accuracy Studies‐2 (QUADAS‐2). However, studies of HIV‐positive adults irrespective of signs and symptoms had low representation of asymptomatic individuals, as most participants in fact presented with signs and symptoms of tuberculosis. To date, no study has evaluated LF‐LAM in an asymptomatic population. This review evaluated LF‐LAM at the current manufacturer‐recommended cut‐off for positivity. Therefore, the findings should be considered applicable to the test. However, it is important to note that this review assessed sensitivity and specificity in applied research settings. Although the participant characteristics and settings matched our review question in most cases, as studies were carried out under research conditions, it is possible that the accuracy of LF‐LAM may be lower in routine practice settings. All studies were performed in low‐ or middle‐income countries, but only a single study was conducted outside sub‐Saharan Africa. It is therefore possible that the LF‐LAM would perform differently in settings outside Africa. For the reference test domain, most studies had low concern for applicability. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011420-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD011420-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Studies with symptomatic participants ‐ Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study." data-id="CD011420-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Studies with symptomatic participants ‐ Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Studies with unselected participants ‐ Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study." data-id="CD011420-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Studies with unselected participants ‐ Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among symptomatic participants. The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD011420-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among symptomatic participants. The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among symptomatic participants, by health care setting. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. The individual studies are ordered by decreasing sensitivity. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD011420-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among symptomatic participants, by health care setting. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. The individual studies are ordered by decreasing sensitivity. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies with symptomatic participants, stratified by CD4 (CD4 &gt; 200 and CD4 ≤ 200; CD4 &gt; 100 and CD4 ≤ 100). The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD011420-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies with symptomatic participants, stratified by CD4 (CD4 &gt; 200 and CD4 ≤ 200; CD4 &gt; 100 and CD4 ≤ 100). The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Plot by CD4 of diagnostic accuracy in adults with signs and symptoms of tuberculosis.(A) Sensitivity by CD4 strata; (B) Specificity by CD4 strata. The circle represents the pooled estimates (median), with bars representing 95% credible intervals." data-id="CD011420-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Plot by CD4 of diagnostic accuracy in adults with signs and symptoms of tuberculosis.</p> <p>(A) Sensitivity by CD4 strata; (B) Specificity by CD4 strata. The circle represents the pooled estimates (median), with bars representing 95% credible intervals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants not assessed for signs and symptoms of tuberculosis. The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD011420-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants not assessed for signs and symptoms of tuberculosis. The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants, by health care setting. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. The individual studies are ordered by decreasing sensitivity. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD011420-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants, by health care setting. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. The individual studies are ordered by decreasing sensitivity. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="(A) AlereTM TB LAM Ag test. To the sample pad (white pad marked by the arrow symbols) 60 µL of urine is applied and visualized bands are read 25 minutes later. (B) Updated Reference Scale Card accompanying test strips to ‘grade' the test result and Alere positivity. Copyright © [2019] [Abbott Inc]: reproduced with permission." data-id="CD011420-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>(A) Alere<sup>TM</sup> TB LAM Ag test. To the sample pad (white pad marked by the arrow symbols) 60 µL of urine is applied and visualized bands are read 25 minutes later. (B) Updated Reference Scale Card accompanying test strips to ‘grade' the test result and Alere positivity. Copyright © [2019] [Abbott Inc]: reproduced with permission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/appendices#CD011420-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Reference card grading of Alere Determine™ TB LAM. Comparison of the current reference card (top) with the prior reference card (bottom). Copyright © [2019] [Abbott Inc]: reproduced with permission." data-id="CD011420-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Reference card grading of Alere Determine™ TB LAM. Comparison of the current reference card (top) with the prior reference card (bottom). Copyright © [2019] [Abbott Inc]: reproduced with permission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/appendices#CD011420-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Summary plot of LF‐LAM sensitivity and specificity for tuberculosis detection in symptomatic participants. The blue circles represent individual study estimates for sensitivity and specificity for the studies among symptomatic participants. The size of the circle is proportional to the sample size of the study. The filled black circle is the pooled estimate for sensitivity and specificity. The solid red line marks the 95% credible region around the summary estimate, the dashed red line marks the 95% prediction region." data-id="CD011420-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Summary plot of LF‐LAM sensitivity and specificity for tuberculosis detection in symptomatic participants. The blue circles represent individual study estimates for sensitivity and specificity for the studies among symptomatic participants. The size of the circle is proportional to the sample size of the study. The filled black circle is the pooled estimate for sensitivity and specificity. The solid red line marks the 95% credible region around the summary estimate, the dashed red line marks the 95% prediction region. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/appendices#CD011420-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Summary plot of LF‐LAM sensitivity and specificity for tuberculosis detection in unselected participants. The blue circles represent individual study estimates for sensitivity and specificity for the studies among unselected participants. The size of the circle is proportional to the sample size of the study. The filled black circle is the pooled estimate for sensitivity and specificity. The solid red line marks the 95% credible region around the summary estimate, the dashed red line marks the 95% prediction region." data-id="CD011420-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Summary plot of LF‐LAM sensitivity and specificity for tuberculosis detection in unselected participants. The blue circles represent individual study estimates for sensitivity and specificity for the studies among unselected participants. The size of the circle is proportional to the sample size of the study. The filled black circle is the pooled estimate for sensitivity and specificity. The solid red line marks the 95% credible region around the summary estimate, the dashed red line marks the 95% prediction region. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/appendices#CD011420-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG14.png" target="_blank"><b></b></a></p> </div><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants, by CD4 strata (CD4 &gt; 200 and CD4 ≤ 200) and health setting. The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD011420-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants, by CD4 strata (CD4 &gt; 200 and CD4 ≤ 200) and health setting. The individual studies are ordered by decreasing sensitivity. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/appendices#CD011420-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-AFig-FIG15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-AFig-FIG15.png" target="_blank"><b></b></a></p> </div><img alt="Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants, by CD4 strata (CD4 &gt; 100 and CD4 ≤ 100) and health setting. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)" data-id="CD011420-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Forest plots of LF‐LAM sensitivity and specificity for tuberculosis against a microbiological reference standard for studies among unselected participants, by CD4 strata (CD4 &gt; 100 and CD4 ≤ 100) and health setting. TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/appendices#CD011420-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-AFig-FIG15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-001" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-001.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, all settings." data-id="CD011420-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-001.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 1</div> <div class="figure-caption"> <p>Symptomatic adults, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-001.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-002" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-002.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, inpatients." data-id="CD011420-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-002.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 2</div> <div class="figure-caption"> <p>Symptomatic adults, inpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-002.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-003" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-003.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, outpatients." data-id="CD011420-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-003.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 3</div> <div class="figure-caption"> <p>Symptomatic adults, outpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-003.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-004" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-004.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, CD4 &gt; 200, all settings." data-id="CD011420-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-004.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 4</div> <div class="figure-caption"> <p>Symptomatic adults, CD4 &gt; 200, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-004.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-005" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-005.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, CD4 ≤ 200, all settings." data-id="CD011420-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-005.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 5</div> <div class="figure-caption"> <p>Symptomatic adults, CD4 ≤ 200, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-005.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-006" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-006.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, CD4 ≤ 200, inpatients." data-id="CD011420-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-006.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 6</div> <div class="figure-caption"> <p>Symptomatic adults, CD4 ≤ 200, inpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-006.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-007" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-007.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, CD4 ≤ 200, outpatients." data-id="CD011420-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-007.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 7</div> <div class="figure-caption"> <p>Symptomatic adults, CD4 ≤ 200, outpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-007.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-008" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-008.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, CD4 &gt; 100, all settings." data-id="CD011420-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-008.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 8</div> <div class="figure-caption"> <p>Symptomatic adults, CD4 &gt; 100, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-008.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-009" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-009.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, CD4 ≤ 100, all settings." data-id="CD011420-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-009.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 9</div> <div class="figure-caption"> <p>Symptomatic adults, CD4 ≤ 100, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-009.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-010" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-010.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, CD4 ≤ 100, inpatients." data-id="CD011420-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-010.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 10</div> <div class="figure-caption"> <p>Symptomatic adults, CD4 ≤ 100, inpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-010.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-011" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-011.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, CD4 ≤ 100, outpatients." data-id="CD011420-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-011.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 11</div> <div class="figure-caption"> <p>Symptomatic adults, CD4 ≤ 100, outpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-011.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-012" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-012.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, CD4 101‐200, all settings." data-id="CD011420-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-012.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 12</div> <div class="figure-caption"> <p>Symptomatic adults, CD4 101‐200, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-012.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-013" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-013.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, CD4 101‐200, inpatients." data-id="CD011420-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-013.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 13</div> <div class="figure-caption"> <p>Symptomatic adults, CD4 101‐200, inpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-013.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-014" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-014.xxx" target="_blank"><b></b></a></p> </div><img alt="Symptomatic adults, CD4 101‐200, outpatients." data-id="CD011420-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-014.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 14</div> <div class="figure-caption"> <p>Symptomatic adults, CD4 101‐200, outpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-014.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-017" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-017.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, all settings." data-id="CD011420-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-017.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 17</div> <div class="figure-caption"> <p>Unselected adults, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-017.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-018" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-018.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, inpatients." data-id="CD011420-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-018.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 18</div> <div class="figure-caption"> <p>Unselected adults, inpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-018.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-019" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-019.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, outpatients." data-id="CD011420-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-019.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 19</div> <div class="figure-caption"> <p>Unselected adults, outpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-019.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-020" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-020.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, CD4 &gt; 200, all settings." data-id="CD011420-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-020.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 20</div> <div class="figure-caption"> <p>Unselected adults, CD4 &gt; 200, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-020.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-021" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-021.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, CD4 ≤ 200, all settings." data-id="CD011420-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-021.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 21</div> <div class="figure-caption"> <p>Unselected adults, CD4 ≤ 200, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-021.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-022" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-022.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, CD4 ≤ 200, inpatients." data-id="CD011420-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-022.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 22</div> <div class="figure-caption"> <p>Unselected adults, CD4 ≤ 200, inpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-022.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-023" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-023.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, CD4 ≤ 200, outpatients." data-id="CD011420-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-023.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 23</div> <div class="figure-caption"> <p>Unselected adults, CD4 ≤ 200, outpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-023.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-024" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-024.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, CD4 &gt; 100, all settings." data-id="CD011420-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-024.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 24</div> <div class="figure-caption"> <p>Unselected adults, CD4 &gt; 100, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-024.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-025" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-025.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, CD4 ≤ 100, all settings." data-id="CD011420-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-025.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 25</div> <div class="figure-caption"> <p>Unselected adults, CD4 ≤ 100, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-025.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-026" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-026.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, CD4 ≤ 100, inpatients." data-id="CD011420-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-026.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 26</div> <div class="figure-caption"> <p>Unselected adults, CD4 ≤ 100, inpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-026.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-027" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-027.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, CD4 ≤ 100, outpatients." data-id="CD011420-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-027.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 27</div> <div class="figure-caption"> <p>Unselected adults, CD4 ≤ 100, outpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-027.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-028" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-028.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, CD4 101‐200, all settings." data-id="CD011420-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-028.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 28</div> <div class="figure-caption"> <p>Unselected adults, CD4 101‐200, all settings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-028.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-029" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-029.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, CD4 101‐200, inpatients." data-id="CD011420-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-029.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 29</div> <div class="figure-caption"> <p>Unselected adults, CD4 101‐200, inpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-029.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011420-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/urn:x-wiley:14651858:media:CD011420:CD011420-TST-030" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_t/tCD011420-TST-030.xxx" target="_blank"><b></b></a></p> </div><img alt="Unselected adults, CD4 101‐200, outpatients." data-id="CD011420-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-030.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 30</div> <div class="figure-caption"> <p>Unselected adults, CD4 101‐200, outpatients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/media/CDSR/CD011420/image_n/nCD011420-TST-030.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011420-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">LF‐LAM for symptomatic participants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Review question:</b> what is the diagnostic accuracy of LF‐LAM for the diagnosis of active tuberculosis in HIV‐positive adults with signs and symptoms of tuberculosis? </p> <p><b>Studies:</b> cross‐sectional studies and randomized controlled trials </p> <p><b>Participants:</b> HIV‐positive adults with tuberculosis signs and symptoms </p> <p><b>Setting:</b> all settings (inpatient and outpatient) </p> <p><b>Index test:</b> LF‐LAM </p> <p><b>Threshold for index tests</b>: manufacturer's recommended threshold for positivity i.e. grade 1 of 4 (revised reference card) or the corresponding grade 2 of 5 (prior reference card) </p> <p><b>Reference standard:</b> microbiological (mycobacterial culture and/or nucleic acid amplification test) </p> <p><b>Role:</b> an add on to clinical judgement and with other tests to assist in tuberculosis diagnosis </p> <p><b>Pooled sensitivity (95%CrI): 42% (31% to 55%</b> ); <b>pooled specificity (95% CrI): 91% (85% to 95%)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1000 participants tested (95% CrI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 1%</b> </p> <p><b>Typically seen in asymptomatic persons in outpatient settings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> <p><b>Typically seen in symptomatic persons in all settings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> <p><b>Typically seen in seriously ill persons in inpatient settings</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True positives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4</b> (3 to 6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42</b> (31 to 55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>126</b> (93 to 165) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1277 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a,b,c,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False negatives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> (4 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>58</b> (45 to 69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>174</b> (135 to 207) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True negatives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>901</b> (842 to 941) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>819</b> (765 to 855) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>637</b> (595 to 665) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2172 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>c,e,f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False positives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>89</b> (49 to 148) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>81</b> (45 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>63</b> (35 to 105) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Abbreviations: Crl:</b> credible interval. </p> <p><b>Explanations</b> </p> <p><sup>a</sup>As assessed by QUADAS‐2, in the patient selection domain, we judged six studies (75%) at high risk of bias because they did not avoid inappropriate exclusions. We downgraded one level for risk of bias.<br/> <sup>b</sup>For individual studies, sensitivity estimates ranged from 23% to 68%. We thought that differences in enrolment criteria (different populations targeted) or CD4 count could explain in part the heterogeneity. We did not downgrade for inconsistency.<br/> <sup>c</sup>The median tuberculosis prevalence in the studies was 42% and thus the results tend to be more applicable to settings with a higher tuberculosis prevalence. For tuberculosis prevalence of 1% and 10%, whether or not to downgrade remains unclear. It is possible the test will perform differently at lower prevalences. We did not downgrade for indirectness.<br/> <sup>d</sup>We thought the 95% CrIs around true positives and false negatives would likely not lead to different decisions depending on which credible limits are assumed. We did not downgrade for imprecision.<br/> <sup>e</sup>As assessed by QUADAS‐2, in the reference standard domain, we judged seven studies (88%) at high risk of bias because we thought the reference standard used was unlikely to correctly classify the target condition. We downgraded two levels for risk of bias.<br/> <sup>f</sup>We thought the 95% CrIs around true negatives and false positives would likely lead to different decisions depending on which credible limits are assumed. We downgraded one level for imprecision.<br/> <br/> <b>GRADE certainty of evidence</b> (<a href="./references#CD011420-bbs2-0120" title="McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEpro 2015</a>; <a href="./references#CD011420-bbs2-0104" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>)<br/> <b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p>The table displays normalized frequencies within a hypothetical cohort of 1000 patients at three different prevalences of tuberculosis (pre‐test probabilities): 1%, 10% and 30%. Credible limits (Crls) were estimated based on those around the point estimates for pooled sensitivity and specificity. </p> <p><b>Note:</b> the results on this table should not be interpreted in isolation from the results of the individual included studies contributing to each summary test accuracy measure. These are reported in the main body of the text of the review. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">LF‐LAM for symptomatic participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011420-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">LF‐LAM for unselected participants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Review question:</b> what is the diagnostic accuracy of LF‐LAM for the diagnosis of active tuberculosis in HIV‐positive adults irrespective of signs and symptoms of tuberculosis? </p> <p><b>Studies:</b> cross‐sectional studies and randomized controlled trials </p> <p><b>Participants:</b> HIV‐positive unselected adults not assessed for signs and symptoms of tuberculosis i.e. irrespective of symptoms </p> <p><b>Setting:</b> all settings (inpatient and outpatient) </p> <p><b>Index test:</b> LF‐LAM </p> <p><b>Threshold for index tests</b>: manufacturer's recommended threshold for positivity i.e. grade 1 of 4 (revised reference card) or the corresponding grade 2 of 5 (prior reference card) </p> <p><b>Reference standard:</b> microbiological (mycobacterial culture and/or nucleic acid amplification test) </p> <p><b>Role:</b> an add on to clinical judgement and with other tests to assist in tuberculosis diagnosis </p> <p><b>Pooled sensitivity (95% CrI): 35% (22% to 50%); pooled specificity (95% CrI): (89% to 98%)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1000 participants tested (95% CrI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 1%</b> </p> <p><b>Typically seen in asymptomatic persons in outpatient settings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> <p><b>Typically seen in symptomatic persons in all settings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> <p><b>Typically seen in seriously ill persons in inpatient settings</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True positives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> (2 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>35</b> (22 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>105</b> (66 to 150) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>432 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False negatives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> (5 to 8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>65</b> (50 to 78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>195</b> (150 to 234) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True negatives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>941</b> (881 to 970) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>855</b> (801 to 882) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>665</b> (623 to 686) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2933 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>d,e,f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False positives</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>49</b> (20 to 109) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>45</b> (18 to 99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>35</b> (14 to 77) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Abbreviations:</b> Crl: Credible interval. </p> <p><b>Explanations</b> </p> <p><sup>a</sup>As assessed by QUADAS‐2, in the patient selection domain, we judged four studies (57%) at high risk of bias because they did not avoid inappropriate exclusions. We downgraded one level for risk of bias.<br/> <sup>b</sup>For individual studies, sensitivity ranged from 0% to 67%. We thought that the percentage of patients with tuberculosis symptoms or differences in CD4 count could explain in part the heterogeneity. One study, <a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a>, with sensitivity of 0% differed from the other studies by including a) a population of exclusively pregnant women attending an antenatal care setting, b) a low proportion of symptomatic participants (19%), c) a low tuberculosis prevalence (1%), and d) a high median CD4 cell count (437 cells per µL). One study, <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>, with sensitivity 67% differed from the other studies by being conducted in Myanmar, and was the only study included in this review that evaluated LF‐LAM in a setting outside sub‐Saharan Africa. We did not downgrade for inconsistency.<br/> <sup>c</sup>We thought the 95% CrI around true positives and false negatives would likely not lead to different decisions depending on which credible limits are assumed. We did not downgrade for imprecision.<br/> <sup>d</sup>As assessed by QUADAS‐2, in the reference standard domain, we judged five studies (71%) at high risk of bias because we thought the reference standard used was unlikely to correctly classify the target condition. We downgraded one level for risk of bias.<br/> <sup>e</sup>For individual studies, specificity ranged from 67% to 99%. Eighty‐six per cent (6/7) of the included studies had specificity of 94% or higher. One study, <a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a>, with specificity 67% differed from the other studies by being conducted in Myanmar, and is the only study included in this review that evaluated LF‐LAM in a setting outside sub‐Saharan Africa. We did not downgrade for inconsistency.<br/> <sup>f</sup>We thought the wide 95% Crls around true negatives and false positives would lead to different decisions depending on which credible limits are assumed. We downgraded one level for imprecision.<br/> <br/> <b>GRADE certainty of evidence</b> (<a href="./references#CD011420-bbs2-0120" title="McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEpro 2015</a>; <a href="./references#CD011420-bbs2-0104" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>)<br/> <b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate</b> : we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low</b> : our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> <p>The table displays normalized frequencies within a hypothetical cohort of 1000 patients at three different prevalences of tuberculosis (pre‐test probabilities): 1%, 10% and 30%. Credible limits (Crls) were estimated based on those around the point estimates for pooled sensitivity and specificity. </p> <p><b>Note:</b> the results on this table should not be interpreted in isolation from the results of the individual included studies contributing to each summary test accuracy measure. These are reported in the main body of the text of the review. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">LF‐LAM for unselected participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011420-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (% symptom)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median CD4 cell count per µL (IQR)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TB prevalence % (n/N)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Did the study avoid inappropriate exclusion?</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specimens collected</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High‐quality reference standard<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unique study characteristics</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>HIV‐positive adults with signs and symptoms of TB</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0003" title="DrainPK , GounderL , SahidF , MoosaMY . Rapid urine LAM testing improves diagnosis of expectorated smear‐negative pulmonary tuberculosis in an HIV‐endemic region. Scientific Reports2016;6:19992. ">Drain 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b><br/> Two of four TB‐related symptoms (cough, fever weight loss, night sweat) for &gt; 2 weeks; smear microscopy negative x 2 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168 (89 to 256)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63%<br/> (57/90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); HIV positive (93.2%); targeting a relatively well outpatient population; Karnofsky performance score &gt; 50 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Cough &gt; 2 weeks or any cough and one of weight loss, night sweats or fever; severely ill; CD4&lt; 200 or BMI below 17 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients (33%); Inpatients (67%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 (43 to 214)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57% (156/275)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples; urine Xpert only for patients without sputum available</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 15 years); LAM‐guided treatment; excluded many participants from analysis<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0007" title="JumaFO , YongaG , WaweruP , RevathiG , NelsonM , ShahR . The diagnostic accuracy of Determine TB LAM antigen in detection of extra pulmonary tuberculosis (EPTB). Journal of Infection2017;75(6):583‐6. ">Juma 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Suggestive of extrapulmonary TB, not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33%<br/> (29/67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Extrapulmonary samples only, no sputum samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 14 years), HIV‐positive (68%); excluded patients with concomitants active pulmonary TB </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0010" title="NakiyingiL , MoodleyVM , ManabeYC , NicolMP , HolshouserM , ArmstrongDT , et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV‐infected adults. Journal of Acquired Immune Deficiency Syndromes2014;66(3):270‐9. ">Nakiyingi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Any of cough, fever weight loss, night sweat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients (45%); Inpatients (55%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 (41 to 337)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37%<br/> (367/997) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples; Blood culture for all</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); multisite; large sample size.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Presence of a pericardial effusion and suspected of pericardial TB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139<br/> (81 to 249) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%<br/> (36/38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Extrapulmonary samples (pericardial effusion); pulmonary samples for some</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); HIV‐positive (74%); excluded participants from analysis affecting specificity<sup>c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0012" title="PeterJG , TheronG , vanZyl‐SmitR , HaripersadA , MottayL , KrausS , et al. Diagnostic accuracy of a urine lipoarabinomannan strip‐test for TB detection in HIV‐infected hospitalised patients. European Respiratory Journal2012;40(5):1211‐20. ">Peter 2012a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Any of cough, fever weight loss, night sweat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (47 to 197) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48%<br/> (116/241) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant pulmonary samples; clinically relevant extrapulmonary samples. No study defined algorithm. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); multisite; TB diagnostic work‐up was not standardized but up to clinical judgements </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Any of cough, fever weight loss, night sweat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210<br/> (103 to 375) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32%<br/> (181/569) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); multisite; nested within a randomized, parallel‐arm trial.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0014" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point‐of‐care, urine‐based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV‐positive hospital inpatients: a pragmatic, parallel‐group, multicountry, open‐label, randomised controlled trial. Lancet2016;387(10024):1187‐97. ">Peter 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic:</b> </p> <p>Any of cough, fever weight loss, night sweat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> <p>(26 to 198)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29%<br/> (342/1172) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples; clinically relevant extrapulmonary samples. No study defined algorithm.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); multisite; LAM arm of a randomized controlled trial.</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>HIV‐positive adults irrespective of signs and symptoms of TB</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>91% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients (85%); Inpatients (15%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/> (35 to 256) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12%<br/> (55/469) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); majority symptomatic.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0002" title="DrainPK , LosinaE , ColemanSM , GiddyJ , RossD , KatzJN , et al. Value of urine lipoarabinomannan grade and second test for optimising clinic‐based screening for HIV‐associated pulmonary tuberculosis. Journal of Acquired Immune Deficiency Syndromes2015;68(3):274‐80. ">Drain 2015a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>proportion symptomatic not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/> (107 to 379) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17%<br/> (54/320) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0004" title="FloridiaM , CiccacciF , AndreottiM , HassaneA , SidumoZ , MagidNA , et al. Tuberculosis case finding with combined rapid point‐of‐care assays (Xpert MTB/RIF and Determine TB LAM) in HIV‐positive individuals starting antiretroviral therapy in Mozambique. Clinical Infectious Diseases2017;65(11):1878‐83. ">Floridia 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>34% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278<br/> (142 to 395) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%<br/> (90/972) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 15 years). LAM‐guided treatment.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0005" title="HanifaY , FieldingK L , ChihotaV N , AdonisL , CharalambousS , KarstaedtA , et al. Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa. PLOS One2016;11(6):e0156866. [DOI: 10.1371/journal.pone.0156866] ">Hanifa 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>53% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111<br/> (56 to 161) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%<br/> (40/408) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples; blood culture for all</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years); CD4 &lt; 200; reference standard included any sample taken within six months from enrolment. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0008" title="LaCourseSM , CranmerLM , MatemoD , RichardsonB , KinuthiaJ , John‐StewartG , et al. Active tuberculosis case finding in HIV‐infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. Journal of Acquired Immune Deficiency Syndromes2016;71(2):219‐27. ">LaCourse 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>19% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437<br/> (342 to 565) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%<br/> (3/266) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pregnant women (&gt; 16 years) attending ANC; healthy population; one person with CD4&lt; 400; Few TB cases (n = 3). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>91% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149<br/> (55‐312) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33%<br/> (139/413) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples; Blood culture for all; Clinically relevant extrapulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years). Included many samples from different sites</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011420-bbs2-0015" title="ThitSS , AungNM , HtetZW , BoydMA , SawHA , AnsteyNM , et al. The clinical utility of the urine‐based lateral flow lipoarabinomannan assay in HIV‐infected adults in Myanmar: an observational study. BMC Medicine2017;15(1):145. ">Thit 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unselected:</b> </p> <p>33% symptomatic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients (90%); Inpatients (10%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270<br/> (128 to 443) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%<br/> (54/517) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary samples</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conducted in Myanmar. Adults (median age 34). Reference standard included samples taken within six months from enrolment. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b>Abbreviations: LF‐LAM:</b> lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); <b>ANC:</b> antenatal clinic; <b>BMI:</b> body mass index; <b>IQR:</b> interquartile range; <b>TB:</b> tuberculosis; <b>Xpert:</b> Xpert MTB/RIF<br/> <sup>a</sup>For a microbiological reference standard, we considered a higher quality reference standard to be one in which two or more specimen types were evaluated for TB diagnosis in all participants as part of a defined standardized study algorithm.<br/> <sup>b</sup><a href="./references#CD011420-bbs2-0006" title="HuergaH , FerlazzoG , BevilacquaP , KirubiB , ArdizzoniE , WanjalaS , et al. Incremental yield of including Determine‐TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV‐positive patients in Kenya. PLOS One2017;12(1):e0170976. [DOI: 10.1371/journal.pone.0170976] ">Huerga 2017</a> excluded participants from analysis if missing Xpert results or culture contaminated for any of the samples in the absence of a positive result; overall samples size 474 (156 with TB); 275 included in analysis (156 with TB).<br/> <sup>c</sup><a href="./references#CD011420-bbs2-0011" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports2016;6:32924. [DOI: 10.1038/srep32924] ">Pandie 2016</a> excluded a large number of non‐TB participants from analysis; Overall samples size 102 (36 with TB); 38 included for analysis (36 TB cases). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011420-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">LF‐LAM pooled sensitivity and specificity for TB diagnosis, by study population</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Type of analysis </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Symptomatic participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Unselected participants </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies (total participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with TB (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies (total participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with TB (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall accuracy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies</p> <p>(3449)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1277</p> <p>(37%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42%</p> <p>(31% to 55%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91%</p> <p>(85% to 95%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 studies</p> <p>(3365)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>432</p> <p>(13%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35%</p> <p>(22% to 50%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> <p>(89% to 98%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>By setting</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies</p> <p>(2253)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>868</p> <p>(39%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52%<br/> (40% to 64%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87%<br/> (78% to 93%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>(537)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> <p>(30%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62%<br/> (41% to 83%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84%<br/> (48% to 96%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(1196)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409</p> <p>(34%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29%</p> <p>(17% to 47%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96%</p> <p>(91% to 99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies</p> <p>(2828)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273</p> <p>(10%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31%</p> <p>(18% to 47%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%</p> <p>(87% to 99%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>By CD4 cell</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 &gt; 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>(738)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> <p>(22%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16%<br/> (8% to 31%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94%<br/> (81% to 97%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>a</sup> </p> <p>(156)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(1825)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>722</p> <p>(40%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45%<br/> (31% to 61%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89%<br/> (77% to 94%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(706)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> <p>(12%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26%<br/> (9% to 56%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96%<br/> (87% to 98%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 &gt; 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(1519)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>425</p> <p>(28%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17%<br/> (10% to 27%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95%<br/> (89% to 98%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(952)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> <p>(12%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%<br/> (10% to 35%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98%<br/> (95% to 99%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(1239)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>512</p> <p>(41%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54%<br/> (38% to 69%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88%<br/> (77% to 94%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>(417)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(31%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47%<br/> (40% to 64%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%<br/> (77% to 96%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 101‐199</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>(586)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> <p>(36%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24%<br/> (14% to 38%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%<br/> (77 to 96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study</p> <p>(103)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> <p>(13%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>By CD4 and setting</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 200</p> <p>inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(1009)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> <p>(34%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54%</p> <p>(34% to 73%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80%</p> <p>(58% to 91%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>c</sup> </p> <p>(54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> <p>(26%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 100</p> <p>inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(734)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> <p>(37%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61%</p> <p>(40% to 78%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81%</p> <p>(61% to 91%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(200)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> <p>(42%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57%</p> <p>(33% to 79%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90%</p> <p>(69% to 97%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 101‐199</p> <p>inpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(275)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> <p>(28%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32%</p> <p>(16% to 57%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81%</p> <p>(55% to 92%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>d</sup> </p> <p>(9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> <p>(44%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 200</p> <p>outpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>f</sup> </p> <p>(249)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> <p>(39%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(652)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(10%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21%</p> <p>(8% to 48%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96%</p> <p>(89% to 99%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 ≤ 100</p> <p>outpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>g</sup> </p> <p>(121)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> <p>(40%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>(217)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> <p>(21%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> <p>(20 to 64)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87%</p> <p>(68 to 94)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD4 101‐199</p> <p>outpatients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>h</sup> </p> <p>(128)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> <p>(40%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study<sup>e</sup> </p> <p>(94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> <p>(10%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b>Abbreviations: LF‐LAM:</b> lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); <b>Crl:</b> credible interval; <b>TB:</b> tuberculosis.<br/> <sup>a</sup><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, Sensitivity 27% (6% to 61%); Specificity 99% (96% to 100%); <sup>b</sup><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, Sensitivity 38% (14% to 68%); Specificity 99% (94% to 100%); <sup>c</sup><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, Sensitivity 64% (35% to 87%); Specificity 82% (67% to 93%); <sup>d</sup><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, Sensitivity 75% (19% to 99%); Specificity 100% (48% to 100%); <sup>e</sup><a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>, Sensitivity 22% (3% to 60%); Specificity 99% (94% to 100%); <sup>f</sup><a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>, Sensitivity 24% (16% to 33%); Specificity 94% (89% to 97%); <sup>g</sup><a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>, Sensitivity 30% (18% to 46%); Specificity 93% (85% to 98%); <sup>h</sup><a href="./references#CD011420-bbs2-0013" title="PeterJ , TheronG , ChandaD , ClowesP , RachowA , LesoskyM , et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV‐infected outpatients under investigation for TB and able to self‐expectorate sputum for diagnostic testing. BMC Infectious Diseases2015;15:262. ">Peter 2015</a>, Sensitivity 18% (8% to 31%); Specificity 95% (87% to 99%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">LF‐LAM pooled sensitivity and specificity for TB diagnosis, by study population</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011420-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses, LF‐LAM</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Type of analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Symptomatic participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Unselected participants</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Including studies at low risk of patient selection bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>1413</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48%</p> <p>(29% to 67%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82%</p> <p>(61% to 92%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>1338</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39%</p> <p>(17% to 66%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93%</p> <p>(69% to 98%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Including studies at low risk of reference standard bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study</p> <p>997</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>821</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24%</p> <p>(8% to 53%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99%</p> <p>(95% to 99%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Including studies that used only fresh specimens</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>2511</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52%</p> <p>(38% to 68%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91%</p> <p>(82% to 95%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies</p> <p>2544</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41%</p> <p>(26% to 56%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93%</p> <p>(82% to 97%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Re‐classificiation of <a href="./references#CD011420-bbs2-0001" title="BjerrumS , KenuE , LarteyM , NewmanMJ , AddoKK , AndersenAB , et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV‐infected adults in Ghana‐ findings from the DETECT HIV‐TB study. BMC Infectious Diseases2015;15:407. ">Bjerrum 2015</a>; <a href="./references#CD011420-bbs2-0009" title="LawnSD , KerkhoffAD , BurtonR , SchutzC , BoulleA , VogtM , et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB‐LAM for routine diagnostic testing for tuberculosis in HIV‐infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine2017;15(1):67. ">Lawn 2017</a> as studies among symptomatic participant (&gt; 80% participants symptomatic) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 studies 4331</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42%</p> <p>(33% to 52%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93%</p> <p>(88% to 96%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies</p> <p>2483</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31%</p> <p>(16% to 50%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94%</p> <p>(84% to 98%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Abbreviations: LF‐LAM:</b> lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); <b>Crl:</b> Credible Interval </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses, LF‐LAM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011420-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Original Alere LAM review, main findings</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Type of analysis </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Symptomatic participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Unselected participants </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies (total participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies (total participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall accuracy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies (2313)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45% (29% to 63%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92% (80% to 97%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies<sup>a</sup> (1055 ) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30% (20% to 43%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94% (86% to 97%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>By setting</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies (1299)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53% (38% to 70%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 % (73% to 96%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Insufficient data</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Insufficient data</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Insufficient data</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Abbreviations: LF‐LAM:</b> lateral flow urine lipoarabinomannan assay (Alere Determine™ TB lipoarabinomannan assay); <b>Crl:</b> credible interval </p> <p>Main findings from the original review on LF‐LAM accuracy (<a href="./references#CD011420-bbs2-0172" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV‐positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011420.pub2] ">Shah 2016</a>).<br/> <sup>a</sup>Reported at grade 1 on the previous reference scale card with five bands that is outdated and no longer the recommended positivity threshold. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Original Alere LAM review, main findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/full#CD011420-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011420-tbl-0007"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p>Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic adults, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3449</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">2 Symptomatic adults, inpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2253</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic adults, outpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1196</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">4 Symptomatic adults, CD4 &gt; 200, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>738</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">5 Symptomatic adults, CD4 ≤ 200, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1825</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">6 Symptomatic adults, CD4 ≤ 200, inpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1009</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">7 Symptomatic adults, CD4 ≤ 200, outpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">8 Symptomatic adults, CD4 &gt; 100, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1519</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">9 Symptomatic adults, CD4 ≤ 100, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1251</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">10 Symptomatic adults, CD4 ≤ 100, inpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">11 Symptomatic adults, CD4 ≤ 100, outpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">12 Symptomatic adults, CD4 101‐200, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>586</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">13 Symptomatic adults, CD4 101‐200, inpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">14 Symptomatic adults, CD4 101‐200, outpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">17 Unselected adults, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3365</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">18 Unselected adults, inpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>537</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">19 Unselected adults, outpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2828</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">20 Unselected adults, CD4 &gt; 200, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">21 Unselected adults, CD4 ≤ 200, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>706</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">22 Unselected adults, CD4 ≤ 200, inpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">23 Unselected adults, CD4 ≤ 200, outpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">24 Unselected adults, CD4 &gt; 100, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>952</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">25 Unselected adults, CD4 ≤ 100, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">26 Unselected adults, CD4 ≤ 100, inpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">27 Unselected adults, CD4 ≤ 100, outpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">28 Unselected adults, CD4 101‐200, all settings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">29 Unselected adults, CD4 101‐200, inpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">30 Unselected adults, CD4 101‐200, outpatients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011420.pub3/references#CD011420-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011420.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011420-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011420-note-0001">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011420-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011420-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011420-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011420\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011420\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011420\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011420\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011420\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011420.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011420.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011420.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011420.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011420.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725191186"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011420.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725191189"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011420.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e753658101be5',t:'MTc0MDcyNTE5MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 